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The enzymes CYP 1A1 and CYP 1B1 have been shown to be overexpresscd in a wide 
variety of tumors. The enzyme CYP1B1 has been shown to convert a cancer preventative 
agent (resveratrol) to a compound with antileukemic activity (picccatannol). Based on 
these findings interactions of CYP1 family enzymes with cancer preventative flavonoids, 
that have structure similar to resveratrol, were investigated. The flavonols qucrcetin, 
myricetin and kaempferol and the flavones chrysin, eupatorin and diosmetin inhibit the 
dealkylation of 7-ethoxyresorufin to resorufin by CYP 1B1, and to a lesser extent by 
CYP1A1 (with the exception of chrysin) and CYP1A2. The flavoncs diosmetin, 
eupatorin, sinensetin, genkwanin, scutellarein and chrysin are substrates for CYP1 family 
enzymes. 
Furthermore the metabolism of natural flavones and their cytotoxic action in MDA-MB 
468, MCF7 human breast adenocarcinoma and MCF l0A human breast cells, as well as 
the ability to inhibit the progression of these cells through the phases of the cell cycle was 
evaluated. The flavones diosmetin, genkwanin and eupatorin were shown to be 
metabolised in MDA-MB 468 cells and MCF7 cells pretreated with IOnM TCDD for 24 
hrs but not in MCFlOA cells or MCF7 cells with no TCDD treatment. The latter 
compounds along with other structurally related flavones, were shown to inhibit the 
growth of MDA-MB 468 and MCF7 cells, while having minor effects on the growth of 
MCF1OA cells (with the exception of baicalein). The flavones eupatorin and cirsiliol 
caused G2/NI arrests in MDA-MB 468 cells at 48 hr and diosmetin and sinensetin caused 
G, arrests in the same time period. 
Finally the ability of natural flavones to induce the expression of CYP 1 family enzymes 
in MCF7 cells was investigated. The flavones diosmetin, genkwanin, eupatorin, 
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eupatorin-5-methyl ether and cirsiliol induced CYP1 enzyme expression in MCF7 cells 
after 24 hr treatment, as evident by increased EROD activity. Eupatorin and cirsiliol 
caused an increase in CYPIBI and CYPJA1 mRNA levels, as shown by RTPCR. 
Overall the data confirm the hypothesis that CYP 1BI and CYP IA1 can act as tumour 
suppresor enzymes, via metabolic activation of naturally occuring flavonoids. Thus the 
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1. INTRODUCTION 
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1.1 Cancer and cancer therapy 
Cancer is a disease of abnormal gene expression, which results when the controls of 
normal cell growth break down. The progression of a normal cell to a cancer cell is a 
multistep process and is called carcinogenesis. Evidence for this finding has been 
provided from conditions that represent intermediate stages, where only some of the cell 
cycle controls have been disrupted. Carcinogenesis is caused mainly by environmental 
factors, such as oncogenic viruses and certain chemicals. This results to mutations in the 
DNA sequence of the cells. 
Certain sets of genes, which are called oncogenes, have been found to be involved in 
carcinogenesis and their mutated versions account for corresponding oncogenic proteins, 
which promote the formation of cancer. Another set of genes called tumour suppressor 
genes protect the cell from accumulating mutations in their normal state. When 
inactivated, these genes lead to carcinogenesis, because their normal function is 
disrupted. 
Cancer therapy includes radiation, surgery and chemotherapy. Initial approaches of 
chemotherapy have been found to be extremely cytotoxic and ineffective due to severe 
side effects. Cytotoxic chemotherapeutic agents include antimetabolites, which are agents 
that disrupt DNA synthesis, alkylating agents, which cause cross-linking between the 
DNA strands and natural products such as the vinca alkaloids, which cause disruption of 
the mitotic spindle during mitosis. Targeted therapy has emerged over the last 10 years to 
limit the severe side effects, caused by cytotoxic chemotherapy, with the most promising 
molecules being inhibitors of tyrosine kinase enzymes, which are involved in cell 
signalling. 
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1.1.1 Cancer epidemiology 
In the year 2000 cancer, was diagnosed in 10 million people worldwide and caused 6.2 
million deaths, an increase of about 22% since 1990 (Ferlay et al., 2001). Cancer causes 
10% of all deaths worldwide and is second only to cardiovascular disease as the main 
cause of death in developed countries (Ferlay et al., 2001). Worldwide there are about 22 
million people living with cancer at any one time (Ferlay et al., 2001). The number of 
cases of cancer worldwide is predicetd to increase by 5 million to 15 million new cases 
each year by 2020 (www. who. in/whosis). The two most common cancers worldwide are 
lung and breast cancer, which account for 12% and 10% of all cancers diagnosed 
respectively (Ferlay et al., 2001). 
1.1.2 General properties 
In contrast to free living cells such as bacteria, the cells of a multicellular organism are 
commited to collaborate with each other. Therefore, growth and development of cells and 
the maintenance of cell population sizes in such an organism must be subject to various 
types of controls. Cancer cells have lost these controls. Cancer cells are distinguished by 
the fact that they reproduce against the normal restraints and then invade the areas 
normally reserved for other cells. It is the combination of these two features that makes 
them particularly dangerous. A tumour or neoplasm is a relentessly growing mass of 
abnormal cells (Knowles and Selby, 2005). The tumour is characterised as benign if the 
neoplastic cells remain clustered together and as malignant if its cells can invade 
surrounding tissue. Metastasis is the ability of the cancer cell to spread from its site of 
origin to other sites of the body and form secondary tumours (Knowles and Selby, 2005). 
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In order for Cancel- MIS to metastasize tlle'y Il1Utit 
loosen their adhesion toi their neighbour 
cells. break through the basal lamina, enter the circulation by invading the blued 
rahiILin es, travel through the bloodstream. adhere to a Capillary wall and Iinally 
hrolilcratc in the new environment. 'I'hr 1mal steps are the most d1iIlicult and unlN it Small 
portion of' cancer cells (less than one in it thousand) will survive to fiºriti metastatic 
colonies (I igurc 1.1). 
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Figure 1.1 Steps in the process of metastasis, by, which cells from a primary tumor travel 
through the bloodstream to a distant site of the bode. 
1.1.3 Types of cancer 
"Rumors are described by a generic name. which specit es the general tissue ol' origin 
(Knowles and Selby. 2005). Carcinomas. are the cancers that arise from epithelial cells, 
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whereas sarcomas are those which originate from muscle cells. Leukemias are derived 
from hemopoietic cells and there is also another broad category which involves cancers 
of the nervous system, such as retinoblastoma, astrocytoma etc. About 90% of human 
cancers are carcinomas, because of the exposure of epithelial cells to various factors that 
favour the development of cancer and perhaps because epithelial cells undergo most of 
the body's cell proliferation. Table 1.1 illustrates the major types of cancer and their 
incidence of death worldwide. 
Table 1.1 Cancer Incidence and Mortality in the world, 2001. Adapted front Ferlay et al. 
, 2001 
Type of cancer New Cases per Year Deaths per year 










1.1.4 Development of cancer 
Most cancers derive from a single abnormal cell, and even when a tumour has formed 
metastases, its origin can be traced to a single primary tumour, derived from an aberrant 
cell, that is a single cell that has a heritable change. A cell can become aberrant due to a 
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genetic or an epigenetic change. In the first case an alteration to the cells DNA sequence 
occurs, and in the second, a change in the pattern of gene expression occurs without 
requiring a change in the DNA sequence. Mutations can also occur in homcotic genes, 
i. e. genes that regulate concerted expression of a range of other genes. Most cancers arc 
initiated by a genetic change and the cases which fall in the second category are rare. 
This genetic change is caused in most of the cases by environmental factors, since a 
single mutation is not enough to convert a normal cell to cancerous one. If this was the 
case and considering the fact that mutations occur spontaneously at a fixed rate per cell 
division, as a result of the accuracy of DNA replication and repair, then the chance of 
developing cancer in any given year would be independent of age. However 
epidemiological studies have shown that the incidence of cancer increases exponentially 
with age as shown in Figure 1.2 (Knowles and Selby, 2005). This due to the phenomenon 
of tumour progression, whereby an initial mild disorder of cell behaviour evolves to 
cancer. Hence cancer can be characterised as an evolutionary process, which involves a 
large element of chance, increased mutation rate and natural selection and usually takes 
many years to develop. 
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Figure 1.2 Cancer incidence as a function of age. The number of newly diagnosed cases of 
colon cancer in men in England in in 1999 is plotted as a function of age. Adapted frone 
Knowles and Selby, 2005 
1.1.5 Molecular genetics of cancer 
1.1.5.1 General terminology 
It has been shown that changes in a very small set of genes are responsible for the 
deranged cell behaviour observed in cancer. In recent years, major progress has been 
made in identifying the genes which are mutated during carcinogenesis. The genes which 
are responsible for causing cancer are named oncogenes. Oncogenes are mutated versions 
of other genes, called proto-oncogenes. This type of mutation has a dominant effect (only 
one copy of the gene is required to cause change in the cell behaviour) and makes the 
gene overactive (Chin and DePinho, 2000). A second category of genes, which cause 
cancer when mutated are the tumour suppressor genes. These genes act in a 
fundamentally different way from oncogenes. When they become inactive as the result of 
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mutations that eliminate their normal activity, the disappearance of their encoded 
proteins, causes other genes to become oncogenic (Knudson, 1996). The normal versions 
of these genes inhibit a normal cell from entering mitosis and ccll division. Unlike 
oncogcnes both alleles of a tumour suppressor gene need to be inactivated, hence they act 
in a genetically recessive fashion (Knudson, 1996). 
1.1.5.2 Role of viruses in the development of cancer 
About 13% of human cancers, in the whole world, are thought to arise by mechanisms 
that involve viruses (www. who. in/whosis). Mutations in proto-oncogenes can be 
triggered by viruses, which have played a remarkable part in the development of cancer 
and in the understanding of the key mechanisms which cause it. Rctroviruscs, arc viruses 
that insert their RNA into their host (Coffin et al., 1997). The enzyme reverse 
transcriptase transcribes their RNA to cDNA, which then insegrates with the host's 
genome (Coffin et al., 1997). These viruses can act as vectors for oncogencs (Coffin et al., 
1997). 
Oncogenic effects are caused by retroviruses, in a process called insertional mutation, in 
which the altered genome is inherited by all the progeny of the original host cell 
(Varmus, 1988). Random insertion of the DNA copies of the viral RNA in the host's 
genome occurs as a part of the normal retroviral life. Another way in which retroviruses 
can cause mutation of a proto-oncogene is by expressing it in excess under the control of 
powerful promoters and enhancers in the viral genome. 
The most striking example is the Rous sarcoma virus. The gene responsible for sarcomas 
was found in a virus called Rous sarcoma virus and was designated as v-src. By DNA- 
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DNA hybridisation, a sequence very similar to v-src and designated c-src was found in 
the vertebrate genome (Martin, 1970). This gene is the actual proto-oncogene which was 
picked up accidentally from the virus and had undergone mutation in the process. 
However the predominant viruses, which are characterised as oncobenic are DNA 
viruses. Evidence for this suggestion has been given by epidemiological studies (Table 
1.2 presents an overview of some of the viruses associated with human cancers). For 
example the incidence of liver cancer is high in areas where hepatitis-B infections are 
also common. The virus can be responsible for only one of the steps in the progression of 
cancer and other environmental factors can also be involved. Although DNA viruses 
incorporate their DNA into the host's genome and can possibly cause a mutation of a 
proto-oncogene, the resulting combined gene is a part of the viral genome and plays no 
role in the normal host cell (Knowles and Selby, 2005). Unlike retroviruscs, DNA viruses 
act not by activating a proto-oncogene into an oncogene, but by interfering with the 
tumor suppressor genes function and thereby allowing cells with accumulated mutations 
to enter cell division (Knowles and Selby, 2005). Papillomaviruses contain genes which, 
when transcribed produce viral proteins that bind to protein products of key tumour 
suppressor genes of the host cell putting them out of action, and which have been 
implicated in malignant tumours such as uterine cervix cancers (Doorbar 2006). 
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Table 1.2 Viruses associated with human cancers. Adapted from Alberts ct al., 1994 
Virus Associated Tumors Areas of High Incidence 
DNA viruses 





Human T-cell leukemia 
virus type I (HTLV-I) 
Human immunodeficien 
Virus (HIV-1) 
Ilepatocellular carcinoma Africa 
Burkitt's lymphoma Africa, New Guinea 
Adult T-cell leukemia/lymphoma Japan 
cy Kaposi's sarcoma Africa 
1.1.5.3 Tumour suppressor genes 
The most important tumour suppressor genes are the Retinoblastoma (Rb) and the p53 
gene. The Rb gene is located on the long arm of chromosome 13, and it was the first 
tumour suppressor to be isolated (Sherr and McCornick, 2002). Originally this gene was 
critical for childhood tumours to develop from precursor cells in the immature retina. 
However Rb is involved in other types of tumours and although retinoblastoma is rare, 
loss of Rb has been implicated in osteosarcoma, soft tissue sarcoma, bladder carcinoma 
and breast carcinoma (Sherr and McCornick, 2002). In all of them, loss of heterozygosity 
(loss of heterozygous combination of maternal and paternal alleles, as a result of deletion 
or point mutation) seems to be important for the progression towards malignancy (Sherr 
and McCornick, 2002). The gene acts by producing Rb protein which can shuttle between 
an unphosphorylated and phosphorylated state. It remains unphosphorylated for cells that 
do not undergo cell division. In this state, Rb protein prevents DNA replication by 
inhibiting transcription of proto-oncogenes. Mutation of Rb sets the cell free from this 
restraint and it has been shown that deletion of amino acids (703-737) in exon 21 of the 
gene produces Rb proteins which are unable to function normally (Linardopoulos et al., 
1993). 
However the gene that really puts tumour suppressors on the map is the one called p53. 
Deletions in this gene have been shown to be associated with more than 50% of all 
human cancers. The gene is located on the short arm of chromosome 17 and encodes for 
a 52kDa protein, which is required to bind to another regulatory gene and induce its 
transcription (Vousden and Lu, 2002). The product which is a 2lkDa (Figure 1.3) binds 
with protein kinases and blocks the cell from entering the S phase of the cell cycle. P53 
seems to be expressed at high levels as a response mechanism in cells which are exposed 
to environmental factors that can cause cancer (Vousden and Lu, 2002). Hence loss of 
p53 can aid the development of cancer first by removing the cell cycle block and 
allowing cells to continue proliferation and second allowing further mutations to occur 
when these cells divide (Vousden and Lu, 2002). Because of its importance mutations in 
p53 develop at the later stages of tumour progression and only when this gene's function 
is disabled can cells give rise to cancer (Figure 1.4). 
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Figure 1.3 P53 maintains the genome integrity by repairing DNA inducing apoptosis or cell 
cycle arrest through p21. 
DNA 
hypomethylation 
activation loss of 
of Pas 18q 156 loss of loss of APC  p53 
normal hyperplastic J earlyf intermediate + late invasion & 01 carcinoma 
epithelium epithelium adenomas metastasis 
Figure 1.4 Sequence of genetic changes in the development of a colorectal carcinoma. The 
identity of the tumor suppressor gene 18q TSG remains unclear and so does the precise 




So far about 60 oncogenes have been discovered. Most oncogcnes code for proteins 
which regulate cell signalling pathways in the body. One category of oncogenes eems to 
code for proteins related to various steps in the response mechanism for growth factors, 
whereas another group of oncogenes codes for nuclear DNA binding proteins that act as 
transcription factors. The most important oncogenes are listed below: 
- The sis oncogene which codes for a subunit of platelet-derived growth factor and the 
fms oncogene which codes for a mutated version of the receptor for colony-stimulating 
factor-1, a growth factor that stimulates bone marrow cells during blood cell formation 
(Turner et al., 2000). 
- The various ras oncogenes which code for members of the G-protein family. Ras 
oncogenes possess point mutations which produce G-proteins that remain active for more 
than normal (discussed in more detail in section 1.1.5.6.2) and they have been involved in 
thyroid, colon and lung carcinomas and acute myelogenous leukaemias (Turner et al., 
2000). 
- The myc gene is located on chromosome 8 and it is responsible for the transcription of 
other genes required for cell division. It is overexpressed in cancer cells by different 
mechanisms either under the influence of a viral enhancer or by translocation of the 
coding sequence to another chromosome. Overexpression of myc oncogenes has been 
associated with breast and lung carcinomas and neuroblastoma (Turner et at., 2000). 
- The erbA and erbB oncogenes which code for truncated versions of the epidermal 
growth factor receptor. Expression of erb oncogenes has been reported in breast and 
ovarian carcinomas. 
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1.1.5.5 Chemical carcinogenesis 
The evidence that chemicals can induce cancer in humans has been accumulating for 
more than two centuries. The first observation was made by John hill, who in 1761 noted 
that nasal cancer occurred in people who used snuff excessively (reviewed by Ruddon, 
1995). Skin cancer was also observed to be occurring in people who had spent tlicir 
childhood as chimney workers (1775) and in workers whose skin was in continous 
contact with tar and paraffin oils (1895) (reviewed by Ruddon, 1995). These observations 
led to attempts to induce cancer in animals with chemicals. The first succcsful attempt 
was made in 1915, when Yamagina and Ichikawa induced skin carcinomas by the 
repeated application of coal tar to the ears of rabbits. This led to the search for the active 
carcinogen in coal tar and to the conclusion that the carcinogenic agents in tars are the 
polycyclic aromatic hydrocarbons. The list of known carcinogenic chemicals expanded in 
the 1940s, when other carcinogenic compounds were identified, such as 2-acetyl 
aminofluorene, halogenated hydrocarbons, urethane, beryllium salts and certain 
anticancer alkylating agents. Since the 1940s, various intercalating agents, asbestos, 
nickel, chromium compounds and nitrosamines have been added to the list. 
Several studies on the reactions of carcinogens with cellular macromolecules have led to 
the conclusion that most of these interactions resulted from covalent bond formation 
between an electrophilic form of the carcinogen and nucleophilic sites in proteins (sulfur, 
oxygen and nitrogen atoms in cysteine, tyrosine and histidine respectively) and nucleic 
acids (purine or pyrimidine ring nitrogens and oxygens)(reviewed by Ruddon, 1995). The 
parent compound in these type of experiments, had to be frequently incubated with liver 
homogenates. This led to the realisation that metabolic activation of certain carcinogens 
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was required to produce the ultimate carcinogen that reacts with crucial molecules in the 
cells. Carcinogens not included in the above category are the very chemically reactive 
alkylating agents, which are activated in aqueous solution at physiological pII and the 
agents that intercalate with the DNA double helix. 
1.1.5.5.1 Donor of Alkyl groups 
This group contains the dialkylnitrosamines, dialkylhydrazines, aryldialkyltriazines, 
alkylnitrosamides and alkylnitrosimides (reviewed by Ruddon, 1995). The 
alkylnitrosamides can directly interact with H2O or cellular nucleophillic groups. The 
alkylnitrosamines, alkylhydrazines and alkyltriazines are metabolically activated by the 
mixed function oxidase system (described in detail in section 1.3) in the ER of cells. The 
monoalkyl derivatives undergo a non-enzymatic conversion to monoalkyldiazonium ions 
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Figure 1.5. Schematic representation of nitrosamine activation adapted by Ruddon, 1995. 
AAF (2-Acetylaminofluorene) in 1960 was shown to be converted to a more potent 
carcinogen N-hydroxy-AAF after the parent compound was fed to rats (reviewed by 
Ruddon, 1995) (Figure 1.6). Subsequent studies showed that N-hydroxy AAF is 
converted in rat liver to a sulfate N-sulfonoxy AAF which reacts with nucleic acids and 
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Figure 1.6. Metabolic activation of AAF adapted from Ruddon, 1995 
Metabolic activation of other aromatic amines idads to formation of positively charged 
nitrenium ion that is formed from naphthylamine and aminobiphenyl compounds and is 
implicated in urinary bladder cancer in humans (reviewed by Ruddon, 1995). The 
mechanism of activation involves hydroxylation in the liver to a hydroxylamine 
derivative and subsequent glucuronidation (reviewed by Ruddon, 1995). The glucuronide 
conjugate is excreted in the urine, where the acidic pH converts it back to hydroxylamine, 
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Figure 1.7. Activation pathway of aromatic amines in the body, adapted from Ruddon, 1995 
1.1.5.5.2 Polycyclic aromatic hydrocarbons (PAHs) 
In 1950 it was suggested that the carcinogenicity of PAHs was mediated through 
metabolically formed epoxides. Extensive studies offered more mechanistic information 
on the carcinogenic action of PAHs. It is now generally accepted that conversion of 
PAHs to their dihydrodiol epoxides is a crucial pathway in the formation of the ultimate 
carcinogens. 7ß, 8a-dihydroxy-9a, 1 Oa-epoxy-7,8,9,10-tetrahydroxybenzo[a]pyrene has 
been shown to be the ultimate mutagenic and carcinogenic metabolite of benzo[a]pyrene 
(reviewed by Ruddon, 1995). Further studies tested the mutagenicity of benzo[a]pyrene 
metabolites in mice. It was found that diol epoxides of benzo[a]pyrene (7,8 diol-9,10 
epoxides) were potent mutagens as well. They could induce formation of lung adenomas- 
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adenocarcinomas, liver tumors and lymphomas when injected in newborn mice (reviewed 
by Ruddon, 1995). It was shown that benzo[a]pyrene (BP) 7,8 dihydrodiol and 
benzo[a]pyrene (BP) 7,8 diol-9,10 epoxide were respectively 15-fold and 40-fold more 
active than benzo[a]pyrene itself (reviewed by Ruddon, 1995). Diol was termed as a 
proximate carcinogen with the diol epoxide being the ultimate. 
p7z (+)-BP 7,8 oxide 
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Figure 1.8. Mutagenic metabolites of benzola]pyrene. 7,8,9,10 epoxide-2(+) binds 
preferentially to DNA with 20-fold greater potency than 7,8,9,10 epoxide-2(-) adapted from 
Ruddon, 1995 
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1.1.5.5.3 DNA adduct formation 
Reaction of DNA with chemical carcinogens is the most simple mechanism explaining 
malignant transformation, which is caused by a heritable change. Nitrosamines react with 
the bases of DNA and form N-7 and 0-6 guanine derivatives. Other aromatic amincs, 
such as N-methyl-4-aminobenzene produce C-8 substituted guanine residues as their 
primary DNA adduct (Neidle, 1979). 
Various mechanisms exist by which the DNA adducts lead to cancer initiation. In some 
cases, such as PAHs, the flat planar ring stabilises an intercalation reaction with the 
stacked bases of the double helical DNA, leading to a frameshif mutation during DNA 
replication after the point of intercalation (Knowles and Selby, 2005). DNA adducts can 
create a base transition mutation, due to misplacement of their alkyl groups with wrong 
base during DNA replication (Knowles and Selby, 2005). Moreover many of the base 
adducts, which involve modifications of N-3 or N-7 positions on purines can induce an 
instability in the glycosidic bond between the base and the sugar, which in turn undergoes 
cleavage by DNA glycosylase, resulting in loss of the base and creation of an apurinic 
site in DNA (Knowles and Selby, 2005). This site can be filled with any base during 
DNA replication, resulting in a base transition or a base transversion. Further research on 
the interaction of carcinogens with DNA has revealed that the specificity of carcinogen 
binding is determined to some extent by the base sequence of DNA. For example 
benzo[a]pyrene diol epoxide preferentially binds in a 300-base-pair sequence 5' to the 
RNA cap site of chicken ß-globin DNA (reviewed by Ruddon, 1995). This demonstrates 
that the carcinogen binds to areas most active in gene transcription. 
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1.1.5.6 Epidermal growth factor receptors, MAPKs, Ras and cancer 
The epidermal growth factor receptor (EGFR) family comprises four members: 
EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. Each receptor contains an 
extracellular cysteine-rich domain and an intracellular region where autophosphorylation 
occurs upon binding with the ligand. These receptors can be coexpressed in various 
combinations, where they form homo- or heterodimers. The ligands include EGF, TGF-a, 
heparin binding EGF like growth factor (HB-EGF), betacellulin and others (Guillemard 
and Saragovi, 2004). The above ligands can bind to EGFR, HER3 and IIER4 but to date 
no cognate natural ligand has been identified for HER2. HER2/neu was first identified as 
the transforming gene in a rat neuroblastoma cell line (Guillemard and Saragovi, 2004). 
Overexpression of HERZ has been shown in a panel of human cancers clinical data 
showed a correlation between HERZ overexpression and reduced survival of patients due 
to increased metastatic potential (Guillemard and Saragovi, 2004). EGFR is also 
frequently overexpressed in a number of human cancers and its hyperstimulation 
enhances cellular proliferation, decreases apoptosis and promotes tumour cell motility 
and invasion. As in the case of HERZ high levels of EGFR expression correlate with high 
metastatic rate. Moreover increased rate of tumour formation in non small cell lung, 
bladder, cervical, kidney and ovarian cancer has been noticed along with EGFR 
overexpression in those tissues (Guillemard and Saragovi, 2004). 
1.1.5.6.1 MAPK pathways 
Various extracellular signals are converted into intracellular responses through serial 
phosphorylation cascades, catalysed 
by a group of serine/threonine kinases, called the 
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MAPKs (mitogen activated protein kinases). Three distinct but parallel MAP kinase 
cascades (ERK, JNK and p38) have been identified in mammalian cells and each one 
consists of a module of three kinases: a MAPK kinase kinase (MAPKKK), which 
phosporylates a MAPK kinase (MAPKK), which in turn phosphorylates a MAPK. The 
ERK (extracellular signal-regulated kinase) is activated by mitogenic stimuli, such as 
growth factors (e. g. EGF) which bind to a growth factor receptor (e. g. EGFR), which is a 
tyrosine kinase enzyme. The JNK (JUN-N terminal kinase) and p38 MAPK are activated 
by environmental stress stimuli, such as UV and ionising radiation. Once activated these 
three MAPKs (ERK, JNK and p38) can phosphorylate many transcription factors such as 
c-Myc, p62TCFIE1k-1, c-Jun, ATF2, MEF2C, FOS and SAP-1 (Kong et al., 2001). The 
net result of this cascade is the altered activity of the transcription factors, which dimerisc 
and bind to specific DNA sequences called response elements, thus promoting 
transcription of growth related genes. Figure 1.9 represents an example of the signal 
transduction molecular events, which take place upon binding of a growth factor to its 
receptor. 
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MAPK signaling cascades 
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Figure 1.9. Mitogen activated protein kinase (MAPK) cascades. Signalling through the 
MAPK cascades leads to altered activity of target genes, including; several transcription 
factors. The picture also shows the involvement of Ras in relaying the signal from the 
growth factors to Raf, MEK1/2 and EKK1/2 kinases. Adapted from Manson 2003 
1.1.5.6.2 The Ras GTP binding protein 
The Ras protein is a 21 kI)a GTP binding protein, which relays the signal produced h\ 
the mitogenic growth factors to the MAPKs, phosphoinositols or cvtoskeletal proteins. 
Ras (Figure 1.9) which is located on the cytoplasmic face of the cell membrane, is active 
when bound to GTI' and inactive with GDP. The protein contains intrinsic (i l'Pase 
activity, which inactivates its function. I Iowevcr another protein. GAP is needed for this 
process. which is an inhibitor of Ras activation. Ras is synthesised as a precursor with a 
C-terminal CAAX motif (C=cysteine. A=Aliphatic amino acid. X=variable). The last 
three amino acids are cleaved by proteolysis and the cysteine group is modified by 
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attachment of a 15-carbon isoprenyl (farnesyl) group, catalysed by the enzyme famcsyl 
transferase. Downstream effector, as shown in Figure 6 is Raf, a scrine thrconinc protein 
kinase, which plays a crucial role in Ras activation by recruiting it to the cell membrane. 
Raf is the first serine/threonine kinase in the ERK pathway. 
The ras oncogene is mutated in about 40% of all human cancers (reviewed in King, 
2000). The mutations destroy the GTPase activity of Ras and hence it remains in the 
active GTP-bound form. Tumour associated mutant Ras proteins harbor single amino 
acid substitutions, primarily at residues 12,13 and 61 that render Ras insensitive to GAI' 
stimulated GTP hydrolysis (Pruitt and Der, 2001). These oncogenic mutants of Ras 
continue to signal in the absence of extracellular signals. 
Except the MAPKs the second best characterised downstream effectors of Ras are the 
phosphoinositide-3-phosphate lipid kinases (PI3Ks). Activated PI3K, converts 
phosphatidylinositol 4,5-phosphate (PIP2) to phosphatidylinositol 3,4,5-phosphate (PIP3). 
PIP3 levels are usually elevated in Ras-transformed cells and promote the activation of 
the Akt/PKB (Protein kinase B) serine threonine kinase (Pruitt and Der, 2001). 
1.1.5.7 The cell cycle and the cyclin dependent kinases (CDKs) 
Mitosis only represents about 5% of the cell cycle and about 40% is required for DNA 
synthesis. DNA synthesis and mitosis are separated by gaps, during which RNA and 
proteins are made. The first gap is called G, and its duration covers about 45% of the cell 
cycle. G1 is the regulation point which ensures that the cell 
has adequate "machinery" for 
future events and for transmission of genetic information (reviewed in King, 2000). After 
Gi S phase follows where DNA synthesis occurs. Once DNA has been duplicated the G2 
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phase checkpoint ensures the elimination of damaged cells, which have escaped G, 
control or which have not accurately duplicated their DNA (Pines, 1999). 
The key mechanism in the control of the cell cycle, is the regulation of protein 
phosphorylation levels. The protein kinases involved in this process are scrinc thrconine 
kinases, made up of a regulatory and a catalytic subunit. The regulatory subunits arc 
called cyclins and the catalytic subunits cyclin dependent kinascs (CDKs). There arc 
three different classes of CDKs associated with either the G1, the S or the G2/M phase of 
the cell cycle and four different classes of cyclin proteins (cyclins D, E, A and B). 
Mitogenic signals promote the entry of quiescent cells into the first gap phase (GI) and 
initiation of DNA synthesis in the S phase (Pines, 1999). This progression into G, phase 
is cooperatively regulated by the various classes of CDKs and their CDK inhibitors 
(CKIs). CKIs can be divided into two major classes: INK4, so named by their ability to 
inhibit CDK4 which are p16MK4a, p17 INK4b' p1g1NK4c and p191NK4d and Cip/Kip family of 
inhibitors which are p21c'P', p27K'pl and p57K'p2 (reviewed in Sherr and Roberts, 1999). 
INK4 inhibitors act on CDK4 and CDK6 whereas Cip/Kip inhibitors affect the action of 
cyclin D-, E- and A- dependent kinases (Pines, 1999). 
Transcription of cyclin Dl is regulated by growth factors and other signals through the 
Ras/Raf/ERK pathway. Turnover of D-type cyclins depends on the PI3K/Akt pathway, 
which negatively regulates the phosphorylation of cyclin D1 on a single threonine 
residue, by glycogen synthase kinase-30 (GSK-30) (reviewed in Sherr and Roberts, 1999). 
Inhibition of this signalling pathway accelerates the ubiquitin-dependent proteasomal 
degradation of cyclin D1 in the cytoplasm and shortens its half life to as little as 10 min. 
Cyclin D-dependent kinases (CDK4 and CDK6) phosphorylate Rb in mid G1 phase, after 
26 
which cyclin E-CDK2 becomes active and completes this process by phosphorylating Rb 
on additional sites (Sausville, 2005). Rb hyperphosphorylation in late GI disrupts its 
association with various E2F members of transcription factors and this allows the 
transcription of various genes which are required for DNA synthesis (Sausville, 2005). 
Cyclin A- and B- dependent CDKs maintain Rb in a hyperphosporylated state until cells 
exit mitosis and Rb is returned to a hypophosphorylatcd state in the next G1 phase 
(Sausville, 2005). When overexpressed E2F can drive quiescent cells into S phase, 
whereas active repression by the Rb-E2F complex, as opposed to a block in E2F 
transcriptional activation, is required to enforce G1 arrest by certain antiproliferative 
signals (reviewed in Sherr and Roberts, 1999). A representation of the cell cycle is shown 
in Figure 1.10. 
The second most important function of cyclin D-CDK4 complexes is the sequestration of 
Cip/Kip family CIKs, such as p21c'P' and p27K'°I. In proliferating cells most p27K'p, is 
complexed to cyclin D-dependent kinases (reviewed in Sherr and Roberts, 1999), while 
in quiescent cells p21c'pl levels are low and p27k'pl levels are high. p27' and and 
p2lei'1 bind to higher order complexes with assembling cyclin D-dependent kinases and 
this relieves cyclin E-CDK2 from Cip/Kip constraint, facilitating its activation in late G1 
phase (reviewed in Sherr and Roberts, 1999). This activation occurs from a single 
phosphorylation reaction of cyclin E-CDK2 on p27'"pl, once the process of Cip/Kip 
sequestration has lowered the effective CKI level to a critical point. Once CDK2 becomes 
active it triggers the destruction of p27KipI (Pines, 1999). This results to an irreversible 
commitment of the cell to enter the S phase of the cycle and thus mitogenic signals are 







Figure 1.10. Schematic representation of the cell cycle. Cyclins and their corresponding 
CDK partners are shown, as well as their interaction with the Rh protein. 
1.1.6 Cancer treatment 
Cancer treatment requires the combination of various techniques. Cancer cells can be 
removed surgically or destroyed with toxic chemicals or radiation. Unfortunately it is 
usually very difficult to eradicate all cancer cells. Surgery can rarely remove every 
metastasis and chemotherapy is usually toxic to normal cells as well. If a few cancerous 
cells survive they can proliferate to produce a reccurence of the disease and may develop 
resistance against chemotherapeutic agents. 
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1.1.6.1 Cytotoxic chemotherapy 
Chemotherapy has been the main form of drug treatment at all stages of cancer 
development over the last 40 years. Chemotherapeutic drugs, which were first discovered 
to treat cancer patients can be classified broadly into three categories, according to their 
mechanism of action: Alkylating agents, antimetabolites and natural products. 
1.1.6.1.1 Alkylating agents 
Alkylating agents have two functional groups each of which can react with a DNA base 
and form interstrand and intrastrand crosslinks within the DNA double helix (reviewed in 
King, 2000). This causes the formation of DNA adducts that disrupt DNA synthesis. Two 
of the most commonly used alkylating agents are cyclophosphamide and cis-platin 
(Figure 1.11). These two agents react with DNA bases and form cross-linked guanines, 
which block proliferation at several stages of the cell cycle. Cyclophosphamide is used in 
combination with methotrexate and 5-fluorouracil for the treatment of many canccrs. Its 
side effects include sterility, hair loss and immunosuppression. Cis-platin forms DNA 
adducts at the N-2 position of guanine or N-3 position of adenine (Burley, 2002). 
Intrastrand adducts distort the DNA helix, whilst interstrand links prevent strand 
separation so that replication is inhibited. Cis-platin is clinically used against testicular 
and ovarian cancers and it has minimal effect on the bone marrow. Its main toxicities are 
nausea, renal dysfunction and renal effects. 
1.1.6.1.2 Antimetabolites 
Antimetabolites inhibit nucleic acid synthesis with the actual mechanism depending on 
the compound. The most widely known are methotrexate and 5-FU (Figure 1.12). 
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Methotrexate is a derivative of folic acid and is a competitive inhibitor of the cnzyme 
dihydrofolate reductase (DHFR), which is essential for purinc and pyrimidine 
biosynthesis (reviewed in King, 2000). Folic acid (Fl12) is reduced to tetrahydrofolic acid 
(F114) by DHFR and the latter can form N5, N10 methylene tetrahydrofolic acid or N1O 
formyl FH4 which are used for purine synthesis (reviewed in King, 2000). Methotrcxate 
inhibits the reduction of folic acid to tetrahydrofolic acid and it can treat the cancer 
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Figure 1.11. Structures of cyclophosphamide and cis-platin. The reaction demonstrates the 














5-FU is a derivative of uracil that can be phosphorylated and incorporated into RNA. 
Additionally it produces 5-fluoro-dUMP that forms an inactive ternary complex with the 
N5, NI0-methylene-F114 thereby inhibiting DNA synthesis (reviewed in King, 2000). It is 
used to treat breast and stomach cancers and like methotrexate shows toxicity in bone 
marrow cells. 
1.1.6.1.3 Natural products 
Doxorubicin is one of the natural products discovered to treat cancer. It acts as a non 
specific DNA intercalating agent and blocks the religation step of the DNA by inhibiting 
the enzyme topoisomerase II (Hurley, 2002). It is also likely that other mechanisms, such 
as direct oxidative damage to DNA might contribute to the overall efficiency of the drug 
(Hurley, 2002). It is used for the treatment of leukaemias and solid cancers such as breast, 
lung and ovary and it shows side effects on heart function (reviewed in King, 2000). 
Vincristine and vinblastine are two other natural products that are used as 
chemotherapeutic agents. These two plant alkaloids act by preventing tubulin 
polymerisation. They bind to tubulin and by disrupting the mitotic spindles, they cause a 
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block of the cell cycle in mitosis. Taxo1TM (paclitaxel) is a terpene that acts at the same 
locus but prevents tubulin depolymerisation (reviewed in King, 2000). These compounds 
have bone marrow and neural toxicity and are used to treat a broad spectrum of cancers 
such as leukaemia, ovarian cancer and testicular cancer. 
1.1.6.1.4 Hormone related cancer therapy 
In some types of cancer, such as breast and prostate, steroids are the main compounds, 
that drive cell proliferation, through continous stimulation of cells via specific receptors. 
Treatment of hormone sensitive cancers is based on the principle of depriving them of the 
mitogenic hormone. This can be achieved either by blocking the target cell receptor 
machinery or by preventing steroid synthesis. 
Steroid receptor antagonists have been used to treat hormone related cancers. The most 
widely known anticancer compound that belongs to this class is tamoxifen. Tamoxifen is 
a stilbene which has been used to treat breast cancer. It antagonises binding of the 
hormone oestradiol to the oestrogen receptor. 
Steroid synthesis can also be prevented though, by agonists of the hormones released 
from the hypothalamus-pituitary axis. The secreted hormone from the hypothalamus or 
the hormone secreted from the pituitary can be inhibited by agonists that bind very 
strongly to the hormone receptors so that they downregulate secretion of downstream 
hormones e. g. from the pituitary or the third endocrine gland. An example is L11RLi 
superantagonists which have been used for the treatment of prostate cancer. LHRI1 is 
released from the hypothalamus and stimulates the pituitary gland for formation of LH, 
which in turn acts on the prostate to elicit secretion of testosterone (Figure 1.13). The 
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inhibitors act by desensitizing the pituitary gland causing decreased formation or 
testosterone by the prostate. 







Figure 1.13 Regulation of testosterone secretion by the hypothalamus and pituitary 
1.1.6.2 Chemotherapy-Molecular approaches 
The main disadvantage of conventional chemotherapy is the severe side effects seen in 
the normal tissues. The first chemotherapeutic agents discovered were inhibiting key 
processes in DNA replication and cellular proliferation, as discussed earlier, thus acting 
on all dividing cells and lacking selectivity towards the tumour cells. In the last 10 years, 
targeted therapy has emerged, as an approach that would significantly reduce undesired 
side effects and would increase drug killing at the tumour site. 
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1.1.6.2.1 Tyrosine kinase inhibitors 
As discussed in section 1.1.3.3, transmembranc receptor tyrosine kinases play a pivotal 
role in growth factor signalling, and their overexpression can lead to malignant 
transformation. As a result, receptor tyrosine kinases have become a favourite target for 
drug development. 
The first promising tyrosine kinase inhibitor was Imatinib mesylate (or ST1571, 
GleevecTM) (Figure 1.13), which was developed by Novartis in 1996, and approved by 
the FDA in 2001 for the treatment of chronic myeloid leukaemia (CML), and 
unresectable or metastatic malignant gastrointestinal stromal tumours (GIST). Imatinib 
acts by blocking the ATP binding site of Bcr-Abl and c-Kit kinases, thus preventing 
phosphorylation reactions required for signal transduction that stimulate cell proliferation 
(Druker et al., 1996). In CML the Abelson (Abl) kinase is improperly activated by the 
accidental fusion of the bcr gene with the gene encoding the intracellular non-receptor 
tyrosine kinase c-Abl (Druker et at., 1996). Under normal conditions c-Abl exists in a 
regulated state with a very low kinase activity (Buchdunger et at., 1996), whereas in 
CML the fusion of Bcr to the NH2 terminus of c-Abl results in the constitutive activation 
of Abt kinase activity by a mechanism that is not well understood (Nagar et at., 2002). 
Imatinib also inhibits platelet derived growth factor receptor (PDGFR) and is currently 
undergoing phase I/II clinical trials 
for the treatment of recurrent malignant gliomas and 
phase II to treat childhood soft tissue sarcoma 
bone cancer (Guillemard and Saragovi, 
2004). Imatinib is one of the most promising anticancer drugs ever developed, because it 
inhibits several tyrosine kinases and further drug development has concentrated on the 
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inhibition of similar tyrosine kinasc targets, such as the EGFIR and VI: GFR family of 
rcccptors. 
1.1.6.2.1.1 EGFR directed strategies 
The quinazolines Gefitinib (ZD1839) and Erlotinib (OS1774) (Figure 1.13), which arc the 
most advanced in clinical development, arc competitive inhibitors at the tyrosine kinase 
ATP binding site of the EGFR. Gefitinib has been liccnscd for use in relapsed advanced 
NSCLC (Non small cell lung carcinoma) in Japan, Australia and USA under the name of 
Iressa and is being studied in phase II trials along with Erlotinib (Tarccva) in patients 
with advanced squamus cell carcinoma of the head and neck (SCCIIN) (Ranson, 2004). 
Response rates of approximately 5-10% have been reported with up to a third of patients 
showing stable disease (Ranson, 2004). Erlotinib is also undergoing phase I to Ill clinical 
trials for the treatment of pancreatic cancers as well as the metastatic carcinoma of the 
endometrium alone or in combination with standard chemotherapy. An advantage of 
Gefitinib is that the desired therapeutic effect can be achieved at a dose below the MTD, 
(maximum tolerated dose) as demonstrated in clinical trials for relapsed NSCLC. 
Furthermore this agent has been shown to potentiate the effect of current cytotoxic 
agents, such as paclitaxel or docetaxel, in combination treatment against A431, LX-1, 
SK-LC-16, TSU-PR1 and PC-3 tumour xenografts (Sirotnak et at., 2000). Co- 
administration of Gefitinib and the taxanes paclitaxel or docetaxel resulted in partial or 
complete regression of the above tumour xenogralIs, whereas only growth inhibition was 
observed when the taxanes were administered alone (Sirotnak et al., 2000). Potentiation 
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of cytotoxic treatment in the above preclinical models did not require high levels of 
EGFR expression in the target tumours, as demonstrated by immunohistochcmical and 






















Figure 1.14. Structures of the most promising recently developed tyrosine kinase inhibitors 
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Such prcclinicai observations raised the hope, that the addition of Gcfitinib to cytotoxic 
chemotherapy would result in improved efficacy. However, two randomised clinical 
phase III trials, involving 2000 patients with static 111/1V NSCLC, one with 
carboplatin/paclitaxcl and the other with cisplatin/gcnuitabitic, did not dcmonstratc that 
the addition of Gefitinib improves the response rates, time to progression or survival 
compared to combination chemotherapy alone (Ranson, 2004). 
C11033, PKI166, EKB569 and GW572016, which product inhibition of multiple EGFR 
family members, are in early phase clinical development (Ranson, 2004). C11033 is a 
potent kinase inhibitor of all members of the crbi3 receptor family, under development by 
Pfizer, which produces irreversible inhibition of EGFR kinase with an ICso in the low 
nanomolar range and antitumour activity in EGFR and crbi32 dependent preclinical 
models (Ranson, 2004). Phase 11 trials are now in progress. PKI166 is a reversible dual 
EGFR and erbB2 tyrosine kinase inhibitor, under clinical development by Novartis which 
entered clinical trials in 1999. PK1166, except inhibiting epithelial tumor growth and 
angiogenesis, has been shown to potentiate the activity of gemcitabine in preclinical 
models of pancreatic cancer (Ranson, 2004). GW572016 is a reversible dual erbII2 and 
EGFR tyrosine kinase inhibitor under development by GlaxoSmithKline, which has 
passed phase I in NSCLC and EKB569 is an irreversible dual inhibitor of EGFR and 
HER2 tyrosine kinases, which is currently under clinical phase II trials (Ranson, 2004). 
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1.1.6.2.1.2 VEGFR inhibitors 
Much work has been done on the inhibition of the VEG[ receptor. IMCICI I is a mAb 
that targets VEFGR2 and was evaluated in phase I for the treatment of colorectal cancer 
(Guillcmard and Saragovi, 2004). Bcracizumab is a recombinant humanised mAb against 
VEGF, currently in phase III for the treatment of renal cell carcinoma, phase If for 
metastatic prostate cancer, relapsed or refractory multiple mycloma, malignant 
mesothelioma, breast cancer and non-Ilodgins lymphoma (Guillemard and Saragovi, 
2004). Such antibodies target the cxtraccllular domain of the VEGFR. Targeting the 
intracellular domain of the VEGFR has been a popular approach with over 40 
antiangiogenic drugs currently undergoing evaluation in phase 1,11 or Ill clinical trials. 
The small molecule inhibitor SU5416 (Semaxanib) inhibits VEGFR2 and is in phase II 
for the treatment of a variety of solid tumors, stich as Kaposi sarcoma, mon small cell 
lung and breast cancer and in phase III for metastatic colorectal cancer (Guillemard and 
Saragovi, 2004). The small molecules PTK787/ZK22584 and CGP4125 inhibit VEGFR2 
and are in phase I/II clinical trials for the trcattnent of solid tumors (Guillcmard and 
Saragovi, 2004). ZD6474 is an orally bioavailable VEGFR and VEGFR2 receptor 
tyrosine kinase inhibitor, which has additional activity against EGFR and fms-like 
tyrosine kinase 4 (VEGFR3) (Ranson, 2004). It is in early phase II clinical trials with 
broad spectrum anticancer efficacy. 
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1.1.6.2.2 CDK inhibitors 
Tumour cells posscss faulty checkpoints and can proliferate dcspitc a compromiscd 
gcnomc. Very oflcn the mechanisms by which transformed cells override checkpoints are 
closely related to CDK function. For this reason restoration of cell cycle control through 
pharmacological inhibition of CDKs has been actively pursued over the last 10 years as it 
new strategy to treat cancer. 
Initial attempts to design CDK inhibitors were based on substituted purincs/ndcnines 
which will antagonisc the binding of ATI' (Kim, 1998). Some examples are shown in 
Figure 1.13. Flavopyridol (Figure 1.16) was the first phamiacologic CDK inhibitor. It 
was originally discovered as an EGF"rcceptor tyrosine kinase inhibitor but it was later 
found to be 100-fold more potent as a CDK inhibitor. The mechanism of action of 
tlavopyridol has not been fully understood and extensive structure activity relationships 
around flavonoid compounds have been established. Flavopyridol has been demonstrated 
to inhibit CDKs 1,2,4,6 and 7 as well as the CDK9/cyclin T complex (reviewed in 
Blagden and de Bono, 2004). It also targets protein kinase A and C. Rationally designed 
flavopyridol mimics such as the thio and oxo ilavopyridol analogues appear to have good 
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Figure 1.15. CDK inhibitors with purinc based structures 
To date no compound has been identified that has individual CDK selectivity and perhaps 
this is unlikely to happen due to the high homology between individual CDKs, 
particularly within the ATP binding pocket. Nevertheless such highly selective inhibitors 








Figure 1.16 Flavopyridol and sttucturally related CI)K inhibitors 
1.1.6.2.3 HDAC inhibitors 
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Ilistones are proteins, which are involved in the formation of the chromatin structure of 
DNA. Acetylation and deacetylation of histone proteins are known to have profound 
influences on the regulation of gene expression and on other proccsscs acting on gcnomic 
DNA in chromatin. Acetylation occurs at lysine residues of histones and is regulated by 
the opposite activities of histone acetyltransferases (HATS) and histone dcacetylase 
enzymes (HDACs). 
Recent studies show that inhibition of IIDACs elicits anticancer effects in several tumor 
cells by inhibition of cell growth and induction of cell differentiation. As a result there 
has been great interest for the identification and synthesis of novel LIDAC inhibitors as 
anticancer drugs. Natural products, such as trichostatin A (TSA) and the cyclic 
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tctrapcptidcs apicidin and trapoxin as well as synthetic inhibitors such as suberanilo 
hydroxamic acid (SAIIA) have been studied in cancer cell lines and in tumor animal 
models as new approaches for cancer chemotherapy (Wang ct al., 2005). 
A major task of clinical cancer research focuses on how to kill cancer cells selectively. 
Further scientific research on cell biology and related areas has advanced the 
understanding of how cancers initiate and develop and aims to exploit shuttle differences 
between normal and cancer cells, which could eventually lead to the design and synthesis 
of novel selective chemotherapeutic drug. 
Finally, there is also a focus towards chcmoprevention instead of chemotherapy. Notably 
natural compounds which are found in the diet have been shown to exert beneficial 
effects against cancer development. Plant foods, vegetables and fruits contain a wide 
variety of phytochemicals, which may reduce cancer susceptibility, as shown by the 
inverse association between their consumption and cancer risk, in epidimiological studies 
(Messina et al., 1998). Some of these chemopreventative agents are promising, because 
they are generally non toxic and able to interfere with the steps of carcinogenesis. 
Cancer can be prevented by agents that decrease the activation of chemicals to their 
highly reactive state, increase the detoxification of chemical carcinogens or prevent their 
binding to their cellular targets. Amongst the various natural products present in the diet, 
the class that has been more extensively studied for its cancer preventative properties, is 
the flavonoids. Flavonoids can prevent cancer through various mechanisms of action such 
as antioxidant, antioestrogenic, antimutagenic, anti inflammatory activity, induction of 
detoxification enzymes etc. 
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1.2.1 Flavonoids overview 
A phenolic molecule is composed of a benzene ring and a hydroxyl group attached to it. 
It is often characteristic of a plant species or cvcn a particular organ tissuc of that plant 
and plays an important structural role in the plant ccll wall. Polyphenol is the name used 
to encompass many different forms of phenolic compounds. The actual definition conics 
from the Greek "aokV which means a lot, but the term was introduced sonic years ago to 
replace the term vegetable tannin and used the following definition: Water soluble 
phenolic compounds having molecular weights between 500 and 3000 and besides giving 
the usual phenolic reactions, such as ester formation and oxidation, they have special 
properties such as the ability to precipitate alkaloids, gelatin and other proteins. I lowever, 
subsequent use of the term has broadened to include lower molecular weight compounds 
so it now covers natural products with more than one phenolic group. The main classes of 
polyphenols are defined according to their carbon skeleton (Table 1.3), but the most 
commonly found are the flavonoids, which are the most abundant polyphenols in our 
diet. 
Table 1.3 Chemical structure and basic skeleton of sonne classes of polyphenols 










Flavonoids (Figure 1.17 and 1.18) are involved in several biologically important 
mechanisms in plants, such as pigmentation, nitrogen fixation, repair of injury, protection 




















Figure 1.18 The most common form presents with a third carbon ring (C ring) between 
rings A and B 
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Over 4000 flavonoids are known. They are generally found as glycosides, which are 
composed of the phenolic structure, termed the aglycone and a sugar moiety termed the 
glycone (Figure 1.19). Glycosides are generally water soluble and are stored in the 
vacuoles in the plant cell. Fruits are generally richer sources of Ilavonoids than 
vegetables. Beverages such as red wine, coffee, tea and fruit juices are rich sources of 
flavonoids. Moreover, beer and orange juice provide a limited content of flavonoids 
(orange juice is more rich in ascorbate). Some trends regarding the main sources of 
polyphenols and flavonoids consumed can be deduced from Table 1.4. 
Table 1.4 Polyphenol content of commonly consumed foodstuffs. The number of different 
polyphenols is shown in various quantities of different foodstuffs. Adapted frone Scalbcrt 
and Williamson, 2000 
Foodstuff Phenolic Flavanols Proanthoc Anthocya Catcchin Reference 
acids yanidins nins monomers 
Potato, 28 Vinson et 
200 g al 1998 
Tomato, 8 1 Crozier et 
1009 al 1997 
Lettuce, 8 1 Vinson et 
100 g al 1998 
Apple, 11 7 200 21 llertog et 
200 g al 1992 
Cherry, 37 1 35 200 3 Clifford 
50 g 1999 
Dark 86 16 Adamson 
chocolate, et al 1999 
20 g 
Red wine, 12 2 45 4 34 Silva et al 
125 mL 1992 
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GLYCOSIDE = AGLYCONE + GLYCONE 
I11 
anthocyanin anthocyanidin sugar 
Figure 1.19 The different components of a flavonoid glycoside. Anthocyanidin is an 
extended conjugation made up of the aglyconc of the glycoside anthocyanins. Next to 
chlorophyll, anthocyanins are the most important group of plant pigments visible to the 
human eye 
A great number of plant medicines contain flavonoids, which have been reported by 
many authors to have antibacterial, antithrombotic and vasodilatory actions (Halliwell 
and Gutteridge, 1998). There is a very great structural diversity of flavonoids, which is 
based on the following components: Different types of aglycone that differentiate the 
flavonoid subfamilies (Figure 1.20) and substitution of the aglycone by hydroxyl and 
methoxyl groups. The above structural components result in the great variety and the 
various classes of flavonoids: flavonols, flavanones, flavones, anthocyanins and 
isoflavonoids (Figure 1.20 and Table 1.5). 
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Flavone Flavonol 
Figure 1.20 Core structures of the various subclasses of flavonoids. Further variety is 





Table 1.5 Six different classes of flavonoids, including class members and plant sources 
Important Class Plant Sources 
Flavonoid Class Members 
Flavanols Catechins Green tea, grape seeds, pine bark 
Flavones and Quercetin, kaempferol Apples, green tea, ginkgo leaves, 
flavonols grape skins, milk thistle fruits 
Proanthocyanidins Oligomeric catechins Pine bark, grape seeds, leaves of 
bilberry, birch, ginkgo biloba 
Flavanones Hesperidin, naringin Citrus peels 
Anthocyanins, Cyanidin, delphinidin, Red and black grapes, red wine, 
anthocyanidins malvidin, petunidin bilberries 
and 
anthocyanosides 
]soflavones Genistein, daidzein Soy beans 
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1.2.2 Bioavalaibility and metabolism of fiavonoids 
The structural diversity of polyphenols makes the estimation of their content in food 
difficult. Also food fractionation may result in a loss or enrichment of some phenolic 
compounds (Scalbert and Williamson, 2000) . It 
is extremely difficult to estimate the 
average daily intake of polyphenols, because of structural diversity and variation of 
content in particular foodstuffs. However according to published results (Kulhnau, 1976), 
the daily Western intake of mixed flavonoids have been estimated to be in the range of 
0.5 to 1 g, although recent studies have reported that the actual daily intake is lower 
(iertog et at., 1993). The most abundant flavonoids in the diet are flavonols, flavanols, 
anthocyanins and their oxidation products. Other polyphenols, which account for one 
third of the total intake, are phenolic acids. The maximun concentration of flavonoids in 
plasma rarely exceeds 1 µM, after the consumption of 10-100 mg of a simple phenolic 
compound (Scalbert and Williamson, 2000). 
The beneficial effects and properties of the polyphenols depend on their bioavailability 
and most evidence on this concept has been obtained by measuring their concentration in 
plasma and urine after the ingestion of either pure compounds or foodstuffs, which 
contain a portion of the compound of interest. There are few bioavailability studies in 
humans and they show that the quantities of polyphenols found intact in urine vary from 
one phenolic compound to another. Moreover a large part of the polyphenols ingested is 
not found in urine, implying an absorption and excretion process in the bile or 
metabolism by the colonic microflora or the body tissues (Figure 1.21). There are isolated 
reports in the literature (Donovan et al., 1999, Manach et al., 1998) regarding the 








Figure 1.21 Possible routes for consumed polyphenols in humans. Adapted from Scalbert 
and Williamson 
Table 1.6 gives an account for the content of polyphenols in humans in terms of their 
concentration in plasma and their excretion in urine. The maximum concentrations are 
often reached one or two hours after ingestion (Hollman et al., 1992). 
Faeces 
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Table 1.6 Bioavailability in humans of polyphenols consumed alone or in foods. Adapted 
from Scalbert and Williamson 





Quercetin Onion 0.74 1.39 liollman ct al 1997 
Quercetin Apple 0.30 0.44 ilollman et al 1997 
Quercetin Apple juice 0.5 Young et al 1999 
4-O-glucoside 
Quercetin Pure compound 3.2 llollman ct al 1999 
Catechin Red wine 0.072 Donovan ct al 1999 
Catechin Pure compound 2.0 0.45 Balant et at 1979 
Anthocyanins Red wine 1.0-6.7 Lapidot et at 1998 
As already mentioned before certain classes of polyphenols, such as flavonols and 
anthocyanidins (Figure 1.3) are usually glycosylated, with the linked sugar being glucose 
(glucoside) or galactose (galactoside), rhamnose (rhamnoside), arabinose (arabinoside), 
xylose, glucuronic acid or other sugars (glycoside). Removal of the hydrophillic moiety 
will usually be necessary for passive diffusion across the small intestine to occur and 
therefore the first step of metabolism should be removal of the sugar by enzymes 
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(glycosidases), which occur in the food itself or in the cells of the GI mucosa. Non- 
enzymatic cleavage of the sugar moiety does not occur and the absorption of polyphcnols 
is controlled by enzyme specificity with human cells expressing P"glucosidases in a 
tissue specific pattern and colon microflora a-rhamnosidascs breaking attached 
rhamnose, being present in rat tissues. 
It is important to note that the metabolism of polyphenols does not end with the 
hydrolysis of the compound to its free aglycone but there is a number of deconjugation 
and reconjugation reactions involved, similar to those found in the pathways followed in 
drug metabolism, probably occurring in the liver (Scalbert and Williamson, 2000). 
Therefore there is a number of enzymes involved in the polyphenol metabolism, besides 
glucosidases such as catechol-O-methyl transferase and UDP glucuronyl transfcrasc 
involved in conjugation reactions i. e. methylation and glucuronidation. The metabolism 
is continued by the gut microflora with phenolic compounds carried to the colon, whereas 
these phenolics that are processed in the liver and excreted in the bile or directly from the 
enterocyte back to the small intestine, reach the colon as a glucuronide conjugate 
(Scalbert and Williamson, 2000). Colonic microflora catalyse the breakdown of the 
polyphenols to more stable compounds, such as phenolic acids. 
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1.2.3 Anticancer properties of flavonoids 
1.2.3.1 Epidemiology 
Many dietary factors have been associated with cancer prevention. Epidemiological 
studies have been consistenly shown an inverse association between consumption of 
vegetables and fruits and cancer risk. Plant foods contain a variety of flavonoids and 
isoflavonoids, which can reduce susceptibility to cancer. 
One of the the most widely known epidimiological studies is the Finland study (I Iertob 
et al., 1993). A large cohort was followed in the beginning of 1967 for 24 years and a 
report was published by Knekt in 1997. The incidence of cancer at all sites was inversely 
associated with flavonoid intake, with the protection being greatest in individuals who 
were under 50 years of age. The intake involved predominatly compounds such as 
myricetin, quercetin, luteolin and kaempferol. Another study conducted in Spain in 1998 
(Garcia-Closas et al., 1998) accessed the intake of these four flavonoids in relation to 
lung cancer risk in Spanish women and weak associations were observed between least 
susceptibility to lung cancer and flavonoid intake. Similar studies in China and Japan 
have indicated the inverse association with soy food consumption and cancer risk, which 
is linked to the isoflavone genistein. Isoflavonoids are much more narrowly distributed in 
foods with soybeans being the primary human food that is rich in these compounds. This 
has led to the assumption that the lower occurrence of cancer in South East Asia, where 
soy-based foods are the primary food source, is caused by isoflavonoid intake. These 
preliminary investigations have led to the need for more extensive and conclusive studies 
to identify the mechanism of action of flavonoids. Prostate cancer rates were least among 
individuals who consumed diets abundant in rice and tofu and low in men who consumed 
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diets rich in seaweed (Birt et al., 2001) . There is also evidence that dietary soybeans 
exert a protective effect against breast cancer in South East Asia (W u et al., 1998). 
1.2.3.2 Antioxidative ability 
Flavonoids and isoflavonoids might protect against cancer by preventing oxidative 
damage of DNA which is likely to be an important cause of mutation. They serve as 
derivatives of conjugated ring structures and hydroxyl groups that have the potential to 
scavenge the superoxide anion, lipid peroxy radicals and stabilise free radicals involved 
in oxidative processes through hydrogenation reactions. Flavonoids can also chelate 
metal ions, which can give rise to hydroxide anion and alkoxy radicals via the Fenton 
reaction. The ability of these compounds to chelate metal ions, seems to be stronger, 
when possesing a catechol structure, that is two hydroxyl groups close to each other in 
either the A or the B ring of the flavonoid structure. 
The structural components of the flavonoids which are proposed from many studies to be 
responsible for their antioxidative ability are: i) The number of hydroxyl groups in the 
rings, which can donate one electron ii) The C4 keto group and iii) The C2-C3 double 
bond, which is necessary for spreading the negative charge through resonance effects 
(Rice Evans et al., 1996). Flavonoids themselves become free radicals in the process, but 
their conjugated structure allows the remaining orbital electron to be relatively inactive. 
The most powerful flavonoid antioxidant compounds according to TEAC value (Trolox 
Equivalent Antioxidant Activity) that have been reported are: i) Epicatechin gallate of the 
flavanol subfamily ii) Quercetin of the flavonol subfamily iii) The anthocyanidins 
delphinidin and cyanidin (Rice Evans et al., 1996). The flavones luteolin, apigenin, 
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chrysin and the flavonol kaempherol exhibit intermediate efficacies (Rice Evans et al., 
1996). 
1.2.3.3 Estrogenic and antiestrogenic activity 
The estrogenic activity of isoflavonoids was first noted in the 1940s and since then a list 
of isoflavonoids have been shown to be agonists in various animal models (l3irt et al., 
2001). Miksicok in 1993 showed that commonly occuring flavonoids also possess 
estrogenic activity, by using an estrogen receptor dependent transcriptional response 
assay (Miksicek, 1993). The results published in this study revealed an estrogenic 
potential in the following order genistein> kaempferol> apigenin >luteolin > catechin> 
hersperitin (Miksicek, 1993). Compounds such as the above have been shown to protect 
against hormone related cancers. In a different study genistein showed growth inhibition 
of MCF7 cells at concentrations of 10 pM or greater, while at concentrations lower than I 
µM it stimulated growth (Le Bail et al., 1998). The authors proposed that this isoflavone 
can block the effects of oestradiol, even though it is itself oestrogenic. 
The binding affinity to the oestrogen receptor of all the reported isofalvonoids or 
flavonoids seems to be weak, 103 to 105 fold less than 1713-oestradiol as reported from 
Davis et al in 1998 and depending on the concentration of natural estrogens they can be 
antiestrogenic if their circulating concentrations are 100-fold greater than estradiol (Birt 
et al., 2001). Oestradiol has a plasma concentration range of 200-1500 pmol/1 in females 
(Gaw et al., 1999), hence it is possible for isoflavonoids to reach the concentration in 
which they would exert agonistic effects on the oestrogen receptor. 
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1.2.3.4 Antiinflammatory and related effects 
Chronic inflammation can lead to genetic instability, via nitric oxide overproduction and 
subsequent generation of peroxynitrite which is a source of DNA damage. Thus 
flavonoids which act as antioxidants, have profound effects on the function of immune 
and inflammatory cells. Furthermore certain flavonoids can inhibit cell-cell interactions 
by possible effects on adhesion molecule function. Some may also interact directly with 
cytokines and cytokine receptors. 
Some flavonoids can inhibit the enzyme NO synthase and therefore strengthen cellular 
protection against oxidative stress by blocking NO-associated DNA damage. The green 
tea polyphenol epigalocatechin gallate blocked the induction of NO synthase by down 
regulating NFxB activity in macrophages (Naraytna et al., 2001). Moreover it was found 
that daidzein, an isoflavone, potentiates lymphocyte activation, suggesting that these 
effects may be involved in chemoprevention (Narayana et al., 2001). 
1.2.3.5 Antiproliferation 
It is well known that dietary flavonoids behave as general growth inhibitors. Although 
they appear non-toxic to human and animals they have been demonstrated to inhibit 
proliferationin many kinds of cultured human cancer cell lines. Kandaswamni and 
colleagues reported antiproliferative effects of flavonoids found in citrus fruits (quercetin, 
taxifolin, nobiletin and tangeretin) in the early 1990s on squamus cell carcinoma HTB43, 
whereas other studies have shown antiproliferative activities of flavonoids and 
isoflavonoids on A549 non small cell lung carcinoma and B16 melanoma cell lines 
(Kawaii et al., 1999). Strong inhibitory effects of flavone, flavanone and flavonol 
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subfamilies were also demonstrated in six different cancer cell lines with luteolin and 3', 4. 
-dihydroxyflavone being the most potent (Fotsis et at., 1997). The IC50 values of the 
compounds examined in the above study were relatively high (> 40 PM) and only 
eriodictyol, luteolin, quercetin, and tangeretin had IC5o of close to 10 µM or lower in the 
case of luteolin (Kawaii et al., 1999). Similarly Fotsis et at. found that chrysin, apigcnin, 
luteolin and quercetin had IC50 values below 10 µM in SHEP human neuroblastoma and 
MCI~7 cells. 
1.2.3.6 Antimutagenic/Anticarcinogenic activity 
Flavonoids may inhibit carcinogenesis by acting as "blocking agents" by one or more 
mechanisms. The most widely accepted mechanism is the inhibition of metabolic 
activation of a pro-carcinogen to its carcinogenic reactive intermediates. Several 
hydroxylated flavonoids, such as quercetin and myricetin, were found to inhibit the 
mutagenic activity of bay-region diol epoxides of B[a]P, which inhibited the 
tumorigenicity of -2-B[a]P-7,8-diol-9,10-epoxide-2 on mouse skin and in newborn mice 
(Middleton et al., 2000). Several flavones, flavonols and flavanones were shown to 
reduce the mutagenic activity of 2-amino-3-methylinidazo[4,5-f]quinoline (Middleton et 
al., 2000). The carbonyl at C-4, of the flavones was the main functional group required 
for this type of activity. Quercetin was further accessed by other groups for its ability to 
inhibit the initiation process of tumour promoters in the mouse skin carcinogenesis model 
and found to counteract the tumour promoter activity of TPA (Middleton et al., 2000). 
Quercetin also showed anticancer activity in various other animal studies. It inhibited 
hamster buccal pouch carcinogenesis and DMBA induced mammary cancer as well as 
azoxymethanol induced colon cancer in rats (Middleton et at., 2000). Finally various 
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naturally occuring flavonoids were shown to inhibit the activation of aflatoxin B1 to its 
AFB1-8,9 epoxide (Middleton et al., 2000). 
1.2.3.7 Antiadhesive/Antimetastatic properties 
Fotsis and coworkers (1993) used a fractionation assay system by which they extracted 
flavonoids and isoflavonoids present in urine from healthy humans, who were fed a 
vegetarian diet. The extracts were then tested and it was found that genistein was a potent 
inhibitor of endothelial cell proliferation, stimulated by bFGF. Genistein also inhibited in 
vivo angiogenesis and TNF stimulated induction of endothelial cell adhesion molecules 
(Middleton et al., 2000). Other flavonoids investigated by Fotsis and coworkers were 
apigenin, luteolin, fisetin, 2', 3-dihydroxyflavone and 3', 4-dihydroxyflavone, which were 
shown to be antiangiogenic in vitro. The flavonoid (+)-catechin has been shown to bind 
laminin, which is an extracellular molecule involved in invasion and metastasis of tumour 
cells. The effect of laminin on the morphology and adhesion of two cell types M04 and 
M5076 was abrogated by high concentrations of (+)-catechin (Middleton et al., 2000). 
Tangeretin and genistein inhibited the invasion of M04 cells into embryonic chick heart 
fragments in vitro and of a BALB/c mammary carcinoma in vivo respectively (Middleton 
et al., 2000). 
1.2.3.8 Effects on heat shock proteins 
Heat shock proteins are induced usually due to heat stress and other stimuli and are 
involved in protein assembly and in other cell functions. Quercetin and other flavonoids 
inhibited the induction of heat shock proteins in HeLa cells (Middleton et al., 2000). In 
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the same cell line quercetin was found to be a hyperthermic scnsitiser. This flavonoid was 
also shown to block heat shock protein synthesis in K562 cells at different levels 
depending on the temperature used and on the stressor employed. In human colon cancer 
cells treatment of quercetin in a concentration dependent manner abolished the 
development of thermotolerance, which was directly related to inhibition of heat shock 
protein synthesis. 
1.2.3.9 Induction of detoxification enzythes 
Another proposed mechanism for protection against cancer by flavonoids includes 
induction of Phase II metabolism enzymes. Many environmental carcinogens are 
oxidised to harmful metabolites and then detoxified by phase II enzymes into forms that 
are relatively inert and more easily excreted. There is significant evidence that cellular 
resistance to carcinogen exposure can be increased by induction of detoxifying enzymes. 
Two of the most important are quinone reductase and glutathione S transferase. 
Glutathione S transferase (GST) catalyses the conjugation of a variety of compounds with 
the tripeptide glutathione. Glutathione conjugation serves as a protective mechanism by 
which potentially toxic electrophillic metabolites are converted into less reactive 
compounds. Induction of GST has been noted for certain dietary antioxidant flavonoids, 
such as quercetin and epicatechin (Narayana et al., 2001). Moreover compounds such as 
B-naphthoflavone, which is a synthetic flavone derivative have been shown to induce 
GST (Narayana et al., 2001). 
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Similarly quinone reductase is a major enzyme in xenobiotic metabolism that catalyses 
two electron reductions and protects cells from potentially harmful carcinogenic species, 
such as free radicals, hydroperoxides and peroxide radicals generated by one electron 
reductions. It has been shown by Wang et al 1998 that this enzyme can be induced in a 
colonic Colo205 cell line, by isoflavones with genistein being the most potent inducer 
(Birt et al., 2001). 
1.3 Cytochrome P450s 
1.3.1 P450s in general 
Cytochrome P450 is classified as a haem-containing enzyme with iron protoporphyrin IX 
as the prosthetic group. It is the terminal oxidase component of an electron transfer 
system, present in the endoplasmic reticulum responsible for the oxidation of almost all 
drugs. P450s contain haem b, which is not covalently bound to the polypeptide chain. 
The porphyrin ring provides four of the six ligands required for octahedral 
stereochemistry (four nirogen atoms). The 
fifth axial ligand is the thiolate group of a 
cysteine residue, compared to other 
haemoproteins, such as haemoglobin, where it is the 
nitrogen atom of a histidine residue, whereas the sixth axial co-ordination site 
is vacant. 
These enzymes are named after the characteristic y (Soret) absorbance peak at 450nm, 
which is observed in the electronic spectra of their 
ferrous (Fe2+) CO adducts and derives 
from cysteine axial ligation. In the cell P450s are located either 
in the smooth 
endoplasmic reticulum or 
in the mitochondria, since they require a membrane for their 
catalytic activity. They are composed of several 
domains; there is a hydrophobic N- 
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terminus, which acts as a membrane anchor for the P450s; a substrate binding site; an 
oxygen binding site; and a free hydrophillic C terminal. 
Cytochrome P450 is not a single enzyme, but rather consists of a family of closely related 
enzymes and exists as multiple forms of monomeric molecular weight of the range 
45,000-55,000 Daltons (Gibson and Skett, 2001). To date over 36 gene families have 
been identified, 12 of which exist in all mammals and this includes over 800 cytochrome 
P450 genes, encompassing all of the major phyla, such as animalia, plantae, fungi and 
monera kingdoms (Gibson and Skett, 2001). This resulted in the construction of a 
commonly agreed nomenclature system, in order to avoid confusion regarding the 
identity of individual enzymes. For example the nomenclature of CYP2C9 is as follows: 
The CYP abbreviation refers to the protein which is encoded by the cyp gene. The first 
numeral refers to the family with members of the same family having more than 40% 
amino acid sequence homology. The capital letter refers to the subfamily with members 
of the same subfamily having more than 55% aminoacid sequence homology. The last 
numeral refers to the isoform. Table 1.7 gives an account of the mammalian cytochrome 
P450 families. 
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Table 1.7 Mammalian Cytochrome P450 families. Adapted from Gibson and Skett 2001 
P450 family No. of subfamilies No. of isoforms Reactions 
CYP1 2 3 Drug metabolism 
CYP2 8 58 Drug and steroid met. 
CYP3 2 10 Drug and steroid met. 
CYP4 6 20 Fatty acid w hydroxylations 
CYP5 1 1 Thromboxane synthase 
CYP7 1 1 Cholesterol 7a hydoxylase 
CYP 11 2 4 Steroid 11p hydoxylase 
CYP17 1 1 Steroid »p hydroxylase 
CYP19 1 1 Aromatase 
CYP21 1 2 Steroid 21 hydroxylase 
CYP24 1 1 Vitamin D3 25 hydroxylase 
CYP27 1 1 Cholesterol 27 hydroxylase 
Currently there are about 60 human P450s and analysis of the human genome sequence 
has indicated that it is unlikely to be any more. Functionally there are two broad classes 
of P450, those who metabolise xenobiotics (foreign compounds) and includes CYP1, 
CYP2, CYP3 and to a lesser extent CYP4 and those who metabolise endogenous 
compounds such as cholesterol and steroid hormones and includes CYP5, CYP7, CYP 11, 
CYP17, CYP19, CYP21, CYP24 and CYP27. The xenobiotic metabolising forms of 
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P450 are also capable of metabolising endogenous compounds and thus possess other 
endogenous functions. 
The liver is the main normal tissue in which P450s are expressed. CYP 1 A2, CYP2A6, 
CYP2C, CYP2D6, CYP2EI and CYP3A4 are all present in the liver. CYP3A4 is the 
predominant CYP enzyme and accounts for about 30% of the total human hepatic P450. 
However individual cytochrome P450 forms are also expressed in specific extrahepatic 
tissues, including small intestine kidney and lung. 
P450s catalyse a variety of chemical reactions. The most important and intensively 
studied drug metabolism reaction is the Mixed Function oxidase (MFO) reaction. The 
general equation for the reaction is as follows: 
NADPHH+ + 02 + RH -+ NADP+ + H2O + ROH, 
where i}H can be an oxidisable drug substrate and ROH the hydroxylated metabolite. 
During this reaction one atom of oxygen is incorporated in the metabolite and the other 
atom is reduced to water. The MFO system also requires another enzyme called NADPII 
cytochrome P450 reductase, a flavoprotein consisting of flavin mononucleotide (FMN) 
and one flavin adenine dinucleotide (FAD). The central features of the cytochrome P450 
catalytic cycle are outlined in Figure 1.21 and can be summarised in six steps. 
Step 1: This step involves binding of the substrate to the ferric state (Fe3) of P450. In 
the free (resting) enzyme the sixth co-ordination site is occupied by water and this results 
in a stable low spin configuration with a reduction potential of -300mV. Upon binding of 
the substrate near the heure, the water ligand is lost from the Fei+, which then becomes 
high spin with an increase in reduction potential to -170mV. The substrate does not ligate 
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the Fe3+ but it is held in a binding pocket interacting by various means, such as 




(7) (1 } Fe3+ 
Fe3+ 
RH 1st e- 
RaH (2) 
Fe 2+ (ý} RH 02 
(Fe-0) 
RH... s+Fe............. 
......... (5) (4) RH 
0 2 
H2 Fe3+ 2 2nd e- 
+ -RH --------------. 2H 
Figure 1.21 The catalytic cycle of cytochrome P450 
Step 2: This involves the first electron reduction of substrate-bound ferric cytochrome 
P450 to the ferrous state (Fe2). Raising the reduction potential upon substrate binding 
makes the Fe 3+ more easily reducible to Fee+. The electron required for this reduction is 
initially derived from NADPHH+ and is transferred by the flavoprotein NADPH- 
cytochrome P450 reductase. 
65 
Step 3: This step involves binding of molecular oxygen to the ferrous substrate 11450 
complex. This reaction is not well characterised in the mammalian system, due to 
unstable nature of oxyferrous substrate complex. 
Steps 4,5 and 6. These steps involve electron rearrangement, introduction of the second 
electron and subsequent oxygen insertion in the substrate with hydroxylated metabolite 
release. Step 5 involves the input of the second electron, usually derived from NADI'I i- 
cytochrome P450 reductase. Step 6 involves two steps namely abstraction of a hydrogen 
atom from the substrate and oxygen rebound. The oxidation states of iron in the 
intremediate states are not precisely known, but are thought to involve metal to ligand 
charge transfer, such that the complex is low spin ferric iron with superoxide. After the 
second electron is passed, the newly formed Fee+/O2~ intermediate can undergo further 
metal to ligand charge transfer to give ferric peroxide substrate bound P450 Fei+/O2 2, 
which rapidly decays to give water and a Fes+ oxo compound, a seven co-ordinate Fes' 
complex, with 02. acting as a bidentate ligand. This preferentially exists as the sixth co- 
ordinate radical species Fe4+-O', which reacts with the substrate to give hydroxyfcrryl 
intermediate and substrate radical. Finally via the rebound mechanism the hydroxyferryl 
species reacts with the substrate radical to give hydroxylated substrate and five co- 
ordinate ferric heure. 
These enzymes are very powerful catalysts, since in the absence of P450 this oxidation 
requires a very high temperature. The usual outcome of P450 metabolism is activation or 
inactivation of the substrate; paradoxically sometimes P450 can lead to either acute or 
chronic cellular toxicity (Patterson and Murray, 2002). 
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1.3.2 CYP1 family enzymes 
The human CYPI gene family, which is one of the major cytochrome P450 involved in 
the metabolism of xenobiotics is now known to consist of throe individual forms 
classified into two subfamilies. The CYP1A subfamily contains two well characterised 
but distinct members, CYP 1 Al and CYP 1 A2. CYP IA1 is primarily expressed in 
extrahepatic tissues, whereas CYP1A2 is a major P450 expressed in the liver, accounting 
for approximately 15% of total P450 activity. A second human CYI'I subfamily was 
identified almost 10 years ago, which to date contains only one member CYPli31. 
Sequence analysis shows about 40% homology of CYP 1BI with both CYP 1AI and 
CYP 1 A2 (Kress and Greenlee, 1997). 
Murray et al. in 1997 showed with immunohistochemical studies, that CYI' IBI is 
expressed in a wide variety of tumours and only in 5 out of 127 tumor samples CYP 1ß1 
was not detected. In every type of cancer CYP1B1 immunoreactivity was localised 
specifically to tumour cells with non tumour cells, including inflammatory and 
endothelial cells present in the sections of the tumour, showing no immunoreactivity 
(Murray, 2000). The samples tested were primary malignant tumours of bladder, brain, 
breast, colon, connective tissue, oesophagus, kidney, liver, lung, lymph node, small 
intestine, testis, stomach and uterus tissues (Murray et al., 1997). Elevated expression of 
CYP 1B1 has also been reported in primary ovarian cancer, (92% of 167 samples tested) 
with the enzyme being localised in the cytoplasm (McFadyen et al., 1999). The same 
study showed overxpression of CYPIBI in metastatic ovarian cancer (94% out of 48 
samples). The overexpression of CYP 1B1 in colon, lung and breast cancer has been 
confirmed by various other studies (Murray, 2000, McFadyen et at., 2001 ). It has also 
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been shown that CYP1A1 is expressed in breast cancer but to a lesser extent (25%) 
(McKay et al., 1995). However other studies show that CYPIAI mRNA is found to a 
larger extent in breast tumours (possibly because of the smaller number of samples being 
tested) and also that CYP1AI mRNA is present in normal breast tissues (Iluang ct al., 
1996). CYP1A1 activity was identified in colon cancer and in normal colon, whereas in 
another study CYP1A overexpression was identified in colon canccr with no detection of 
such expression in normal tissues respectively. CYPIAI mRNA has been identified by 
northern hybridisation in lung cancer (Patterson and Murray, 2002) and CYP1Al activity 
has also been detected in normal small intestine in small amounts. CYP IAI und CYP I A2 
have been shown to be expressed in squamus cell carcinomas (Nakajima et al., 1991). 
The same enzymes were detected in both hepatocellular carcinoma and in normal liver by 
another study, but the authors suggested a possible downregulation of CYP1A expression 
(McKinnon et al., 1991). 
1.3.3 Carcinogen activation hypothesis 
Since the CYP1 family enzymes and mostly CYP1A1 and CYP1BI have been shown to 
be expressed in a variety of tumors and bearing in mind that they are involved in the 
metabolism of xenobiotic substances, a lot of studies have related them to carcinogenesis. 
It has been proposed by certain studies that CYPI family enzymes are capable of 
activating procarcinogens and mutagens by forming reactive intermediates from 
compounds such as polycyclic aromatic hydrocarbons (PAH) (Shimada et al., 1996, Kim 
et al., Kress, 1997). The most commonly encountered members of PAH family in the 
literature include benzo[a]pyrene, 3-methylchloranthrene and 7,12- 
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dimethylbenzanthracene. In vitro metabolism of benzo[a]pyrenc by CYI'1 enzymes loads 
to the formation of the ultimate carcinogens diol epoxide, phenol metabolites and 
quinone metabolites (Kim et al., 1999). Phenol metabolites are less mutagcnic compared 
to quinone, since they can be detoxified by Phase II enzymes. Diol cpoxides have been 
shown to cause mutations by attacking the p53 tumour suppressor gene in normal 
bronchial epithelial cells (Kim et at., 1999). The same epoxidcs have been shown to 
induce mutations in proto-oncogenes involving cell proliferation such as 1I-ras. CYP I 
family enzymes have also been shown to catalyse the metabolism of aryl amines to 
carcinogenic compounds, with CYP1A2 being highly active in catalysing several aryl 
amines, particularly 2-acetylaminofluorene, 2-amino-3-methylimidazo[4,5-f]quinolinc, 2- 
amino-6-methyldipyridol and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxalinc and 
CYP1B1 being the most active in catalysing activation of 2-aminoanthracene (Shimada ct 
al., 1996). 
PAHs are not only substrates for CYP 1 family enzymes but they have also been shown to 
induce the expression of these enzymes through a specific cytosolic receptor termed the 
aryl hydrocarbon receptor (AhR). As shown in Figure 1.22 PAiIs enter the cell and 
combine with cytosolic AhR. AhR in its free form exists with other proteins llsp90 and 
AhR interacting protein (AIP). Upon binding with the inducer these two proteins 
dissociate with AhR and AhR-induced complex is translocated to the nucleus. There it 
binds with another protein called AhR nuclear translocator protein (ARNT) and forms a 
heterodimer. The inducer-AhR-ARNT complex targets a number of genes in the nucleus. 
This complex interacts with specific gene regulatory sequences called xenobiotic 
responsive elements (XREs) of the sequence 5'-TNGCGTC, which function as 
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transcriptional enhancers and negative control elements, situated at approximately I 
kilobase of the transcriptional start site in the 5' flanking region of the gene. This initiates 
transcription of CYPI family genes (Gibson and Skett, 2001). 
AHR Iigand 
0 








AHR N2NT r Increased 
aP CYP1A1, CYP1A2, 
CYPIB1 transcription 
Figure 1.22 Receptor mediated induction of CYP1 family enzymes 
The AhR is a cytosolic protein of molecular weight of 88kDa and is a member of the 
family of the basic helix-loop-helix transcription factors. It consists of several domains, 
such as ligand binding and DNA binding. It is important to note that the AhR/ARNT 
complex is involved in the induction of other genes besides the CYPI family, which 
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encode for other xenobiotic metabolising enzymes, such as GST and UDP-glucuronyl 
transferase enzymes (Gibson and Skett, 2001). The ARNT is a nuclear protein of 
molecular weight of 86 kDa and again consits of distinct functional domains responsible 
for DNA binding, dimerisation and nuclear localisation (Gibson and Skett, 2001). 
The compound that has been extensively used for the induction of CYP1 family enzymes 
from various studies is 2,3,7,8-Tetrachlorodibenzo p-dioxin (TCDD). TCDD elicits a 
diverse spectrum of biological and toxicological responses. It induces CYP 1AI 
expression in HepG2 cells via AhR mediated mechanism (McKinnon et al., 1991). 
CYP1B1 was constituvely expressed in human renal adenocarcinoma cell line (ACIIN) 
and the expression was increased after induction with TCDD 8-fold, whereas no 
induction was seen in HepG2 cells. In early passage human-mammary epithelial cells 
(HMECs) isolated from reduction in mammoplasty tissue of seven individual donors very 
high levels of AhR and ARNT protein were reported to be expressed (Larsen et al., 
1998). CYP1B1 was shown to be constituvely expressed in HMECs as well, whereas 
CYP1A1 expression could be induced by TCDD (Larsen et al., 1998). A comparison of 
protein expression levels of AhR and ARNT between the breast cancer cell line and 
human-mammary epithelieal cells revealed that the level of AhR expression was many 
time higher in cultured HMECs as compared to MDA-MB 231 cells (Larsen et al., 1998). 
The same study showed that CYP1B1 and CYP1A1 demonstrated significant levels of 
7,12- dimethylbenzanthracene (DMBA) metabolism, in enzyme assays, with CYP 1AI 
being 6-fold more efficient. TCDD induces the expression of CYP1 enzymes in a variety 
of other cell lines (Larsen et al., 1998, Jana et al. 1999, Dohr et al., 1995). 
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CYPI family isozymes are further involved in the metabolism of oestrogens, besides 
PAHs and related compounds. It is known that the oestrogens 17P-ocstradiol (132) and 
oestrone (EI) are metabolised via two major pathways: formation of the 2- and 4- 
catechol oestrogens and 16a hydroxylation. CYP1B1 catalyses the C-4 hydroxylation of 
oestradiol to the corresponding catechol, a product shown to be carcinogenic in animal 
models (Kristensen and Borresen-Dale, 2000). Human breast tissue expresses high levels 
of CYP1B1 and as a consequence breast cancer has higher levels of 4-011 ocstradiol than 
normal breast tissue. CYP1A1 also catalyses the C-2, C-4, C-6a and C-15a 
hydroxylation of oestradiol favouring the C-2 hydroxylation compared to C-4 for 
CYP1B1 (Badawi et al., 2001). CYP1A2 catalyses C-2, C-4, C-16a hydroxylation and 
favours C-16a and C-2 hydroxylation of oestradiol (Badawi et al., 2001). Unless 
detoxified catechol oestrogens may be oxidised to electrophillic metabolites, catechol 
oestrogen quinones that can react with DNA to form depurinating and stable adducts. 
These adducts, particularly depurinating adducts, can lead to oncogenic mutations and 
may subsequently initiate many human cancers. Thus it can be hypothesised that 
induction and subsequent expression of CYP1 family enzymes may lead to increased 
synthesis of catechol oestrogens and depurinating DNA adducts. There are several studies 
which have demonstrated increased rates of formation of C-2, C-4 and C-16a 
hydroxylated metabolites of E2 after induction of CYP 1 family enzymes by TCDD and 
related compounds via AhR either in MCF7 cells or in animal models and suggest that 
these may be factors contributing to the biological effects associated with exposure to 
these agents (Badawi et al. 2000, Badawi et al. 2001, Morgan et at., 1998, Spink, 1998). 
Other studies have related the catalytic activity of these enzymes to endocrine regulation 
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and increased toxicity of oestrogens which can eventually lead to the formation of 
oestrogen dependent tumors (Hayes et al., 1996, Liehr and Ricci, 1996). It has also been 
reported that the oestrogen C-4 hydroxylase activity in breast cancer cells can be used as 
a potential tumor marker in combination with C-2 hydroxylase activity (Liehr and Ricci, 
1996). An elevated ratio of 4/2 hydroxy oestradiol formation in neoplastic mammary 
tissue may be a useful marker of benign or malignant breast tumors (Lichr and Ricci, 
1996). 
1.3.4 Rescue enzyme hypothesis 
P450s are believed to have existed since the beginning of life over 3.5 billion years ago, 
but the P450s responsible for foreign compound metabolism appear to have arisen about 
400 to 500 million years ago and it is believed that these enzymes were needed to 
metabolise and detoxify chemicals found in plants(reviewed in Gonzalez and Gelboin, 
1994). In the plant-animal "warfare" hypothesis plants produce toxins to kill predators 
and animals evolve P450s to detoxify these toxins and as this process continues over 
millions of years new catalytic activities of P450s will develop (reviewed in Gonzalez 
and Gelboin, 1994). 
Similarly, one can speculate that in the field of chemical carcinogenesis the P450s and 
other foreign compound metabolising enzymes would evolve for a purpose beneficial to 
the animal. Indeed, the gene sequence of CYP1B1 has been determined and it is thought 
that the CYP1B branch may have separated from CYP1A about 300 million years ago 
(reviewed in Gonzalez and Gelboin, 1994). 
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Although CYP1BI has been implicated in carcinogenesis, this does not adequately 
explain the cause of tumours, since there are many mutagenic origins and oncogcnic 
transformations that result in various types of cancer, and yet CYP 1B1 appears to be 
present in a wide variety of tumours irrespective of their oncogenic origin (Murray ct al., 
1997). CYP1B1 has been proposed to be a tumour suppresor enzyme, since it was shown 
to catalyse the formation of picetannol, a stilbene which possesses antileukaemie activity, 
from resveratrol, a cancer preventative agent found in red wine (Potter et al., 2002). The 
authors of this study suggest that with respect to carcinogenesis, it does not matter if 
carcinogens are activated in cancer cells, since they are already cancerous. Relevant 
observation to support such a hypothesis is the fact that CYP 1B1 can be induced in skin 
cells on exposure to mutagenic UV light. CYP1B1 and the CYP1A subfamily enzymes 
can be induced via the AhR in an alternative way as to that previously described (PAiIs 
and related compounds). The genes encoding for CYP 1A and CYP 1BI proteins, are 
controlled by an inducible transcriptional complex termed the hypoxia inducible factor-I 
(HIF-1) (Blancher and Harris, 1998, Wood et at., 1996). HIF-1 is a heterodimeric DNA 
binding complex consisting of two basic helix-loop-helix (bHLFI) PAS (Per-ARNT-Sim) 
proteins HIF-la and HIF-1 P (Blancher and Harris 1998, Wood et al., 1996). HIF-1 ß is 
actually the ARNT the dimerisation protein of AhR. HIF-1 a is only induced under 
hypoxic conditions, where it dimerises with ARNT and the resulting complex induces the 
transcription of CYP1 family genes by binding to the relevant responsive elements 
(HREs or XREs) (Blancher and Harris, 1998, Wood et al., 1996). One of the major 
driving forces of tumour progression is hypoxia. The vasculature of tumours is relatively 
poor, which leads to decreased blood perfusion and uptake of oxygen by the cancer cells. 
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These low oxygen conditions may play an important role in cellular metabolism and may 
be the stimulus for induction of CYP 1$1 and the other CYP 1A enzymes as a defense 
mechanism against tumor promotion. 
1.4 Aims 
The purpose of the work described in this thesis was to examine whether, dietary 
flavonoids can prevent cancer through inhibition of CYP 1 family enzymes (Chapter 3), 
thus preventing activation of pro-carcinogens, or through selective CYPI enzyme 
mediated metabolism (Chapters 4,5,6), leading to formation of more cytotoxic species 
than the parent compound. The ability of dietary flavonoids to induct CYPI family 
enzyme expression (Chapter 7) and therefore (stimulate their own metabolism in cancer 
tell lines was also investigated. In addition with the above aims this would lead to a more 
conclusive concept of how dietary flavonoids ititeract with CYP I family enzymes and 
might provide evidence for a new mechanism of their chemopreventative action. 
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2. MATERIALS AND METHODS 
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2.1 Chemicals and enzymes 
Apigenin (95% pure), luteolin (98% pure), quercetin (98% pure), myricctin (85% pure), 
kaempferol (90% pure), chrysin (96% pure) and baicalein (98% pure) were from Sigma 
(Poole UK), diosmetin, scutellarein and sinensctin (99% pure) from Indofine 
(Hillsborough NJ, USA) and eupatorin, eupatorin-5-methyl ether, cirsiliol and genkwanin 
(97% pure) from Lancaster (Heysham UK). Stock solutions were prepared in dimethyl 
sulfoxide and stored at -20°C. 7-ethoxy resorufin was purchased from Sigma (Poolc UK), 
prepared as 1 mM stock solution in dimethylsulfoxide and kept at 4°C. CYP I supcrsomcs 
were purchased from BD Biosciences (Cowley UK). They are microsomes derived from 
baculovirus infected cells (www. bdbiosciences. com). Solvents for the IIPLC analysis 
were of HPLC grade and purchased from Fisher (Loughborough, UK). Phosphate buffer 
reagents, NADP+, Glucose-6-Phosphate, Magnesium Chloride, Glucose-6-phosphate 
dehydrogenase, NADPH, FCS, EGF, Insulin, Hydrocortisone, DMEM, MTT, RPM!, PI, 
Rnase, DTT, western blotting RNA extraction, RNA and DNA gel electrophoresis 
reagents were obtained from Sigma (Poole UK). ECL was purchased from Amersham 
(Little Chalafont UK). All reagents except the HPLC solvents, tissue culture and 
molecular biology reagents were of analytical grade. 
2.2 Cell lines 
MDA-MB 231 was derived from pleural effusion of a Caucasian 51 year old female with 
adenocarcinoma of the breast (www. lgcpromochem-atcc. com). MDA-MB 468 was 
derived from pleural effusion of a Black 51 year old female with metastatic 
adenocarcinoma of the breast (www. lpromochem-atcc. com). MCF7 was derived from 
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a Caucasian 69 year old female with breast adenocarcinoma, whereas MCFIOA was 
derived from the mammary gland of a 36 year old Caucasian female with fibrocystic 
disease (www. lgcpromochem-atcc. com). MCF1OA cells were grown in serunm-free 
medium with low Ca' concentrations and lost their ability to undergo senescence 
(www. l cpromochem-atcc. com). 
2.3 EROD and phosphate buffer solutions 
Solution A was prepared by mixing NADP+ (20 mg/ml), Glucose-6-Phosphate (20 
mg/ml) and Magnesium Chloride (13.3 mg/ml). Typically a 10 ml solution was prepared, 
which was aliquoted to 0.5 ml solutions that were stored at -20°C. Solution B was 
prepared by diluting Glucose-6-phosphate dehydrogenase (G6PDII) with phosphate 
buffer to a final concentration of 40 U/ml. The solution was aliquoted to 0.1 ml solutions, 
which were stored at -20°C. Solution C was prepared freshly by mixing solutions B and 
A with phosphate buffer (100 mM) and water to a ratio of 1: 5: 5: 39 respectively. 7- 
ethoxyresorufin solution was prepared as a stock solution by diluting I mg of compound 
with 4.15 ml of DMSO to a final concentration of 1 mM. The solution was kept at 0°C. 
Phosphate buffer for EROD assay and drug metabolism experiments was prepared by 
diluting 8.375 g disodium hydrogen orthophosphate and 5.579 g of potasium dihydrogen 
orthophosphate in 1L of water. The pH of the solution was adjusted to 7.4 with additions 
of small portions of NaOH (1M). The solution was finally stored at 4°C. 
78 
2.4 7-Ethoxy resorufin-O-deethylase activity 
7-Ethoxy resorufin-O-deethylase activity of the three CYPI enzymes was determined 
using continuos fluorimetry with NADPH as a cofactor (Burke ct al., 1994). 
Inhibition of ethoxy resorufin-O-deethylase activity. The reactions were carried out in 96- 
well plates and each incubation in each well (100 µl) contained supcrsomes (5 pmol/ml), 
solution C (NADP+ 1.3 mM, Glucose-6-phosphate 3.3 mM, MgCl2 3.3 mM and glucose. 
6-phosphate dehydrogenase 4 U/ml), 7-ethoxyresorufin (5 µM), phosphate buffer (30 
mM) and inhibitor as appropriate. For an initial screen five concentrations of inhibitor 
were achieved (25,2.5,0.25,0.025,0.0025 and 0 µM). A background was also prepared 
containing phosphate buffer, supersomes and solution C. Reactions were initiated with 
the addition of supersomes, carried out for 20 min at 37°C and were terminated by the 
addition of 100 µl of methanol. The samples were cooled in icc and fluorescncc was 
measured at excitation X 530 nm and emission 590 nm. The results were plotted as 
percentage of inhibition compared to control against inhibitor concentration, using Prism 
software. IC50 were calculated from the graph obtained from each inhibitor. 
2.5 Flavonoid metabolism 
Incubations (100 µl) contained supersomes (20 pmol/ml CYP1BI, CYP1A1, CYP1A2) 
NADPH (0.5 mM) MgC12 (0.5 mM), phosphate buffer (20 mM) and flavonoid (10 µM). 
Following incubation at 37°C, samples were taken at 5 minute intervals until 20 minutes. 
On sampling reaction was terminated by the addition of 100 µl of methanol: acetic acid 
mixture (100: 1). Incubates were centrifuged at 3,500 g for 20 minutes at 4°C. 
Supernatants were analysed by reverse phase HPLC according to the following method: 
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A Luna C18 4.6 x 150 mm 5µ column was used. Solvent A contained water, 1% 
acetonitrile and 0.5% acetic acid and solvent B contained methanol, 4% acetonitrile and 
0.5% acetic acid. The following gradient program was used: 60% solvent A and 40% 
solvent B at time 0,10% solvent A and 90% solvent B at time =10 minutes. Final 
conditions were held for 1 minute until returning to initial solvent composition 
conditions. 8 minutes were left for column reequilibration after each run. Detection was 
monitored by UV between 325-350 nm depending on the compound used and the assay 
was carried out at 37°C. Flow rate was I ml/min. 
2.6 Kinetic experiment 
The same methodology as 2.4 was followed. The incubation time and cnzymc 
concentration were standardised by preliminary experiments (usually 5-10 min and 5-10 
pmol/ml of CY? ), depending on each compound and a concentration range of flavonoid 
was achieved in each reaction (10,8,4,2,1,0.5,0.25 µM). 
2.7 Cell culttli e and the maintance of cell lines 
MCF-7 and MDA-MB 468 cells were maintained in RPMI 1640 with and without phenol 
red respectively. The use of phenol red-free medium is advised when steroid hormone 
effects are being studied, because phenol red can act as a oestrogen receptor agonist 
(Davis JM, 2002). MDA-MB 468 cells have been shown to be oestrogen receptor 
negative (Spink DC et al., 1998), so using a phenol red-free medium would ensure that 
they would retain this pattern of gene expression. The medium also contained Glutamax I 
(Life Technologies) and 10% (v/v) heat inactivated foetal calf serum. The cells were 
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grown at 37 °C, 5% CO2 /95% air with 100 % humidity and passagcd using trypsin 
EDTA. MCF1OA cells were maintained in DMEM at 37 °C, containing Glutamax 1,10% 
(v/v) heat inactivated foetal calf serum as above , EGF (20 nb/ml), Insulin (10 µb/ml) and 
hydrocortisone (500 ng/ml). MDA-M13 231 cells were maintained in the same conditions 
as MCF7 cells. 
2.8 MTT cytoxicity assays 
2x 103 MCF7 cells were plated in 100 µl of medium in 96-well flat-bottomed plates. 
After 4 hrs to allow maximum cell adherance, 100 µl of medium containing TCDD, or 
medium with 0.2% (v/v) DMSO as control were added to the wells to give a final 
concentration of 10 nM or 0.1% (v/v) DMSO. After 24 lvs the medium was carefully 
aspirated and 100 µl of fresh medium was added. Within 30 minutes compound was 
added in quadruplicate in 100 µl medium to give a final concentration of not more than 
0.1% (v/v) DMSO. The cells Were then allowed to grow for 4 days to give 80-90% 
confluence in the control wells. 50 µl MTT (2 mg/ml in PBS) was then added to each 
well for 3 hrs. All medium was aspirated and the formazan product generated by viable 
cells was solubilised with 150 µl of DMSO. Plates were vortexed and the absorbance at 
540 nm determined using a UV plate reader. Results were expressed as the percentage of 
100% (control) proliferation and the IC50 calculated using Graphpad Prism software. 
Dose range generally was in half log dilutions e. g. 100,30,10,3,1,0.3,0.1,0.03,0.01, 
0.003,0.001 µM. In the case of MDA-MB 468 and MCFIOA cells the assay was 
performed as above with the exception that no TCDD was added to induce the cells. For 
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inhibition studies, inhibitor was added to a final concentration of 2 tM in 200 jtI of 
medium along with the compound. 
2.9 Metabolism in cell lines 
2x 104 cells/ml were plated in 24-well flat bottomed plates and left to grow for 48 hours. 
MCF7 cells were preinduced with 10 nM of TCDD 24 hr prior to the experiment. The 
medium was aspirated and the cells were washed once with PBS. Compound was added 
in 200 µl of medium at a final concentration of 10 µM. At least three wells of the plate, 
from each cell line were kept with no compound for protein determination via the 
Bradford assay (Bradford, 1976). The protein concentration of the cells, was estimated 
approximately to be 0.5 mg/ml. The cells were incubated at 37°C for 45 minutes. The 
medium was then removed and the compound was extracted with the addition of 1% 
acetic acid in methanol. 200 µl of reporter lysis buffer was added to each of the wells and 
the cells were left for 30 minutes at -20°C. The cells were then thawed and with the aid 
of a scraper detached from the bottom of the wells. 200 µl of 1% acetic acid in methanol 
was added to the cell lysates. Both cell and medium samples were centrifuged for 15 
minutes at 13,000 rpm and finally analysed with HPLC. 
2.10 Western blotting 
MDA-MB 468 and MCF1OA cells were trypsinised and resuspended in 200 pl lysis 
solution (Sigma, Poole UK) containing protease inhibitor cocktail (Sigma, Poole UK) and 
DTT (1 mM). The protein concentration of that sample was estimated by the Bradford 
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assay (Bradford MM, 1976), so that it would not exceed 0.8 mb/ml per sample. 20 lt) of 
that sample were mixed with SDS PAGE Laemmli buffer (iaemmli UK, 1970) 
(containing 5% mercaptoethanol) in 1: 1 ratio. The sample was heated at 100 'C for 4.5 
minutes and then 40 µl were loaded onto the gel. Two types of gel were prepared for each 
gel holder. First the running gel (10%) was placed followed by 0.5 nil of 50%, which 
would create a distinct line, between the running and the stacking gel. After 20 minutes 
the gel was set, the butanol removed and the stacking gel was added on top along with the 
casting comb. The running and stacking gel were composed of 7.9 and 2.5 nil 1120,6.7 
and 0.625 ml of 30% acrylamide, 5 and 1.05 ml of 1.5 M Tris-Cl (p11 8.8), 0.2 and 0.04 
ml of 10% Sodium Dodecyl Sulfate (SDS) , 0.2 and 0.02 ml of 
10% Ammonium 
persulfate (APS), 20 and 4.5 pl of TEMED (N-, N- tetramethylethylenediamine) 
respectively. After some time the combs were removed so that the samples could be 
loaded on the gel. Inside and outside chambers were filled with 1X running buffer to the 
top and 1/3 of the total volume respectively. The running buffer was prepared as 5X 
stock by mixing 75.5 g of Tris, 360 g of Glycine and 25 g of SDS with 5L of 1120. The 
gel was left to run for 10 minutes at 150 V and for 1 hr at 110 V. The gel was then 
removed from the glass. The stacking gel was separated from the running gel and thrown 
away. The running gel was soaked in Cathode Buffer. Three pieces of blotting paper, 
which were two times larger than the size of the gel, were soaked in Cathode buffer. They 
were placed one on top of the other on the semi-dry blotter and rolled out to remove any 
air bubbles. The Gel was placed on top of the 
blotting paper. Nitrocellulose membrane 
was soaked in Anode buffer II and placed on top of the gel. Three pieces of blotting 
paper, which had the same the size of the gel, were soaked in Anode buffer II and placed 
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on top of the membrane. Another three pieces of the same size blotting paper were 
soaked in Anode buffer I and placed on top of the previous paper. All the bubbles were 
removed carefully by rolling out the papers with a disposable pipette tip. Anode buffer I, 
II and Cathode buffer contained 300,25 and 25 mM Tris, and 20% methanol each. The 
pH of Anode buffer I and II was adjusted to 10.4 and Cathode buffer also contained 40 
mM of 6-aminohexanoic acid. The semi dry blotter was left to run at a constant current of 
0.8 mA/cni2 of gel surface to nearest 10 mA for 1.5 hr. The membrane was removed and 
washed in PBS/0.1% Tween for 10 min with gentle shaking. The membrane was marked, 
so as to determine the protein side. The PBS/0.1% Tween was poured off and 10% milk 
was added. The volume was enough just to cover the surface of the membrane. The 
membrane was left at room temperature for 1 and 1/2 hr with gentle shaking. The 
membrane was then incubated overnight at 4 °C in 1% milk in PBS/0.1% Tween, 
containing primary antibody (1: 1,000 dilution, Gentest IgG raised in rabbit, lot number 3) 
with gentle shaking. The next morning the membrane was rinsed briefly with PBS/0.2% 
Tween and washed three times with PBS/0.2% Tween for 10 minutes each. Secondary 
antibody (Sigma, antirabbit IgG) was diluted in 1% milk containing PBS/0.1 % Tween 
and added to the membrane for 1 hr at room temperature with gentle shaking. The 
secondary antibody solution was then poured off and the membrane was rinsed briefly 
with PBS/0.2% Tween. The membrane was then washed 2 times for 10 minutes with 
PBS/0.2% Tween, followed by washing two times for 10 minutes each in PBS with 
gentle shaking. The membrane was finally rinsed twice with sterile 1120. The membrane 
was then placed on cling film and 1.5-2 ml of ECL detection reagents were added on it 
dropwise. The membrane was left for 1 min and then the excess liquid was removed. The 
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membrane was then placed on a new piece of cling film and inserted into the cassette. A 
piece of Kodak film was exposed for 10-30 minutes. The film was then placed in the 
following solutions for specific time points: Developer (4 min), stop bath (I min), fixer (3 
min) and running water (5 min). 
2.11 FACS instrumentation 
The flow cytometer is a machine that accepts an input of liquid suspended cells, passes 
them individually through a light source and measures a variety of light scattering and 
fluorescent properties for each cell. Input cells are passed through a capillary at a rate of 
thousands per second and subjected to light one by one in the form of a laser beam 
(Hughes and Mehmet, 2003). 
To analyse each cell of a sample suspension through the laser beam, the cells must be 
first separated from each other and the laser beam must be small enough, so that two cells 
cannot be in the beam at the same time. The laser beam is focused to a very narrow cross 
section and the stream is also focused using "hydrodynamic focusing" (Hughes and 
Mehmet, 2003). Sheath fluid, which is usually PBS flows through a constricting nozzle, 
called the flow cell. The suspension of the sample is injected into the middle of the sheath 
through a small tube called the sample insertion rod. The flow of the suspension and the 
sheath fluid is laminar and the fluids do not mix. The sample stream (sample core) is 
surrounded by the sheath stream as the fluids pass through the flow cell. 
Once the sample core comes out of the flow cell it is subjected to a laser beam and the 
resulting fluorescent and light scattering properties are measured by a number of sensors. 
The first two are postioned at 180° and 90° from the light source and called forward and 
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side scatter respectively (Hughes and Mehmet, 2003). Forward scatter reflects the cell 
size and side scatter reflects cellular morphology, granularity and membrane complexity 
(Hughes and Mehmet, 2003). These measurements provide information about 
morphologically different subpopulations within a heterogeneous mixture of cclls. 
Simultaneously a series of reflecting filters separate the fluorescent emissions of each cell 
into specific wavelength categories, each of which is recorded by a different sensor. 
These sensors are called photomultiplier tubes (PMTs). In the Beckman flow cytomcter 
used in this study 4 PMTs were present PMT2 (emission 525 nm), PMT3 (emission 575 
nm), PMT4 (emission 610 nm) and PMTS (emission 675 nm). An Argon laser was used 
as the light source (excitation 488 nm). PMT1 was the side scatter. 
1.12 Cell cycle analysis niethod 
2.12.1 Preparation of samples. MCF7 or MDA-MB 468 cells were pretreated with natural 
compounds or 0.1 % DMSO (negative control) for 24,30 or 48 hrs. The medium was 
aspirated, the cells were washed with cold MIS, fixed in 70% ethanol and stored at least 2 
hours in -20°C (Hughes and Mehmet, 2003). Alternatively cells can be fixed in 100% 
ethanol for 1 hr at -20°C, as described in Pan et al., 2002. The cells were then 
resuspended in propidium iodide solution (70 pg/ml in PBS) containing 13 Kunitz units 
of Rnase and incubated at 37°C for 30 minutes. Fluorescence was measured on a FACS 
Beckman flow cytometer. 
2.12.2 FACS analysis 
The machine was calibrated and the laser aligned using fluorescent beads and a flow 
check protocol, before each sample was run. All PMTs should give a CV of less than 2.5 
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in the calibration. All the parameters required for the DNA analysis protocol, which 
included Voltage, Peak gain, Integrated gain and Discriminator were optimised in 
preliminary experiments. 
For PI PMT4 was used. A DNA histogram was obtained by plotting PMT4 peak (Y axis) 
against PMT4 integral (X axis). PMT4 peak corresponds to the voltage obtained by each 
particle, which is proportional to the maximum amount of f uoresence of each particle. 
PMT4 integral corresponds to the integral of the voltage, which is proportional to the 
total amount of fluoresence of each particle. Doublets were separated from single cells in 
G21M phase by gating. The data obtained from each histogram were then analysed using 
Multicycle Analysis 2.0 software and compared with manual estimation of the proportion 
of cells in each phase. 
2.13 Preparation of RNA by güanidinium-acid-phenol extraction 
The experiment was carried out as described by Chomczynski and Sacchi (Chomczynski 
and Sacchi, 1987). Briefly MCF-7 cells (at least 0.5 x 106 cells/ml) were lysed with 1 ml 
of solution D (4M guanidinium thiocyanate, 25mM sodium citrate pH 7,0.5% sarcosyl 
and 100 mM 2-mercaptoethanol) transferred to an Eppendorf tube and mixed with 0.1 ml 
of sodium acetate (2M pH 4.0), lml water saturated phenol and 0.2m1 of chloroform: 
isoamyl alcohol (49: 1). The sample was centrifuged at 4 °C for 20min at 10,0008 and the 
aqueous phase (containing RNA) was removed and mixed with an equal volume of 
isopropanol. The sample was then stored at -20°C for 1 hr to precipitate RNA and further 
centrifuged at 4°C for 20min at 10,000g. The supernatant was removed and the resulting 
RNA pellet was mixed with 0.3ml of solution D and 0.3 ml of isopropanol and stored at - 
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20°C for I hr. The RNA was precipitated again with isopropanol with a last 
centrifugation step (4°C, 10,000g, 10 min), washed with 0.5ml of 75% ethanol and Zell to 
dry. 50µl of RNAse free water were then added to the tube and following quantitation 
(see 6.5.1) the RNA was stored at -80°C. This solution can be stored at these conditions 
for up to one year without appreciable deterioration. 
2.14 Total RNA extraction with a binding column 
MCF7 cells pretreated with natural compounds were trypsinised and transferred to a 
universal tube. Cells were centrifuged at 900 rpm for 5 minutes, the culture medium was 
removed and the pellet was lysed by addition of 25011 lysis solution (The solution was 
provided from SIGMA in the total RNA extraction kit and the exact composition of the 
washing, lysis solutions and filtration column remains unknown). The sample was 
vortexed thorougly to remove all clumps and the lysed cells were pipetted into a filtration 
column. The column was centrifuged for 2 minutes at 13,000 rpm. This step is essential 
to remove cellular debris. The filtration column was discarded and 25011 of RNAse free 
70% ethanol was added to the filtered lysate, which was then transferred to a binding 
column. The column was centrifuged at 13,000 rpm for 15 seconds and the eluate 
discarded. 500µl of Wash solution 1 was added to the column and the column was 
centrifuged for the same time and at the same speed as above. Both the collection tube 
and the eluent were discarded and the column was transferred to a new collection tube 
with the above step repeated with Wash solution 2. Finally, a second 500 µl volume of 
Wash solution 2 was added to the column, which was dried under centrifugation at 
13,000 rpm for 2 minutes. The flow through liquid was discarded and total RNA was 
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eluted by addition of 50 µl of elution solution and subsequent centrifugation at 13.000 
rpm for 1 minute. 
2.15 INA gel electrophoresis 
A 50 ml solution of 1xTAE (Sambrook and Russel, 2001)(Tris-Acctatc-EtTA) buffer 
was prepared containing Wo agar. The solution was heated in the microwave for 2 
minutes with continuos shaking to disolve the agar and then lets to cool down at room 
temperature for 20 minutes. SDS was added at a final concentration of 0.1% and 
Ethidium Bromide at a final concentration of 0.2 µg/ml. The electrophoresis apparatus 
was rinsed with 3% H202 to eliminate any Rnase activity and the gel was poured in the 
electrophoresis chamber and left to set. Electrophoresis buffer (IXTAE) was added so 
that to cover the surface of the gel. The RNA samples were heated for 15 minutes at 
65°C, to denature any secondary structure. The samples were loaded in the sample wells. 
Typically 5 µl of RNA sample was mixed with 10 µl of loading buffer, which contained 
90% formamide (v/v), 0.25% xylene cyanol (w/v), 0.25% bromophcnol bluc (w/v) and 
10% 1xTBE (Sambrook and Russel, 2001) (Tris-Borate-EDTA) (v/v). The gel was left to 
run for 2 hrs at 80Volts. 
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2.16 DNA gel electrophoresis 
1%(w/v) agarose (0.5 g in 50 ml) was dissolved in 1X TAE (iris-Acetate-EDTA) and 
heated in the microwave. The solution was left to cool down for about 10.15 minutes and 
then 2 t1 of EtBr (10mg/ml) were added. The gel was left to set with casting combs on the 
electrophoresis chamber for about 30 minutes. 1X TAE buffer was added in the chamber 
until the buffer just covered the gel. The DNA was mixed with loading dye and loaded 
into the wells of the gel. Electrophoresis was run at 90 volts for 30-40 minutes and the gel 
visualised on a long wave UV light box. 
2.17 Nucleic acid concentration estimation and quality control 
techniques 
The concentration of each RNA or DNA sample was calculated from the absorbance at 
260 nm. This value multiplied by the factor 44.19 provides the concentration of the 
sample in pg/ml. The purity of each sample with respect to protein contamination was 
estimated from the 260/280 ratio. A pure RNA sample has a ratio of close to 2±0.05, 
whereas a pure DNA sample of 1.8 ± 0.05. Furthermore the absorbance spectrum 
between 240 nm and 320 nm of nucleic acids exhibits a characteristic bell shaped curve 
with a maximum at 260 nm. Any deviations from this characteristic pattern indicate the 
presence of impurities. For the RNA samples the best diagnostic test is RNA gcl 
electrophoresis. 
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2.18 Reverse transcription 
Enhanced Avian Reverse Transcriptase was purchased from Sigma and the protocol 
adapted from the information provided. RNA template of interest (final cone 0.005- 
0.25µg/µ1) was mixed with deoxynucleotide mix (500 µM of each dNTI') and anchored 
oligo(dT)23 , cenrtifuged to collect all the reagents to the 
bottom of the tube and heated at 
70°C for 10 minutes. The tube was placed on ice and Rnase inhibitor (lU/µl) along with 
lOX reverse transcriptase buffer were added. Reverse transcription was initiated with the 
addition of the enzyme (IU/µl of enhanced avian reverse transriptasc) at 43°C at a final 
volume of 20µl. The incubation was extended for 50 minutes at this tcmpcraturc. 11 c 
first strand cDNA was stored at -80°C for subsequent PCR amplification. 
2.19 Polymerase chain reaction 
The method including primer sequences, reagent concentrations and cycling parameters 
was adapted from Dohr et al., 1995. PCR primers were purchased from Invitrogen 
(Paisley UK) predicting a fragment of 541,146 and 360 base pairs for fl-actin , CYPIAI 
and CYPIBJ respectively. PCR reactions were carried out in a final volume of 50Et1 
containing 3-4µl of cDNA, 5µl of lOX Taq buffer and 200 µM of each dNTP in the 
presence of 0.2 µM of each primer and 2.5 units Taq DNA polymerase. Amplifications 
were performed using a DNA thermal cycler for 25-30 cycles depending on the DNA 
sequence with the following profile: 4 min at 94°C for inactivation for the first cycle, 
1min at 94°C for denaturation, 1 min for primer annealing, 1 min at 72°C for primer 
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extension and 7 min at 72°C for the last cycle for final extension. The prinicr nuclcotidc 










2.20 CYP1 family enzyme activity in intact MCF7 cells 
For assays of EROD activity in intact cells, cells in 24-well plates were treated with 
compound for the time and concentration indicated. The EROD activity NNiis measured as 
described by Kennedy and Jones, 1994. The medium was aspirated and the cells were 
washed with PBS (usually 2m1 in each well). 27Oµ1 of fresh medium containing 1.5 mM 
salicylamide to inhibit conjugating enzymes, were added to the wells. The plate was left 
in the incubator at 37°C for 5 minutes and 3Oµ1 medium of ethoxyresorufin (50µM) were 
added to give 5µM as a final concentration. The plate was left in the incubator at 37°C 
for 1 hr with gentle stiring every 5 minutes. 200µl medium was transferred in ependorf 
tubes and the reaction was terminated with the addition of 2001l of ice-cold methanol. 
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The samples were centrifuged at 3,000 rpm for 10 minutes and the supernatant was 
transferred to a 96 well plate and read using a fluoresencc plate reader with excitation and 
emission at 530 and 590nm respectively. Standard curves for resoru(in formation were 
also peflbrmed. 
2. i1 Statistical analysis 
Experiments were repeated at least two times. Significant differences for na3 or n4 
replicates were determined by Student's T test. Statistical analyses were performed using 
SPSS. 
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The long known preventative effect of plant based diets on carcinogcncsis and related 
chronic diseases is well documented and the flavonoids have been indicated as cancer 
preventative compounds by numerous epidemiological, in vitro and in vivo studies as 
described in detail in the introduction chapter. Amongst the different mechanisms of 
action, which explain the chemopreventative nature of the flavonoids, their interaction 
with cytochrome P450s has also been proposed (Middleton et al., 2000). This type of 
interaction will have a significant impact in the case of CYP I enzymes, since they are 
involved in the metabolsim of PAHs and related compounds, as described in section 1.3.3 
and therefore may provide more evidence in the chemopreventative function of dietary 
flavonoids. Doodstar et at. (2000) has shown that flavonoids can inhibit CYP I enzynmes. 
Thus, there is great interest to identify which flavonoids interact with the CYIII family 
enzymes and whether that interaction is inhibition of their activity or a different 
mechanism of action. The purpose of the work described in this chapter was to examine a 
group of structurally related flavonoids, through their ability to inhibit CYP I cnzymes. 
We used the EROD assay described in section 2.3 to screen a panel of naturally occuring 
flavonoids, in terms of inhibitory potency (IC50) towards CYPI family enzymes. 
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3.2 Results and discussion 
The inhibitory effects of flavonols and flavones on CYPI supersonics are reported in 
Table 2, while the different structural components of each compound are summarised in 
Table 1. All the compounds except eupatorin-5-methyl ether, cirsiliol and bcnkwanin 
inhibited CYP1B1 activity more effectively than they did CYPIAI and CYI'IA2 activity. 
The flavone chrysin was the most potent inhibitor of CYPIAI and CYPIA2. Diosntetin 
and chrysin also inhibited CYPIBI at lower concentrations compared to all the other 
compounds (IC50 0.5 µM). The flavonols quercetin, myricetin and kaempfcrol were also 
potent inhibitors of CYP1B1 activity, whereas they seemed to be less effective for 
CYP1A1 and CYP1A2, with the exception of the latter showing more activity for 
CYP1A1. The flavones genkwanin, cirsiliol and eupatorin-5-methyl ether were very 
weak inhibitors of CYP1 enzymes. 6-OH luteolin and baicalein also were very weak for 
CYP1A1 and CYPIA2 and slightly more potent for CYP1B1. Apigcnin, lutcolin and 
eupatorin were of intermediate efficacies. Some of the compounds tested seemed to 
possess selectivity against a certain isoform, such as luteolin, 6 hydroxy lutcolin, 
baicalein, kaempferol, quercetin, myricetin for CYP IB1 and eupatorin-5"methyl ether 
for CYP1A1. The flavonols had the highest selectivity for CYPIBI compared to 
CYP 1A1 (up to 9 fold) and CYP 1 A2 (up to 13 fold). 
In the present study evidence is given that dietary flavonoids can inhibit CYPI enzymes. 
A novel synthetic chalcone (DMU 713, Tan, 2005) was used as a positive control (data 
not shown). The flavone chrysin and the 
flavonols quercetin, myricetin and kaempfcrol 
were potent inhibitors of CYP 1A1 and 
CYP 1B1 activity. Flavonoids with hydroxy 
substitutions at positions 5 and 7, such as chrysin and 
luteolin are potent inhibitors of 
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CYPI enzymes. These substitutions are possibly required for docking the ilavone 
molecule to the active sites of the CYPI enzymes. Hence 6 hydroxy substitution 
decreased the inhibitory activity and methoxy substitution at position 7 completely 
abolished it. In the case of diosmetin the 4'-methoxy substitution seems to have a 
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Flavones 
Chrysin OH H OH H 11 
Baicalein OH OH OH H H il 
Apigenin OH H OH H OH 
Luteolin OH H OH OH OH 
6OH OH OH OH OH OH 
Luteolin 
Diosmetin OH H OH OH OMe 11 
Eupatorin OH OMe OMe OH OMe H 
Cirsiliol OH OMe OMe OH OH 11 
Genkwanin OH H OMe H OH H 




Kaempferol OH H OH H OH 11 
Quercetin OH H OH OH OH 11 
Myricetin OH H OH OH OH 011 
Figure 3.1 Structural features of different classes of dietary flavonoids 
CYP1B1 inhibitory activity as compared to luteolin. Moreover eupatorin having a 4' 
methoxy group and a5 hydroxy group was a lot more potent CYP 1 II 1 and CYP 1A1 
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inhibitor than eupatorin-5-methyl ether. Overall flavonols were potent inhibitors towards 
CYP1B1 activity, compared to their flavone equivalents, indicating that the hydroxy 
group at position 3 of the C ring increases inhibitory activity. This was not the case for 
CYP1A1. 
Table 3.1 The effect of dietary and synthetic (6-011 luteolin) flavonoids on tile r. 1101) 
activity of human CYP1 enzymes. CYP1 (CYP1A1, CYPIA2, CYl'IIil) microsomes (5 
pmol/ml) were incubated with various concentrations of flavonoids (25,2.5,0.25,0.025, 
0.0025 µM). Results are expressed as ICs05, calculated from percentage of inhibition of 
EROD activity compared to control. Each value corresponds to mean ± standard deviation 
for n=4 determinations. ICs0, are in µM. 
Compound CYP 1B1 CYP 1A1 CYP I A2 
Quercetin 0.7 ± 0.3 7±0 12 ± 3.5 
Myricetin 0.9 ± 0.2 4±0 13 ± 0.7 
Kaempferol 1.3 ± 0.2 8±1.4 9±2.1 
Apigenin 2±0 4.2±0 6±0 
Luteolin 1.8 ± 0.4 10 ± 0.7 15 ± 1.4 
60H Luteolin 7.7 ±2 >25 >25 
Diosmetin 0.5±0.1 1.2±0.3 18±4 
Baicalein 7±1.1 20 f0 20 ±0 
Chrysin 0.5 ± 0.1 0.5±0.1 2±0 
Eupatorin 1.1 ± 0.1 2.3 f 0.1 25 ±0 
Eupatorin-5-methyl 21 ±1 6.8 f 0.4 >25 
ether 
Genkwanin >25 >25 >25 
Cirsiliol >25 >25 >25 
The above results provide further insight to previous studies, which underlined the 
importance of A and B ring substituents in the flavonoid structure for inhibition of CYP1 
enzymes. Therefore diosmetin and acacetin, which lack the 3'-hydroxy group, have 
already been reported to be a potent inhibitors of CYP1BI and CYP1AI activity 
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(Doodstar et al., 2000). Zhai and coworkers (1998) has also shown that the hydroxy 
substitutions at positions 3 and 7 of the flavones are important for inhibition of CYI' IAI 
enzyme and hydroxy substitutions at positions 3 and 5 increase the inhibition towards 
CYP1A2, which is in concordance with the data reported here. Furthermore, Tsyrlov ct 
at. (1994) suggested that 3' and 4' positions have a profound effect on the inhibitory 
action of the flavonoids, which does not seem to be necessarily the case, since chrysin 
which does not contain any substituents on the A ring was the most potent inhibitor for 
all three CYP 1 enzymes. 
Selective inhibitors of CYP1B1 and CYP1A1 have already been identified (Chun et al., 
2001, Chun et al., 2002 ). Although they are natural products they do not belong in the 
flavone subfamily. Rhapontigenin is a selective CYP1AI inhibitor (Chun et at., 2001) 
with an IC50 of 0.4 µM. Surprisingly the structure of this molecule can be ovcrlayed on 
diosmetins structure. Both of them contain the same substituents in the A and B rings. 
The only difference is that rhapontigenin is a stilbene and diosmetin is a flavone. The 
data presented here show that diosnietin is a potent inhibitor of both CYP1AI and 
CYP1B1 but not of CYP1A2. Hence, selectivity towards one CYP1 family enzyme is 
lost, due to the six carbon membered ring which is present in the flavone structure. 
Similarly the structure of resveratrol can be overlayed on apigenin. The inhibitory 
potency of apigenin towards CYP 1 
family enzymes followed the order: CYP 1131 > 
CYP1A1 > CYP1A2. Resveratrol has been reported to inhibit CYP1A1 enzyme activity 
in cell based assays (Ciolino and Yeh, 1999) as well as enzyme assays with microsomcs 
prepared from recombinant human P450 CYP1A1 and CYP1A2 (Chun et al., 1999). The 
authors of this study showed that resveratrol had an IC50 of 23 and 1200 µM against 
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CYP1A1 and CYP1A2 respectively, as reported by EROD activity, thus being 50 fold 
more selective for CYP1A1. The results here show that apigenin is a more potent 
inhibitor than resveratrol against all three CYP1 enzymes. Tetramethoxystilbene has been 
reported to be a selective CYP1BI inhibitor (Chun et al., 2002). Unfortunately none of 
the compounds tested resembled that structure and therefore no conclusions can be 
drawn, regarding structure activity relationships. 
Although most of the previous studies have concentrated on inhibition of CYPI fancily 
enzymes by natural products or related synthetic analogues, it is important to note that 
selective CYP1B1 and CYP1A enzyme expression in tumour cells, compared to normal 
cells, is a very attractive target for chemotherapy and chemoprevention via prodrug 
activation. The identification of a selective CYP 1B1 substrate can have great therapeutic 
implications in the treatment of cancer, because it will not get metabolised by normal 
cells. The flavonoids which were shown to be potent inhibitors in this study, could very 
well be potential substrates. Resveratrol as mentioned above has been reported to be a 
substrate and an inhibitor. The EROD assay does not differentiate between the different 
types of inhibition. A molecule which is a strong competitive inhibitor, could be a very 
good substrate, since it will fit in the active site of the enzymes. Further work in chapter 4 
decribes the substrate specificity of such dietary constituents for CYP 1 family enzymes. 
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4. THE METABOLISM OF NATURAL 
FLAVONES BY CYP1 FAMILY ENZYMES 
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4.1 Introduction 
The ability of the enzymes CYP1B1, CYP1A1 and CYP1A2 to metabolise PAlls and 
oestradiol is well documented in in vitro enzyme and cell based assays(Larscn et al. 1998. 
Kristensen and Borresen-Dale, 2000, Badawi et al., 2001). However little is known about 
the metabolism of natural products from such enzymes. To date the only study, which has 
shown metabolism of natural products from CYP1B1 was conducted in our laboratory. 
The natural product investigated was the stilbene resveratrol. Resveratrol is converted to 
piceattanol by CYP1B1 and to two other metabolites (Potter et al, 2002). One of them is 
probably produced from 4-hydroxylation of the second aromatic ring, as the authors 
suggested. Flavones have very similar structure to stilbenes. The main differences are the 
keto group at C-4 position and the oxygen atom at position 1, which are absent from 
stilbenes and present in the C ring of the flavones. The structures of oestradiol, flavones 
and stilbenes could be overlayed on each other. Thus it was hypothesized that CYPI 
family enzymes will hydroxylate unsubstituted positions of the aromatic rings of the 
flavones. In order to justify this hypothesis metabolism studies of the flavones with CYP l 
family enzymes were performed. A similar enzymatic assay as the one described 
previously (Potter et al., 2002) was used. Apigenin and luteolin were investigated from 
previous students and found to be substrates for the CYP 1 enzymes and CYP iB1 
respectively, whereas the flavonols quercetin and kaempferol were poor substrates for 
CYP1 enzymes (Wilsher, 2003). 
A few methoxylated flavones were also chosen in these studies, in order to to test 
whether CYP1 enzymes can catalyse 
demethylation reactions in this type of flavonoid 
subfamily. CYP1 enzymes catalyse the 
deethylation of 7-ethoxyresorufin to resorufin 
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(Burke et al., 1994). Furthermore it has been shown that hersperitin (the flavanone 
equivalent of diosmetin) is converted to eriodictyol (the flavanone equivalent of lutcolin) 
by CYP1A2 and human liver microsomes (Breinholt et at., 2002). Figure 4.1 shows the 














Figure 4.2 2D Mapping of oestradiol, resveratrol and apigenin, a naturally occuring fiavone 
4.2 Results and discussion 









Incubation of'haicalein with C'YPI family enzymes did not sow an, * ni tabolism (Figure 
4.4a). C'hrvsin was metabolised exclusively to haicalein by all three enzymes. as shown in 
(Figure 4.4h. The kinetics ol'the reaction were investigated and the results are presented in 
Figure 4.5. ('YPIAI produced more haicalein than the other two enzymes and ('Y111A2 
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b) Chrysin. The sample was spiked with baicalein and apigenin authentic standard(1 µM); 
Pink standards, blue incubate 
Figure 4.4 HPLC chromatograms of 20 min incubation of CYPI enzymes with a) baicalcin 
(10 pM)and b) chrysin (10 µM). 
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The difference in baicalein retention time between the two chromatograms, is due to 
method optimisation. The column C18 Luna 4.6 x 150 mm 5µ was replaced with a Polar- 
RP 4µ 150 x 4.60 mm and this improved chromatographic analysis. Baseline separation 
was achieved for apigenin and baicalein and this resulted to slightly greater retention time 
compared to the previous method. All the other conditions were left the same. 
Parameter Enzyme 
CYP1BI CYP1A1 CYP1A2 



















Figure 4.5 Enzymatic mechanism and determination of kinetic parameters of chrysin 6 
hydroxylation. Error bars represent min and max values of n=2 determinations. 
2.5 5.0 7.5 10.0 
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Figure 4.6 The conversion of scutellarein to 6-hydroxyIutcolin 




Scutellarcin (6-hydroxyapigenin) metabolism from ('YI11 isorymcs yielded a metabolite 
more polar than the parent compound. which was identified by coelution studies to he 6- 
hydroxyluteolin. This compound was Ii rmcd to a smaller extent from ('YI'I RI. 
compared to CYP IAl and CYP I A2. Other peaks shown in the chromatograms (Figure 
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Figure 4.7. Coelution studies of scutellarein (10 µM) incubation samples from CYPIAI 
enzyme with 6 OH luteolin authentic standard solutions (0.5 µM). The same coelution 




trace: 6 hydroxy Iuteolin standard, light green trace: Scutellarein incubate with ('V14 A I, 
dark green trace: Scutellarein incubate and 6 hydroxy luteolin standard. 







Figure 4.8 The metabolism of diosmetin to luteolin 
II 
Diosmetin was metabolised mainly to luteolin (Figure 4.8 and 4.11) by all three enzymes 
but mostly from CYP IAI and CYP I A2. Figure 4.9 shows the decrease in the 
concentration of the compound following incubation by CYPI enzymes over time, 
compared to control experiments. Two other metabolites were observed. named DI and 
D2, which seemed to be more polar than luteolin. as shown by the IIPLC chromatogram 
(Figure 4.10) and hence were eluted at smaller retention times. 
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Figure 4.9 Rate of metabolism of diosmetin from CYP1 isozymes. Error bars represent 
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Figure 4.10 Metabolites formed after 20 min incubation of diosmetin (10 µM) with CYPI 
family enzymes. Blue; control, pink; CYPIA2, orange; CYPIAI, dark green; CYPI B1. 
Dl was identified as 6 hydroxy luteolin (Figure 4.12). 6-hydroxyluteolin was only a 
minor product from CYP1A2 and CYPIAI mediated metabolism, whereas in the case of 
CYP 1B1 no D1 and D2 were produced. D2 could not be identified, however according to 
the retention time indicated from the chromatogram, it is likely to be the 6 hydroxylated 
metabolite of diosmetin. 
The formation of luteolin from diosmetin was also investigated kinetically and the results 
are presented in Figure 4.13. CYPIAI was more eff icient in promoting the demethylation 
at 4' position of the B ring compared to the other two enzymes. Finally the metabolism of 
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diosn etin was also investigated in a hepatic ('YP panel (Figure 4. I4). Thrre was no 
major decrease in the concentration of diosmetin within 20 minutes incubation with 
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Figure 4.11 Identification of luteolin as the primary metabolite of the metabolism of 
diosmetin (10 µM) from CYPI family enzymes. A 20 min CYPIAI or ('\'11131 incubate Has 
spiked with 2µM of Iuteolin. Similar profile was obtained for ('V I'IA2 (data not shown). 
Experiments were done in triplicate. Luteolin standard has been added in the traces for 
clarity. 
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Figure 4.12 Identification of 6 OH luteolin as the secondary metabolite of the metabolism of 
diosmetin (10 µM) from CYPIA2. A 20 min CYPIA2 incubate was spiked ý. ith I IºM of 60II 
luteolin. The difference in retention times, compared to the other traces, is due to a different 
column employed for this experiment. 
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Figure 4.13 Michaelis Menten kinetics of the demethvlation of diosmetin to luteolin. Error 
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Figure 4.14 Rate of metabolism of diosmetin from a CYP panel. Error bars represent the 








Figure 4.15 Eupatorin is converted to cirsiliol by CYPI family enzymes 
Fupatorin was metabolised mainly to cirisiliol. as indicated by the retention time. by 
CYP I Al and CYP I A2 and to a smaller extent by CYP IRI (Figure 4.16). There were no 
other significant metabolites detected from CYPlUUi metabolism. however ('YPIA2 
yielded two minor metabolites named El and F? with a retention time of 7.5 and 7.7 min 
respectively and CYP 1A1 produced E2 to a smaller extent and F] to a larger (Figure 
4.17). Coelution experiments were also performed to confirm the identity of cirisiliol as 
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Figure 4.16 a)Rate of formation of cirisiliol by CYPI family enzymes b) Rate of metabolism 
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Figure 4.17 Metabolites formed from eupatorin incubation (10 µM) with CYP1 family 
enzymes after 20 minutes; Top picture black control, blue CYPIAI, green CYPIA2, brown 
CYPIBI bottom picture black control, blue CYPIB1, green CYPIAI, brown CYPIA2. The 












Figure 4.18 Sinensetin is metabolised to various products by C'VPI family enzymes 
Sinensetin was metabolised trcmi all three C'YPI enzymes. The rate of metabolism is 
shown in Figure 4.19. Two unidentified major metabolites were detected from ('YI'1AI 
and CYPlA2 and one from CYPIB1, with retention times close to the parent compound 
probably indicating primary metabolism, whereas smaller peaks with shorter retention 
times were also detected as a result of possible secondary metabolism (Figure 4.20). Such 
products could occur as a result of dcmethy-lation steps at positions 3'. 4', 5.6,7 of the A 
and the B ring. 
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Figure 4.19 Rate of metabolism of sinensetin from CYP1 isozymes. Experiments were done 
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Figure 4.20 Metabolites formed from 20 min incubation of sinensetin (10 µM) with CYI'l 
isozymes: top : control brown, CYPIBI orange, CYPIAI blue, CYP1A2 pink. Bottom: 
control light blue, CYPIAI brown, CYPIBI orange, CYPIA2 green. The bottom trace is an 





Figure 4.21 Genkwanin is metabolised to apigenin by CYPI famil} enzymes 
The flavone genkwanin. which possesses a methoxy group at the 7 position was 
converted mainly to apigenin. by a simple dcmcthvlation step. by all three enzymes. 
Genkwanin was also metabolised to another product ((il) with a retention time of' 11.3 
min. which could he 3'-OH genkwanin or 6-011 genkwanin. Other peaks with shorter 
retention times of those of apigenin were obtained probably indicating secondary 
metabolism of apigenin to luteolin and 6-OH apigenin. Coclution studies confirmed the 
identity of apigenin as main product of gcnkwanin metabolism from the CYP1 1aniliv 
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Figure 4.22 Coelution studies for the identification of apigenin as the primary metabolite of 
genkwanin (10 µM) from 20 min incubation with CYPIBI. The incubate was spiked with 
apigenin standard (1 µM). Same coleution was observed for the other two enzymes. Green 
0 OH O OH 
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trace genkwanin incubate with CYP1B1, blue trace genkwanin incubate with apigenin 
standard. 
It is important to note that the formation of apigcnin from CYP1B1 mediated metabolism 
of genkwanin was greater over time than that for the other two enzymes. The opposite 
was observed for G1 product (data not shown). Thus one can speculate that apibenin is 
being preferentially formed by CYP1B1. The overall rate of metabolism of genkwanin 
was similar for all enzymes, probably due to secondary metabolism and formation of G1. 
Initial kinetic experiments demonstrate that genkwanin is a selective substrate for 
CYP 1B1 (Km = 1.5 µM, Kcat = 7.8 pmoUmin/pmol of enzyme, as opposed to Km =4 
µM, Kcat = 4.8 pmol/min/pmol of enzyme for CYP1A1 and 4.3µM and 3.5 













Figure 4.23 Enzyme kinetics of genkwanin CYP1 family catalysed demethylation. Error 
bars represent min and max variation for n=2 determinations. 
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In the present study evidence is provided for a possible pathway of CYPI catalysed 
flavonoid biotransformation (Figure 4.24). The primary site of flavonoid metabolism of 
the flavones examined, was found to be the 3' and 4' position of the B ring and the 6 
position of the A ring. 
Baicalein was the only flavone which was not oxidised by the CYPI family, whereas 
chrysin was metabolised to baicalein, genkwanin to apigenin, apigenin to lutcolin and 
scutellarein (as a result of secondary metabolism). Comparison of the structures of these 
six compounds, suggests that the presence of substituents at positions 5 and 7 of the A 
ring is necessary for hydroxylation at the 6 position to occur. Moreover oxidation on the 
B ring requires pre-existing substitution as well (such as 4' hydroxy in the case of 
apigenin) and as a result chrysin and baicalein which contain unsubstituted B rings were 
not oxidised from CYP1 enzymes to that position. Scutellarein was also metabolised 
exclusively to 6-hydroxyluteolin, which is in agreement with the above finding. 
Eupatorin and diosmetin possess methoxy substituents at the 6,7,4' and 4' postions 
respectively. The main route for these flavones metabolism was 4' demethylation. 
Sinensetin was metabolised by CYP1 family enzymes but most of the metabolites could 
not be identified, due to the unavailability of authentic standards, although it seemed that 
the rate of metabolism increased as the number of methoxy substituents increased. 
Unidentified metabolites were also noticed in the metabolism of diosmetin and 
genkwanin (one in each study). However one can deduce that they would probably result 
from hydroxylation on the 6 position of the A ring, due to polarity differences with the 
other metabolites and the parent compound. The data presented in this chapter indicate 
that diosmetin and genkwanin are selective substrates of human CYP 1A1 and CYP 1B1 
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Figure 4.24 Possible bioactivation pathways of dietary flavones by CYP1 isozymes 
There are a few studies in the literature regarding the metabolism of flavonoids from 
CYP1 enzymes and the evidence is sometimes contradictionary. For example it was 
shown from Otake and Walle (2002) that chrysin was not oxidised by pooled human liver 
microsomes and recombinant CYP1AI and CYPIA2 enzymes. Galijatovic et at. (1999) 
showed also that chrysin was not oxidised by CYP 1 enzymes, but instead it was 




lines. The same metabolic profile was observed for apigenin. The authors suggested that 
conjugation reactions were more important in the non induced HepG2 and CaCo-2 cell 
lines. In another study it was shown that chrysin is metabolised to a large extent to 
apigenin by uninduced and induced Aroclor-1254 rat liver microsomes and to luteolin to 
a minor extent (Nielsen et al., 1998). Here it is shown that chrysin is metabolised to 
baicalein and bacalein is not metabolised by recombinant human CYP1 family enzymes. 
CYPIAI and CYPIA2 have been shown to catalyse to a small extent the hydroxylation 
of 1713-oestradiol to the C-15a and 16-a position respectively (Badawi et al., 2001). Since 
173-oestradiol can be overlayed on chrysin that would explain why chrysin was 
metabolised to the 6 position of A ring. 
Scutellarein was metabolised to 6-hydroxyluteolin. Resveratrol was shown to be 
metabolised to piceattanol and to two other metabolites (Potter et al., 2002) resulting 
from hydroxylation on the second aromatic ring. In the case of scutellarein the 6 position 
of the A ring is already hydroxylated, hence the only position left vacant is the 3' position 
of the B ring. These results are in agreement with Potter et al. (2002). Moreover Wilsher 
(2003) showed that luteolin is exclusively metabolised to 6 hydroxy luteolin by CYP 1B1. 
No other metabolite was detected in the latter study. Hydroxylation of the flavones might 
occur in positions 2', 5' and 6' of the B ring, however this type of reaction has never been 
reported to date by CYP 1 family enzymes, in this subclass of natural products. 
Diosmetin was converted to luteolin and to two other metabolites. One of the other 
metabolites was shown to be 6-hydroxyluteolin (only produced by CYP1A1 and 
CYP1A2). Since Wilsher showed, that 6-hydroxyluteolin is produced from luteolin to a 
minor extent, exclusively from CYP 1B1, the above findings suggest that diosmetin is 
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metabolised to luteolin and 6-hydroxydiosmetin. 6-hydroxydiosmetin is then further 
converted to 6-hydroxyluteolin. CYP1B1 could convert the luteolin produced from 
diosmetin 4' demethylation to 6-hydroxyluteolin. However the amount of luteolin formed 
was probably too low for its 6 hydroxylated metabolite to be produced in detectable 
concentrations from this assay. Breinholt et al. (2002), showed amongst other flavonoid 
compounds that apigenin is converted to luteolin, hersperitin (the flavanone equivalent of 
diosmetin) to eriodictyol (the flavanone equivalent of luteolin) and tamarixetin (the 
flavonol equivalent of diosmetin) to quercetin (the flavonol equivalent of luteolin) by 
human liver microsomes and recombinant human CYP 1 A2 enzymes expressed in E. coll. 
The results presented here are in agreement with this study. 
There are few studies (Nagao et al., 2002, Martihi et al., 2004) on the biological activity 
of the remaining methoxylated flavönes investigated in this chapter (eupatorin, 
genkwanin and sinensetin) and none of them has examined the the substrate specificity of 
these compounds for CYP1 family enzymes. It was shown that eupatorin follows the 
same demethylation pattern of diosmetin at least for one of the metabolites (cirsiliol) and 
that genkwanin is converted to apigenin through demethylation of the 7 position of the A 
ring. It could be speculated for sinensetin that it would undergo possible demethylation 
reactions in the 4' position of the B ring and in the 6 and 7 positions of the A ring as its 
primary metabolic route. Secondary metabolites are also possible. 
The flavonoids investigated have already been implicated as chemopreventive agents and 
several possible explanations for such properties have been proposed. In this chapter it 
has been demonstrated that this is likely due to CYP 1 enzyme catalysed bioactivation. 
Apigenin produced both G2/M and Go/G1 cell cycle arrest in asynchronous human diploid 
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fibroblasts, mediated by inhibition of Cdk2 kinase and phosphorylation of Rb protein 
(Lepley, 1997), and was shown to induce apoptosis in HL-60 (human promyelotic 
leukaemia) cells, through a rapid induction of casptse-3 activity (Wang et al., 1999). 
Moreover it inhibited eukaryotic topoisomerase I catalysed DNA religation by forming a 
ternary complex with Topo I and the DNA substrate during the cleavage reaction, (Boege 
et al., 1996). This evidence could explain the anticancer properties of genkwanin by 
conversion to apigenin via CYP1 enzymes. Similarly, luteolin increased p21 levels in 
human LNCap prostate cancer cells, and caused 1 cell cycle arrest in human melanoma 
cells OCM-1 (Wang et al., 1999). It has also beers shown to inhibit the catalytic activity 
of eukaryotic DNA topoisomerase I interacting with both free enzyme and substrate 
DNA, and be a very potent inhibitor of protein kinase C and PI-3 kinase (Chowdhury et 
al., 2002, Kobayashi et al., 2002). These findings can offer more insight on the 
chemopreventive activities of flavonoids, such as diosmetin and apigenin, which are 
metabolised to luteolin through CYP1 enzymes expressed in tumours. Finally luteolin 
itself can be converted to 6-hydroxyluteolin by the same enzymes, which has also been 
implicated in antiproliferation of murine melanoma (B16F10), uterine carcinoma (HeLa) 
and human castric adenocarcinoma (MK-1)(Nagao et al., 2002). Similar anticancer 
properties have been reported for baicalein, which can explain the activity of chrysin (Liu 
et at., 2002). 
In conclusion the results reported in this chapter provide the first supportive evidence for 
the hypothesis that CYP1 family enzymes act as tumour suppressor enzymes, via 
metabolism of dietary flavones to different products. The anticancer properties of the 
resulting metabolites require more extensive studies. 
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5. BIOACTIVATION 
FLAVONES IN MDA-MB 
CELLS 
OF NATURAL 
468 AND MCF7 
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5.1 Introduction 
Amongst the different mechanisms by which flavonoids can exert their anticarcinogenic 
effects, is their ability to supress tumour growth. The antiproliferative/cytotoxic activity 
of various classes of flavonoids against cancer cells has been an extensive area of 
research for the last 15 years. It has provided structure activity and other mechanistic 
information regarding the way by which flavonoids act as chemopreventative agents. 
Flavonoids such as quercetin and baicalein have been shown to have growth inhibitory 
activity in a variety of tumour derived cell lines (Kawaii et al., 1999). 
In the previous chapter it was shown, by enzymatic assays, that most of the flavones 
examined were metabolised to different products by CYPI family isozymes. In order for 
a proof of principle concept to be established, it is necessary to obtain the same result in 
cell based assays. In addition, we wanted to investigate, whether this type of 
biotransformation would enhance the antiproliferative action of the flavonoids, towards 
the cancer cells. 
Previous work in our laboratory had concentrated on the selection of a cell line, which 
would express CYP 1 family enzymes and thus could be used as a screening model to test 
bioactivation of natural products and related synthetic analogues. MDA-MB 468, which 
is a breast adenocarcinoma cell line (www. lgcpromochem-atcc. com), was chosen. 
Western immunoblotting was perfomed, in order to identify, whether the main CYPI 
isoform expressed in MDA-MB 468 cells is CYP1B1. MCF1OA cells, which were 
derived from primary breast cultures (www. lgcpromochem-atcc. com), were used as a 
negative control cell line, to identify possible toxicity of the flavonoids to normal cells. 
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The metabolism of the flavones was investigated in MDA-MB 468 and MCF1OA cells 














5.2 Structures of the compounds analysed by HPLC 
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5.2 Results and discussion 
MDA-MB 468 cells express CYPI family enzymes as shown by EROD assay (Figure 
5.3). Little or no EROD activity was observed in MCF l0A cells. Therefore these two cell 
lines could be used to assess the metabolism of natural products, from CYP1 family 
enzymes. The antibody used in the western blotting did not detect any bands 
corresponding to molecular weights of 60 kDa, which would be expected for CYP IB1, in 
MDA-MB 468 cells. A band was obtained from the CYP 1B1 microsome, used as a 
positive control, purchased from Gentest, at 60 kDa (Figure 5.4). A lot of background 
reactivity appeared from proteins present at lower molecular weights in the MDA-MB 
468 and the CYP 1B1 microsome samples (Figure 5.4). 
HPLC analysis showed that genkwanin and diosmetin are metabolised in MDA-MB 468 
and not in MCFIOA cells. Diosmetin produced two minor metabolites in MDA-MB 468 
cells (Figure 5.5). The one eluted at about 8.7 min and was luteolin as shown by previous 
data in chapter 4 and the other eluted at 7 min and was probably D2, i. e. 6 hydroxy 
diosmetin as discussed previously. Genkwanin was metabolised to three metabolites with 
retention times of 11,8.4 and 7 min respectively (Figure 5.5). A peak was obtained at 10 
min in both cell lines, which was an impurity present in the standard (data not shown). 
Thus we cannot make any definite conclusions as to whether; the last two metabolites are 
appearing from the metabolism of genkwanin or of the impurity. Eupatorin was also 
metabolised in MDA-MB 468 cells. One of the metabolites was cirsiliol, as seen from the 
relative retention time difference and from the enzyme assays discussed in chapter 4 
(Figure 5.5). The other metabolite eluted at 7 min. No metabolism was observed in 
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Figure 5.3 EROD activities of MDA-MB 468 and MCFIOA cells. Blue bars represent mean 
±standard deviation of three individual experiments. 
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Figure 5.4 Protein immunoblotting of MDA-MB 468 and MCFIOA cells. From left to right; 
lane 2-4; MCFIOA protein extracts, lane 5-7; MDA-MB 468 protein extracts, lane 8; 
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Figure 5.5 Metabolism of flavones (10 pM) in MDA-MB 468 and MCFIOA cells. i) 
Diosmetin; green; MDA-MB 468 brown; MCF1OA. ii) Eupatorin; red; MDA-MB 468 
orange; MCFIOA. iii) Genkwanin; blue; MCF10A Orange; MDA-MB 468. Experiments 
were done in duplicate. 
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The ability of the natural products to inhibit the growth of MDA-MB 468 and MCFIOA 
cells was investigated by measuring cell viability after 96 hr exposure of the cells to the 
compounds. The most potent compounds in MDA-MB 468 cells were eupatorin-5 methyl 
ether, eupatorin, cirsiliol and sinensetin (data not shown) with IC505 of 0.2,0.4,0.2 and 
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Figure 5.6 MTT assays of natural compounds on MDA-MB 468 and MCFIOA cells. i) 
Cirsiliol ii) Eupatorin iii) Eupatorin-5-methyl ether. The ICS0 of eupatorin was calculated as 
an average of eight replicates, taking into consideration the inhibitor study. The assay for 
cirsiliol and eupatorin-5-methyl ether was repeated at least three times. Error bars 
represent standard deviation of the mean. 
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cancer cells significantly with IC5Os of 1 and 4 µM respectively (Figure 5.7). Baicalein, 
scutellarein, chrysin and apigenin (IC50 50 µM data not shown) were less potent natural 
compounds in this cell line (Table 5.1). Acacetin had no effect on the growth of MDA- 
MB 468 cells (data not shown). In MCF I OA cells all the compounds except baicalein and 
cirsiliol had IC50 greater than 20 µM (Table 5.1, apigenin IC50 >100 µM, data not shown). 
Baicalein and cirsiliol showed IC50 of 14 and 18 µM respectively (Table 5.1). Sinensetin 
did not exhibit an IC50 even at concentrations of 100 µM (data not shown). The 
difference in IC50 values, between MDA-MB 468 and MCFIOA cells, in the case of 
chrysin, scutellarein and baicalein was analysed statistically by Students T-test and found 
to be significant in the case of scutellarein (p= 0.0002) , 
baicalein (p=0.02<0.05) and non 
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Figure 5.7 Bioactivation of natural products in MDA-MB 468 cells. i) Diosmetin ii) 
Genkwanin. Error bars represent standard deviation of the mean for at least n=3 replicates. 
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Table 5.1 The effect of dietary flavonoids ott the cell viability of MCF7 (a), MDA-MB 468 
(b) and MCF1OA (b) cells. MCF7 cells were treated with 10 nM TCDD for 24 hr to induce 
CYP1 enzymes. Results are expressed as IC5o calculated from percentage of cell viability of 
cells treated with various concentrations of flavonoids (see chapter 2) compared to control 
(0.1% DMSO treated). Each value corresponds to mean ± standard deviation for at least n 
=3 determinations. IC5o, are in µM. Significlnt differences were determined using Students 
T-test. 
(a) 
Compound Induced Non induced 
Genkwanin 13.7±2.3 17.3±2.5* 
Eupatorin 7t 0* 6.9 ± 0.3* 
Cirsiliol 5.3 ± 0.5** 9.5 ± I** 
Baicalein 16.7 A 2.9* 19.3 ± 0.6* 
Chrysin 60 ± 17.3* 73.3 ± 5.8* 
Scutellarein 16.3 ± 3.5* 18.5 ± 1.3* 
Diosmetin 11.3 ± 2.3** 20 ± 0** 
Apigenin 36.7 ± 2.9* 35: 1: 5* 
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Table 5.1 Continued 
' (b) 
Compound MDA-MB 468 MCF1OA 
Chrysin 24.5 f 5.5* 25.3 ± 3.7* 
Baicalein 7.1 ± 0.3** 15.3 ± 3.8** 
Scutellarein 12.8 ± 1.5** 41.8 ± 2.9** 
* Differences were non significant (p>0.05) 
"Differences were significant (p<0.05) 
In order to confirm that the above effects in MDA-MB 468 cells were due to metabolism 
of the natural compounds from CYP 1 family enzymes, MTT assays were carried out, 
using eupatorin and genkwanin as bioactivating compounds and acacetin as an inhibitor 
of CYP 1 family enzymes, to find out whether that would reverse the inhibition of cell 
growth seen in the cases of the above compounds. Cotreatment of acacetin (2 µM) and 
genkwanin or acacetin and eupatorin reversed the IC50 from 1 µM to 10 µM and from 0.6 
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Figure 5.8 The cytotoxic effect caused by eupatorin and genkwanin in MDA-MB 468 cells is 
reversed with the addition of 2 pM of the CYPI family inhibitor acacetin. i) Eupatorin; red 
line; eupatorin alone, blue line; eupatorin and acacetin. ii) Genkwanin; green line; 
genkwanin alone, red line; genkwanin and acacetin. Error bars represent standard 
deviation of the mean for n=3 replicates. 
Apart from the above two cell lines MCF7 cells were used as a second screening model 
to investigate bioactivation of natural products in tumour cells. MCF7 cells are known 
from previous studies to be inducible (Dohr et al., 1995) from PAHs. TCDD for 24 hr, 
prior to compound treatment, at a concentration of 10 nM was used, to induce CYPI 
enzyme expression in the above cell line and then cell viability was assessed using the 
MTT assay as described before. The efficiency of CYP1 enzyme expression after 
induction with "TCI)D, was checked periodically every 2 months, by EROD assay and 
HPLC metabolic profiles of tlavones. 
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The most potent compounds in this cell line model were cirsiliol (ICsO 5.25 0.5 µM, 
Table 5.1) and eupatorin (IC50 7±0 µM, Table 5.1). The IC. 0 value of cirsiliol in TCDD 
treated MCF7 cells was significantly different (p=0.001 <0.05) than the one seen in 
MCF7 cells alone (9.5 AI µM), whereas no difference was found in the case of 
eupatorin. There was no significant difference in the IC50 values, between MCF7 non 
treated and TCDD treated cells, noticed from 96 hr treatment of the rest of the 
flavones(Table 5.1, Figure 5.9), except in the case of diosmetin (11.3 f 2.3 µM, 
compared to 20 ±0 µM, p=0.02<0.05, table 5.1). Sinensetin also showed a great 
differential in IC25 values between TCDD induced (IC2S = 0.1 µM) and non induced 
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Figure 5.9 Cytotoxicity of dietary flavones in the MCF7 cell line. MCF7 cells were induced 
with 10 nM of TCDD for 24 hr, prior to treatment of the compounds. i) Eupatorin-5-methyl 
ether. ii) Sinensetin. 
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The metabolism of three of the above flavones in MCF7 cells preinduced with 10 nM 
TCDD, was also investigated. Diosmetin was metabolised to luteolin in both cells and 
medium extracts (Figure 5.12). No coelution studies were performed, because the polarity 
of diosmetin and luteolin results to a relative retention time of I minute as reported from 
the metabolism in the CYPI microsomes. This was clearly shown from the reults 
obtained. A second metabolite eluted at 7 min. No metabolism was observed in MCF7 
cells. Eupatorin was metabolised to three metabolites in MCF7 cells pretreated with 
dioxin. Unfortunately these metabolites eluted at different retention times than those 
observed from eupatorin metabolism in the CYPI microsomes in chapter 4 (Figure 5.13). 
This difference is probably due to impurities present in the samples produced from the 
cells and the medium. Genkwanin metabolism produced two unidentified metabolites and 
(Figure 5.14). The peak which appears at 10.5 minutes corresponds to apigenin. Apigenin 
was present as a minor impurity in the genwanin standard (Figure 5.14). There was little 
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Figure 5.12 Diosmetin (10 µM) metabolism in the MCF7 induced cell model. MCF7 cells 
were pretreated with IOnM of TCDD to induce CYPI enzyme expression prior to addition 
of the natural product. i) Medium extracts; black; MCF7 cells pretreated with dioxin, blue; 
MCF7 cells. ii) Cell extracts; black; MCF7 cells pretreated with dioxin, blue; MCF7 cells. 
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Figure 5.13 Eupatorin (10 pM) metabolism in the MCF7 induced cell model. MCF7 cells 
were pretreated with IOnM of TCDD to induce CYP1 enzyme expression prior to addition 
of the natural product. i) Medium extracts; grey; MCF7 cells, blue; MCF7 cells pretreated 
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Figure 5.14 Cenkwanin (10 µM) metabolism in the MCF7 induced cell model. MCF7 cells 
were pretreated with IOnM of TCDD to induce CYP1 enzyme expression prior to addition 
of the natural product. i) Medium extracts; orange; MCF7 cells, brown; MCF7 cells 
pretreated with dioxin. ii) Medium extracts; MCF7 pretreated with lOnM TCDD, spiked 
with 2 µM apigenin. 
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In this chapter the effects of dietary flavonoids on breast cancer cells and normal breast 
cells were summarised. The flavonoids were shown to be cytotoxic in MDA-MB 468 
cells, due to metabolic activation from CYP 1 family enzymes and a lot less toxic in 
MCF10A cells. CYP1 family enzyme expression in MDA-MB 468 cells was confirmed 
by EROD activity and HPLC analysis (p. 129,130). 
With regard to flavonoid structure-activity relationship, some structural features 
associated with cytotoxic activity in MDA-MB 468 cells could be identified. Flavones 
with methoxy substituents on the A ring such as sinensetin, genkwanin, cirsiliol, 
eupatorin and eupatorin-5-methyl ether were very potent to affect cell viability in this 
model. This toxicity seen was due to bioactivation from CYP 1 family enzymes, because 
the same compounds had higher IC5os in MCF1OA cells. All the compounds had 
considerably high IC50 compared to published results on the plasma flavonoid 
concentration, which would be in the range of 1 µM (Kuhnau, 1976, Scalbert and 
Williamson, 2000). This selective activation in MDA-MB-468 cells, due to CYP1 
enzymes was also shown when addition of the CYP1 family inhibitor acacetin reversed 
partially the cytoxicity seen in the case of genkwanin and eupatorin. Flavones with 
hydroxy substitutions on A and B rings, such as apigenin and scutellarein were less 
potent, but still showed a small activation factor. Flavones with no hydroxy substitutions 
on the B ring such as chrysin and baicalein were of intermediate efficacies, but this effect 
was probably not due to bioactivation from CYP 1 family enzymes. Chrysin was a poor 
substrate for CYP 1 family enzymes and baicalein was not metabolised at all as shown in 
chapter 4, which is in agreement with the MTT results, showing no major difference 
between MDA-MB 468 and MCF l0A cells. 
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The metabolic profiles of the flavones investigated, observed in MDA-MB 468 cells, 
were similar to those seen in the enzyme assay based system in chapter 4. Comparison of 
the IC5os obtained for diosmetin and luteolin in MDA-MB 468 (1.4 µM data not shown) 
and MCF1OA (42 µM data not shown) cells, leads to the conclusion that the bioactivation 
observed in the case of diosmetin is probably mainly due to the second metabolite (D2 or 
6-hydroxydiosmetin) which elutes at 7 min. Luteolin was produced in small amounts and 
did not appear to be that toxic in MCF1OA cells. Genkwanin also produced no apigenin 
in the above cell lines as opposed to the enzyme assay. The cytotoxic action of this 
flavone is probably due to metabolism on a different part of the ring than the 7 position. It 
is possible that the unidentified metabolite G1, which could be either 6-hydroxy or 3'- 
hydroxygenkwanin is causing the observed cytoxicity in the breast cancer cells. The 
cytotoxicity seen in the case of eupatorin was partially due to cirsiliol and due to El, as 
noted from the IC50s of these two compounds on both normal and cancer cells. 
In MCF7 cells, pretreated with 10 nM TCDD, all the flavones exhibited little or no 
bioactivation compared to MCF7 cells alone. Initially it was believed that this was 
because no metabolism was occuring. However this was proven not to be the case. HPLC 
analysis showed similar metabolic patterns to those seen in the enzyme assay. Moreover 
sinensetin exhibited an unusual pattern of activation in TCDD treated MCF7 cells. It 
seemed as if the compound was activated to more cytotoxic species, but this was not 
enough to reduce the IC50 to a lower value compared to the one seen in the non induced 
cells. By comparing the IC25 values though, a 1000 fold activation factor was seen 
between the induced and non induced cells. Taken together these data suggest that the 
induction of CYP 1 family enzyme expression, by TCDD in MCF7 cells, is transient and 
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not maintained through the whole 96 hr exposure to the compounds, as opposed to MDA- 
MB 468 cells, where the enzymes are constitutively expressed. Thus these two cell line 
models cannot be used as a comparison. 
Diosmetin was metabolised in both MDA-MB 468 and MCF7 cells preinduced with 
dioxin. The amount of luteolin formed in MCF7 cells was a lot higher than the one seen 
in MDA-MB 468 cells. In chapter 4 it was shown, that luteolin is preferentially formed 
from diosmetin metabolism from CYP1A1. Hence it can be speculated that MCF7 cells 
preinduced with dioxin express mainly CYPIA1 in the active form. Moreover D1 (6- 
hydroxydiosmetin) was seen in both MDA-MB 468 and MCF7 cellular metabolism. The 
amount of that metabolite seemed to be higher in MDA-MB 468 cells, compared to the 
formation luteolin. CYP 1B1 in the enzyme assay system did not produce any DI. This 
probably means that MDA-MB 468 cells express very little CYP1B1. 
Previous work in the literature has underlined the importance of flavonoids as 
chemopreventative agents by inhibition of cell growth in several cancer cell lines (Kawaii 
et al., 1999). Quercetin, luteolin and apigenin are from the most commonly encountered 
flavonoids in the literature. Apigenin, luteolin and chrysin have been shown to inhibit 
MCF7 cell proliferation at high concentrations close to 50 µM (Le Bail et al., 1998). In 
another study (Guthrie et al., 1997) apigenin exhibited an ICSO of 2.4 µg/ml and 3 pg/ml 
in MCF7 and MDA-MB 435 respectively, which is close to 10 µM. Baicalein and 
apigenin have been shown (Sonoda et al., 2004) to significantly inhibit cell growth of 
HL-60 cells with IC5os of 23 and 15 µM respectively. Luteolin and quercetin were shown 
to inhibit cell growth of HT29 colon adenocarcinoma cells with IC5os of 30 and 15 µM 
respectively (Agullo et at., 1996). In the same study apigenin had similar effect to 
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luteolin and diosmetin was less potent than both of these flavones. In a recent study a 
resveratrol analogue 3,4,5,4'-tetramethoxystilbene was shown to be a lot more cytotoxic 
in cancer cells (W138VA, IMR-90SV, LNCap, Hela, HT-29 and HepG2) than normal 
cells (W138, IMR-90, BJ-T) (Gosslau et al., 2005). The same molecule selectively 
induced apoptosis at low levels in the transformed W138VA cancer cell line, whereas 
resveratrol induced apoptosis in the same cells at very high concentrations (Gosslau et al., 
2005). 
It is important to note that all the above studies have examined the intrinsic cytotoxic 
effects of the flavonoids on several cancer cell lines. This is the reason why the IC5os of 
the flavonoids observed in such studies are a lot higher than those seen in MDA-MB 468 
cells. The results presented here, show that biotransformation of dietary flavonoids in 
cancer cells is possible, and can yield highly active metabolites, which can cause 
selective inhibition of cell growth. The increase in activation seemed to be dependent on 
the methoxy groups present in A and B rings of the flavonoids. Generally the more 
methoxy groups were present the greater the activation, since they could undergo 
multiple demethylation reactions by CYP 1 family enzymes. Increase in hydroxylation 
substitutions increases the reactivity of the flavonoids, e. g. quercetin is more reactive 
than kaempferol, because the two hydroxyl groups present on the B ring makes the 
molecule more susceptible to oxidation than kaempferol. Indeed quercetin has been 
shown to have higher mutagenic activity than its hydroxylated flavone equivalents and 
kaempferol in TA 98 strain in in vitro microbial mutagenic assays (Middleton et al., 
2000). The presence of the 3 and 3' hydroxyl group causes quercetin to be oxidised 
rapidly to quinone reactive intermediates, which cause DNA damage in these type of 
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assays. Moreover mutagenic studies in vivo have shown that methylation of free hydroxyl 
groups of flavonoids by catechol-O-methyltransferase (COMT) would significantly 
reduce their mutagenicity (Middleton et al., 2000). Further hydroxyl groups on either the 
A or the B ring of the flavones could interact with key signalling molecules in the cell. 
Piceattanol has already been shown to be a tyrosine kinase inhibitor and CYP 1B1 can 
produce it from resveratrol (Potter et al., 2002). 
Furthermore this is the first study ever to show, that natural products such as diosmetin 
and eupatorin can be metabolised in cancer cells by cytochrome P450s, such as CYP1A1 
and CYP1B1, which were earlier believed to promote carcinogenesis through conversion 
of PAHs to their ultimate carcinogens. In this regard CYP1A1 and CYP1B1 can be 
termed as "rescue enzymes" or tumour suppresor enzymes, which can inhibit tumor cell 
proliferation through metabolic activation of circulating natural products. 
However in order for such molecules to exert their biological activity, they must fit the 
substrate specificity criteria discussed earlier in chapter 4. All the flavonoids examined in 
these studies could be overlayed structurally upon oestradiol, which is the endogenous 
substrate of CYP1B1. Furthermore the double bond between C2 and C3 in the C ring of 
the flavonoid structure seems to make the molecules more rigid and thereby enhancing 
their capacity to enter the active sites of CYP 1 family enzymes. These results provide 
more insight to the chemopreventative action of this class of natural products. 
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CHAPTER 6. EFFECTS OF FLAVONOIDS ON 




The phenomenon of apoptosis or programmed cell death has been reviewed in the past 
years (Jacobson and McCarthy, 2002). Some anticancer drugs have been shown to cause 
apoptosis in cancer cells 0. Flavonoids can cause apoptosis in tumor derived cell lines 
e. g. tangeretin (5,6,7,8,4'-pentamethoxyflavone) induced apoptosis in HL-60 cells at 
concentrations greater than 2.7 µM (Middleton et al., 2000). 
In addition flavonoids with structural features such as piceattanol, which is a tyrosine 
kinase inhibitor, can potentially inhibit the progression of cells through the phases of the 
cell cycle. It is also possible that flavonoids can directly inhibit the phosphorylating 
kinase activity of the cyclin-CDK complexes as shown by the synthetic flavopyridol 
(section 1.1.6.2 Figure 1.14), which resembles the flavone structure. 
Based on the above evidence and having previously shown in chapter 5 that the flavones 
examined inhibited the growth of MCF7 and MDA-MB 468 cells, due to endogenous 
activation from CYP 1 enzymes, it was investigated, whether the inhibition of cell growth 
was due to apoptosis or cell cycle arrest, using flow cytometric DNA analysis. The 
flavones investigated in this type of assay are shown in Figure 6.1. Methoxylated 
flavones were the main focus, because they had previously shown low IC50 values in 
MDA-MB 468 cells. 
6.1.1 Introduction to flow cytometry 
Flow cytometric analysis has been extensively used for the quantitation of DNA in 
tumour cells for both research and clinical purposes. Substantial oss or gain of DNA has 
been shown in the genome of neoplastic cells by flow cytometric analysis. These changes 
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are characterised as aneuploidy and have been used as diagnostic and prognostic markers 
in a variety of solid tumours. Aneuploidy is a chromosomal state in which abnormal 
numbers of specific chromosomes or chromosome sets exist within the 
nucleus(www. linguasphere. org/dictionary/n-2976-ancuploidy. html). 
Moreover flow cytometry has been applied to the study of cell cycle analysis and 
apoptosis in cancer research. It has been proven to be an invaluable tool, which provides 
information about the mechanisr i of action of various chemotherapeutic agents. Flow 
cytometry overcomes the limitations of microscopy, by allowing the analysis of a large 
number df cells in a very short time. Microscopic studies can be used for the analysis of 
individual cells, however the limited number of cells observed in such studies precludes 
the quantitative cell analysis of entire populations. 
A DNA histogram is obtained when cells are stained with a fluorescing compound, that 
binds quantitavely to DNA and the relative fluoresence per cell is analysed for a number 
of cells (Hughes and Mehmet, 2003). In most normal cell populations the majority of the 
cells are in Go/G1 phase of the cell cycle. These cells have a normal diploid (2n) DNA 
content. The rgxnaining cells of the population can be seen in S and G2/M phases. Cells 
which are in G2 or M phase have ä tettaploid (4n) DNA'content and cells in the S phase 
have DNA content between 2n and 4n. FACS instrumentation is described in more detail 











Figure 6.1 Structural features of the flavones investigated by flow cytometry 
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6.2 Results and discussion 
The effect of two flavones eupatorin and eupatorin-5-methyl ether was investigated on 
the cell cycle progression of MCF7 cells. No subG1 peak was detected in all the samples 
tested. At 30 µM cupatorin and eupatorin-5-methyl ether induced a small Gi arrest in 
normal and dioxin treated MCF7 cells (Figure 6.2). The effect was augmented in the 
dioxin treated cells. Both compounds were of similar potency. There was no major effect 
of the compounds on the cell cycle of the MCF7 cells (control) even at very high 






__ DNA Content Figure 6.2 Cell cycle histograms of MCF7 cells (induced and non induced) treated with high concentrations of eupatorin and eupatorin-5-ether. i) MCF7 control (0.1% DMSO); G, 
48.8%, S 22.3%, G2 28.9%. ii) MCF7 pretreated with 30 µM eupatorin for 24 hr; G, 53%, S 
22%, G2 25%. iii) MCF7 (induced with 10 nM TCDD) pretreated with 30 pM eupatorin for 
24 hr; G, 60%, S 22.6%, G2 17.4%. iv) MCF7 pretreated with 30 µM eupatorin-5-methyl 
ether for 24 hr; G, 53%, S 24%, G2 23%. v) MCF7 (induced with 10 nM TCDD) pretreated 











Several compounds were investigated at 10 µM concentration in MDA-MB 468 and 
MCFIOA cells. The incubation time was extended to 30 hrs and if no significant effect 
was observed a second experiment was conducted at 48 hrs for some of the compounds. 
Eupatorin was the most active compound in this type of assay. At 30 and 48 hrs eupatorin 
arrested MDA-MB-468 cells in the GZ/M phase of the cell cycle (Figure 6.3). The results 
were analysed by students T test and found to be significant for the 30 (p=0.02<0.05) and 
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the 48 (p=0.004<0.05) hr period, respectively. Apoptosis was also observed after 30 (211/0) 
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Figure 6.3 The effect of eupatorin on the cell cycle of MDA-MB 468 cells. i) Summary of the 
cell cycle profile of eupatorin treatment on MDA-MB-468 cells. Error bars represent Stdev 
for n=3 determinations. ii) Control; 0.1% DMSO 48 hr exposure; G, 61% S 15% G2 24% 
iii) Eupatorin (10 µM) 30 hr exposure; subG1 2% G, 46% S 16% G2 36% iv) Eupatorin (10 
pM) 48 hr exposure; subG, 5% G, 17% S 8% G2 70%. 
154 
Cirsiliol at 48 hrs caused an increase of MDA-MB 468 cells present in the G2/M phase 
(Figure 6.4), while at 30 hr treatment it did not have any major effect (data not shown). 
Sinensetin and diosmetin caused G, arrest in the above cell line at the 30 hr period and 48 
hr period respectively (Figure 6.5 and 6.6). Eupatorin-5-methyl ether had no major effect 
even after 30 hr treatment with MDA-MB 468 cells at 5 gM (data not shown). 
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Figure 6.4 Cirsiliol induces G2IM block in MDA-MB 468 cells. i) Control 0.1% DMSO; 48 
hr exposure G, 62% S 14% G2 24% ii) Cirsiliol 10 µM 48 hr exposure G, 42.4% S 18.6% G2 
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Figure 6.5 Sinensetin causes growth arrest in the G, phase of the cell cycle in MDA-MB 468 
cells. i) Control 0.1% DMSO; 30 hr exposure G, 57% S 14% G2 29% ii) Sinensetin 10 µM 
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Figure 6.6 Diosmetin causes growth arrest in the Gi phase of the cell cycle in MDA-MB 468 
cells. i) Control 0.1% DMSO; 48 hr exposure G, 58% S 14% G2 28% ii) Diosmetin 10 µM 
48 hr exposure Gi 65% S 12% G2 23%. Experiments were done in duplicate. 
DNA Content 
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In MCFIOA cells diosmetin was non toxic at the 48 hr period and did not cause a block in 
the cell cycle (Figure 6.7). Similar results were obtained Ior eupatorin-5-methyl ether at 
30 hr (data not shown). Eupatorin (10 µM) forced a small fraction of cells to undergo 
apoptosis at the 30 and 48 hr time period, as shown by the the subGI population (5% and 
6% respectively) (Figure 6.8). Sinensetin caused a small G2/M arrest in the 30 hr period 
in this cell line (Figure 6.8). 
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Figure 6.7 Diosmetin is non toxic to MCF1OA cells. i) Control 0.1`% DMSO; 48 hr exposure 
G, 83% S 8% G2 9% ii) Diosmetin 10 pM 48 hr exposure G, 83% S 7% G2 10%. 












Figure 6.8 The effect of eupatorin and sinensetin on the cell cycle of MCF10A cells. i) 
Control; 0.1% DMSO 48 hr exposure; G, 78.3% S 9% G2 12.7% ii) Eupatorin (10 PM) 30 
hr exposure; subG1 5% G, 78.3% S 4.7% G2 12% iii) Eupatorin (10 pM) 48 hr exposure ; 
subG1 6% G, 85% S 3% G2 6% iv) Sinensetin (10 µM) 30 hr; G, 71% S 12% G2 17%. 
Experiments were done in duplicate. 
Eupatorin was found to be the most active compound from all the natural products 
screened in this type of assay in the MDA-MB 468 cell line, which constitutively express 
CYPI family enzymes. "Therefore in an attempt to identify whether the cell cycle arrest 
seen was truly due to metabolism of the flavone from CYPI enzymes, we focused our 
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investigation on this compound. Cotreatment of eupatorin (10 µM) and the CYPI 
inhibitor acacetin (1.5 µM) resulted in reversal of the G2/M block, seen in the 48 hr 
period in the breast cancer cells (Figure 6.9). Acacetin had a significant effect in blocking 
the activity of eupatorin, but failed to completely return the cells to the initial G2/M 
population seen in the control samples. The same result was observed when 3 pM of 
acacetin were used, indicating that the previous concentration was enough to achieve the 
desired effect. However acacetin did not reverse the apoptosis noticed in the 30 and 48 hr 
period. Treatment of acacetin (1.5 or 3 µM) for 48 hrs did not cause any changes in the 
cell cycle of MDA-MB 468 cells, indicating that this inhibitor did not have any toxic 








Figure 6.9 Acacetin inhibits growth arrest caused by eupatorin in MDA-MB 468 cells. i) 
Control; 0.1 %º DMSO 48 hr exposure; G, 57% S 14%º G2 29% ii) Eupatorin (10 µM) and 
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acacetin (1.5 µM) 48 hr exposure; subG, 3% G, 43% S 14% G2 40% iii) Eupatorin (10 µM) 
and acacetin (3 pM) 48 hr exposure ; subG1 5% G, 43% S 15% G2 37%. Experiments were 







Figure 6.10 Acacetin has no effect on the cell cycle of MDA-Mß 468 cells. i) Control; 0.1% 
DMSO 48 hr exposure; Gi 55% S 15% G2 30% ii) Acacetin (1.5 pM) 48 hr exposure; G, 
55% S 12% G2 33%. Experiments were done in duplicate. 
DNA Content 
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In this chapter the inhibitory effects of some of the flavonoids on the cell cycle 
progression of MDA-MB 468 MCF1OA and MCF7 cells was summarised. MCF7 
(induced with 10 nM TCDD and non induced) cells did not seem to be affected to notably 
from treatment with dietary flavones(eupatorin and eupatorin-5-methyl ether). In chapter 
5 it was also shown by MTT that these two flavones had the same ICSO in both MCF7 
and MCF7 preinduced with dioxin cells and this effect was attributed probably to 
transient expression of CYP 1 family enzymes. 
Low concentrations of eupatorin (10 µM) seemed to show stronger activity in MDA-MB 
468 as opposed to MCF7 cells. This is probably due to constitutive expression of CYPI 
enzymes, in this cell line, which is in concordance with previous MTT results (chapter 5). 
The G2/M arrest which was caused by eupatorin was reversed by the addition of acacetin, 
which means that this effect was due to metabolism of eupatorin to an active species. 
This was also confirmed by the cell cycle analysis in MCF1OA cells which did not show 
any G2/M block. Previously it was shown, that eupatorin is metabolised to cirsiliol and 
another two metabolites in the enzyme assay system. In the cell based assay cirsiliol and 
one of the other two metabolites were detected. Treatment of cirsiliol (10 µM) in MDA- 
MB 468 cells for 48 hrs showed only a small G2/M block. This implies that the profound 
effect which was noticed in the 48 hr period from eupatorin was probably mainly due to 
the second metabolite rather than to cirsiliol. In the MDA-MB 468 cell line cirsiliol is 
likely to be metabolised to different products as shown by the IC50 difference between the 
latter cell line and MCF1OA (see chapter 5). However the concentration of the parent 
compound is unlikely to be completely depleted in that time period. Therefore if cirsiliol 
would cause the profound G2/M arrest seen in the case of eupatorin incubation with 
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MDA-MB 468 cells, this effect would have also been observed when cirsiliol was 
incubated with the latter cells alone. As discussed in chapter 4 and 5 the second 
metabolite of eupatorin is most probably 6-hydroxyeupatorin or a similar metabolite 
which contains a hydroxy substitution on the A ring. This metabolite seems to be more 
active than cirsiliol and probably responsible for the cell cycle arrest noticed in MDA- 
MB 468 cells. 
Induction of apoptosis was evident in MCF1OA cells after 30 and 48 hr treatment of 10 
µM eupatorin and in the breast cancer cells (MDA-MB 468) with eupatorin (10 µM) and 
acacetin (1.5 µM) and with eupatorin (10 µM) alone in the same time periods. Hence 
apoptosis was an intrinscic effect of eupatorin itself and did not occur through metabolic 
activation. 
Eupatorin-5-methyl ether did not have major effect on the cell cycle of MDA-MB 468 
cells, suggesting that it might need further incubation time for the metabolism to achieve 
the desired effect. Sinensetin caused cell cycle arrest in both MCF1OA and MDA-MB 
468 cells, but from the data obtained it cannot be deduced, whether the result in the breast 
cancer cells is due to bioactivation of the compound from the CYP1 family enzymes 
expressed, or an intrinsic effect of the compound itself. Diosmetin had no effect in 
MCF1OA cells and caused a GI arrest in MDA-MB 468 cells. Diosmetin is metabolised 
to luteolin and a second metabolite (D2 or 6-hydroxydiosmetin) in this cell line, while in 
MCF I OA cells there was no metabolsim of this compound as shown in chapter 5. Thus it 
could be speculated that the effect of diosmetin on the cell cycle of MDA-MB 468 cells is 
due to metabolism from CYPI family enzymes. 
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In the past 15 years particular attention has been given to natural diet based agents 
capable of inducing selective elimination of cancer cells by inhibiting cell cycle 
progression and/or causing apoptosis. A lot of studies have investigated the effects of 
different classes of flavonoids on tumour cells and tried to underpin a link between diet 
and chemoprevention. The most commonly encountered flavonoids in the literature are 
hydroxylated flavones or flavonols, such as apigenin, quercetin, kaempferol and luteolin, 
whereas little is known about the biological activity of polymethoxylated flavonoids such 
as the previously mentioned eupatorin. 
Studies in the early 90s on quercetin showed that it downregulates signal transduction 
pathways by decreasing PI kinase activity and IP3 concentration (Singhal et al., 1995). 
However the concentrations of the compound used for this effect were as high as 60 µM. 
Early studies on apigenin showed that it induced G2/M arrest and morphological 
differentiation, on rat neuronal B 104 cells (Sato et al., 1994) but the concentrations used 
were also very high in this study (30,60 and 120 µM). Another study showed that 
apigenin arrests the progression of CA-HPV-10 prostate cancer cells in the G2 phase of 
the cell cycle at 5 and 10 gM (Gupta et al., 2001). The same study also showed that 
apigenin induces apoptosis in the above cell line as evidenced by DNA ladders, 
fluoresence microscopy and flow cytometry. The authors also investigated the effects of 
apigenin at 10 tM in the prostate cancer cell 
lines DU145, LNCap, 22Rv1 and PC-3 and 
found that it induced apoptosis, which was shown by DNA fragmentation. A similar 
study examined the effect of apigenin and three other 
flavonols quercetin, myricetin and 
kaempferol on HL-60 leukaemic cells (Wang et al., 1999). Apigenin induced apoptosis 
through a mechanism involving caspase-3 activation (Wang et al., 1999). 
The other three 
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flavonols examined had similar effects but the potency followed the order apigenin> 
quercetin > myricetin > kaempferol. Again these effects were evident at very high 
concentrations (60 IM). 
Agullo and coworkers, examined the inhibitory effects of chrysin, apigenin, luteolin, 
diosmetin, galangin, kaempferol, fisetin, quercetin, morin and myricetin on PI-3 kinase 
activity and found that myricetin was the most potent PI-3 kinase inhibitor (Agullo et at., 
1997). Structure activity relationships from this study showed that hydroxyl groups on 
the B ring increase the inhibitory potency of the flavonoids and unsaturation of C2-C3 
bond is a necessary requirement for this type of activity (Agullo et al., 1997). PI-3 kinase 
is a key enzyme involved in signal transduction and cell transformation and therefore 
there is great interest to develop PI-3 kinase inhibitors, that could be used for the 
treatment of proliferative diseases. In previous chapters it was shown, that natural 
flavones with methoxy substituents can get demethylated by CYPI family enzymes. 
Hence it can be speculated that this bioactivation process could yield possible PI-3 kinase 
inhibitors with increased potency, according to aromatic hydroxylation or demethylation 
reactions taking place. 
Flavone has been shown to arrest A549 cells in G1 phase of the cell cycle at 100 µM 
through induction of p21 (Bai et al., 1,998) and genistein, the isoflavone equivalent of 
apigenin, induces G2/M arrest in LNCap prostate cancer cells again through activation of 
p21 (Kobayashi et at., 2002). Moreover resveratrol has been shown to arrest U937 
lymphoma cells in the S phase of the cell cycle at 30-60 µM through a mechanism which 
is reversed when the compound is removed from the medium (Park et al., 2001). 
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In the present study it was showen that sinensetin caused GI arrest in MDA-MB 468 cells 
at 10 µM. Tangeretin, a similar flavone, which lacks the 3'-methoxy group that 
sinensetin has, but contains an extra methoxy group at position 8, has been shown to 
cause G1 arrest at 50 pM in COLO 205 cells, through inhibition of CDK4, CDK2 and 
upregulation of p21 and p53 (Pan et al., 2002). These two compounds are structurally are 
very similar. With the data presented in this chapter and in chapter 4 it may be speculated 
that sinensetin exerts its effect probably due to metabolic bioactivation, rather than direct 
inhibition of cyclin dependent kinases. However sinensetin caused G2/M arrest in 
MCF1OA cells, which do not express CYP1 enzymes. Unfortunately, there is not enough 
evidence to demonstrate a possible mechanism of action. Similarly more studies are 
required to elucidate a mechanism for the G2/M arrest noticed in the case of eupatorin. 
The effect of diosmetin on the cell cycle of MDA-MB 468 cells is in agreement with 
previous data published in the literature. Diosmetin is metabolised to luteolin (chapter 5) 
and luteolin has been previously shown to inhibit the autophosphorylation of the EGFR 
(Huang et al., 1999). G, arrest of the cell cycle would be expected since the progression 
of G1 to S phase is mainly dependent on mitogenic signals with the transcription of the 
cyclin D, gene occuring via the Ras/Raf/ERK pathway, as mentioned in chapter 1 section 
1.1.5.7. Progression through the S and the G2/M phase is dependent to a smaller extent to 
mitogenic stimuli. Indeed 12 hr treatment of DU145, PC3 and LNCap prostate cancer 
cells with the potent EGFR inhibitor Iressa or ZD1839 caused G1 arrest (Sgambato et al., 
2004). In CAL33 cells 24 hr treatment of Iressa also caused a G1 block (Magne et al., 
2003). These supportive evidence provide more insight about the chemopreventative 
action of diosmetin: Diosmetin causes Gi arrest in MDA-MB 468 cells, because of 
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metabolism to luteolin from CYP 1 family enzymes. Diosmetin is bioactivated into an 
EGFR tyrosine kinase inhibitor in this cell line, whereas no effect is observed in the 
normal breast MCF1OA cells, which do not express CYPI enzymes. MDA-MB 468 cells 
have been shown to express EGFR, in the absence and presence of serum, and at least 
one order of magnitude greater than the normal breast cell line HBL100 (Squires et al., 
2003). 
MDA-MB 468 cells have been used as a model cell line to investigate modulation of key 
survival pathways by the polyphenolic curcumin in a recent study (Squires et al., 2003 ). 
In this study curcumin caused Gz/M arrest at 20 µM, following 48 hr incubation, which 
was also evident in a normal cell line (HBL100), through inhibition of the ERK pathway 
(Squires et al., 2003). Curcumin was also shown to exert the above biological effect 
through inhibition of c-jun phosphorylation and JNK activity (Squires et at., 2003). Even 
though, no plausible mechanism of action for eupatorin's growth arrest was shown, it is 
worthwhile noticing, that it is a lot better chemopreventative candidate than curcumin. 
Eupatorin caused higher G2/M arrest in MDA-MB 468 cells (subGi 5%, G1 17%, S+G2 
78%) than curcumin (G1 27%, S+G2 73%) at a lower concentration (10 instead of 20 µM) 
and in parallel it had little toxicity in normal breast MCF1OA cells. This is due to 
selective bioactivation occurring in the cancer cells and not in the normal cells, from 
CYP 1 family enzymes as discussed earlier. Curcumin probably does not get metabolised 
in the same cell line, since the structure of the molecule is too big to fit the active sites of 
the enzymes and therefore it acquires its biological effects 
in both normal and cancer 
cells through different mechanisms of action. 
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Even though the studies in the literature discussed earlier, propose that flavonoids inhibit 
cell growth through inhibitory effects on the major signalling pathways and cyclin 
dependent kinases, the concentrations used in most of these studies were artificially 
higher (up to 100 times higher) than the physiological levels of the flavonoids in human 
blood serum. The results presented here, show that flavones such as eupatorin could be 
very promising chemopreventative molecules, which can cause selective cell cycle arrest 
in cancer cells at concentrations closer to physiological levels, through metabolic 
activation from CYP1 family enzymes. 
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7. THE INDUCTION OF CYP1 ENZYME 
EXPRESSION FROM DIETARY FLAVONOIDS 
IN TUMOUR CELLS 
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7.1 Introduction 
As discussed in chapter 1 PAHs can be metabolised to carcinogens by the CYP I family 
of enzymes mainly, CYP 1B1 and CYP 1 A1. The mechanism of their action requires 
induction of these enzymes via the aryl hydrocarbon receptor (AhR). The best 
characterised molecular response to ligands of the AhR is the induction of transcription 
of CYP1AJ. A number of chemical inducers of CYP1A1 and CYP1B1 has been identified 
e. g 3-methylcholanthracene, Benzo[a]pyrene, TCDD and 
dimethylbenz[alanthracene(Kim, 1998, Shimada, 1996). Surprisingly several natural 
products have also been shown to act as agonists or antagonists of the AhR and to induce 
CYP] expression. The most widely studied natural "dioxin" or AhR agonist is indole-3- 
carbinol (13C) (Fong et al., 1990). This compound is a major secondary metabolite found 
in cruciferous vegetables (i. e. cabbages, 13russels, sprouts, broccoli), which induces phase 
I and phase II drug metabolising enzymes in laboratory animals (Kojima et at., 1994) 13C 
also inhibits several carcinogen induced tumours at various sites in rodent models and 
decreases the development of spontaneous mammary and endometrial tumors in female 
mice (Chen et al., 1996 ). 13C is a weak agonist of AhR in T47D cells (human breast 
cancer cells), as far as CYP1A1 mRNA levels are concerned, but is shown to significantly 
inhibit TCDD induced EROD activity in this cell line (Chen et al., 1996 ). However the 
concentrations used in this study were significantly higher than the possible levels of the 
compound circulating in plasma. 
The hypothesis, whether the flavones that have been shown in the previous chapters to be 
substrates for the CYPI family enzymes could act in a similar way as 13C and induce the 
expression of phase I metabolising enzymes, was examined. The research focused on the 
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CYPI family enzyme expression in breast cancer cells. MCF7 cells were used as a model 
for these experiments. The structures of the compounds investigated in this type of 
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Figure 7.1 Structures of the flavonoids investigated in the induction assays 
Eupotorin-S-mslhyl nthtr 
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7.2 Results and discussion 
7.2.1 Comparison of the two RNA extraction methods 
The difficulties associated with the isolation of total RNA are usually due to ribonuclease 
(RNase) activity. RNases are a family of enzymes that degrade RNA through both 
endonucleolytic and exonucleolytic activity. Before proceeding into any other step of 
experimental work, it is essential to rule out any contamination possibility. In general, 
running the RNA on a denaturing gel is the single best diagnostic test. Formation of the 
28S and 18S ribosomal RNA (rRNA) on the gel is a good sign that the RNA is intact. 
One should observe a minimum of smearing above between and below these major RNA 
species. Lack of definition to the rRNA usually means that the sample has been subjected 
to nuclease degradation. The intensity of the 28S rRNA is about twice of that of 18S. An 
intact RNA sample manifests its mRNA component as a significantly lighter smearing 
above, below and between the rRNAs. 
Both the acid-phenol RNA extraction method and the column-based RNA extraction 
method yielded RNA of satisfactory quality as shown by Figure 7.2. However the column 
method was selected due its speed and simplicity, making RNA extraction possible 
within just two hours. The acid-phenol extraction requires the preparation of a number of 
solutions, which also increases the risk of the RNA being more susceptible to degradation 






Figure 7.2 RNA gels of samples isolated from MCF7 cells from the acid-phenol (bottom) 
and the column method (lop). Dark areas indicate the staining from hromophenol blue and 
xylene cyanol 
7.2.2 Selection of the cell line and optimisation of the assays 
The M('I 7 eclI line 'gas used as a model, to investigate whether dietary Ilavonoids 
(Figure 7.1) can induce expression of ('YI'1 enzymes. MCF7 cells have been used in the 
past by other studies (C'iolino et at.. 1999, Ciolino and Yell, 1999), for these type of 
assays and theretöre the results generated could he comparable to already published 
results in the literature. Two other cell lines were tested in our laboratory. but did not 
show significant expression oi'('YI'l family enzymes alter treatment with "1'('I)ß). MDA- 
MR 231 and UT-14 cells were treated with lCD! ) (I OnM) for 16 hours and the FROR 
activity is shown in Figure 7.3. 'l'C'UU had no etl'cct on the induction of C'YI'I enzyme 
expression. The Iluoresence obtained in both control and 1'CDD samples treated samples 
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was probably due to background signal from ethoxyresorufin itself: In a previous 
experiment the cells were treated with TCDD (10 nM) for 24 hours and dietary tlavones 
(concentration range 5-0.625 µM) and similar results were obtained i. e. virtually no 
increase in EROD activity was observed. 










Figure 7.3 EROD activity of MDA-MB 231 cells and UT-14 cells with and without 
treatment of 10 nM TCUI) for 16 hours 
: ROD assay in M('F7 cells is usually perförmed for one hour as described above. The 
fluoresence yielded from the conversion of resorulin was measured over time and as 
shown in Figure 7.4 50 minutes was chosen, as a time point, to represent the linear 
portion of the curve. For a primary screen E ROD-dealkylation activity was measured as 
relative fluoresence units. Once a lead compound was identified fluoresence was 
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Figure 7.4 Time dependence of resorufin formation 
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The primers for the PCR amplification of CYP1A1 and CYPIBI cDNA were obtained 
from Dohr et al., 1995. However their protocol which contained all the necessary 
parameters, was found to be not reproducible. The critical points in the PCR are the 
annealing temperature and the primer sequence. Since the primers were already obtained 
the annealing temperature could be estimated from the primer sequence from the 
empirical formula: 61.8 °C + [(G+C) x 41- 675] / E(A+T+G+C). This estimation would 
give two temperatures one corresponding to the forward and one to the reverse primer. 
The optimum annealing temperatures would usually be somewhere close to the average. 
For CYPIAI, CYP1131 and ß-actin the temperatures were calculated to be 51,53,51,53 
and 61 and 52 °C for the forward and reverse primer respectively. ß-Actin is a 
housekeeping gene and it is used because its expression throughout the different cell 
types remains relatively constant (Sambrook and Russel, 2001). 60 °C was the annealing 
temperature provided from the protocol for both CYP1A1 and /. -actin and the cycle 
numbers 23 and 20 respectively. No band was obtained under these conditions. The 
temperature was lowered to 55 °C and the results are shown in Figure 7.5. The marker 
used is a 100 base pair ladder (lane 1 and 2), starting from the lower band and going to up 
(100,200,300 etc. ). A faint band was produced for fl-actin and a very faint band for one 
of the CYPJAJ samples. Cycle number was also increased to 25. The very small bands at 
the end are primer homodimers, indicating that 0.4 pM primer final concentration is quite 
high for CYPJA1 fragment. 
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Figure 7.5 IZTP('R of RNA samples isolated from M11("I" 7 evils, iý hich ý% crc inºluccd tor 24 
hours with TCIDD. Lane I and 2: IOOhp ladder, Lane 5: fl-actin, Lane 3 and 4: ('YP1.4 / 
I'Itc anttcalinu tcmhcrature was IovvLred to 5 °C and the cycle number used was 25. 
Three samples again were tested and two hands ere obtained tier ('}/'/; l / and no hand 
for JI-actin. which indicated that the optimum annealing temperature is 52 and 55 °(' 
respectively. 100 hp ladder was used again. The mere intense hands in the ladder 









Figure 7.6 RTF'CR of RNA samples isolated frone MCF 7 cells, which were induced for 24 
hours with TCDD. Lane 5: 1 Ullhp ladder, Lane 8: fl-actin, Lane I and 2: CYPIAI. 
Once the annealing temperature and the cycle number were optimised the last parameter 
to be optimised was cUNA concentration, so that a clear comparison tier a concentration 
and time dependent change in the ('YPIAI and ('}'P1131 mRNA levels in M('1'7 cells 
could he shown. Figure 7.7 shows an example of the amplification oftwo eDNA samples 
with different initial concentration. tor amplifying the ß actin gene. The final cDNA 
concentration in the PUR, which would he optimum would he close to 0.08 mg/mI. 
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Figure 7.7. RTI (R of RNA samples isolated from MCF 7 cells. Non treated cells #- at-fin 
(lane 3 0.03 mg/m final cDNA cone and lane 7 0.12 mg/ml final cDNA cone). 
Following the results obtained from the previous experiments the annealing temperature 
for ('YP/ßl was set to be 52 °C from forward and reverse primer. The cycle number used 
was between the range 25-30. Moreover the expected primer concentration would fall in 
the range of 0.3-0.4 µM, since the ('YPJB1 fragment was nearly 400 base pairs. A typical 
example of the [)NA fragment corresponding to (TP1ß1 is shown in Figure 7.8.1 khp 
ladder was used. The more intense bands in the ladder represent the starting fragment size 
(1000 hp), and heavier DNA fragments (2kb, 3kb etc. ). 
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Figure 7.8 RTPCR of RNA sample isolated from MCF7 cells, which was induced for 24 
hours with T('UD. Lane 3: CYPIBI Lane 4: 1 kb ladder 
7.2.3 Natural occurring dietary flavones induce CYPIBI and CYPIAI 
expression in MCF7 cells 
MCI 7 cells were treated with flavones at diffcrcnt concentrations for 24 hours and the 
amount of' ('YI'I cnzymc activity was measured using the : ROD assay. Preliminary 
experiments had showed that chrysin and baicalein did not induce ('YPI enzyme 
expression at 1.25 EtM (Figure 7.9). I. uteolin (Figure 7.9) and diosmetin (Figure 7.10) 
caused it small increase in ('YI'I enzyme activity at the same concentration. Apigenin did 
not have a major effect at concentrations of 5,2.5 and 1.25 µM (Figure 7.11). All these 
compounds were tested in the cytotoxicity assay and the data are presented in chapter 5. 
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Figure 7.9 EROD activity of MCF7 cells treated with natural products (1.25 µM) for 24 
hours. IOnM of TCDD and 0.1% DMSO were used for positive and negative control 











Figure 7.10 EROD activity of MCF7 cells treated with diosmetin (1.25 pM)for 24 hours. 
IOnM of TCUU and 0.1% I)MSO were used for positive and negative control respectively. 
Blue bars and error bars represent mean f standard deviation of four replicates 
respectively. 
The flavones eupatorin. eupatorin-5-nmethyl ether. cirsiliol and genkwanin induced CYPI 
enzyme expression after 24 hours in a concentration dependent manner (Figure 7.11). 
The major induction was noticed at 2.5 µM, whereas at 5 pM the activity started to 
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decline. The most potent inducer was cirsiliol. Eupatorin and eupatorin-5-methyl ether 
are weaker inducers of CYP I enzyme activity. Genkwanin was also a weak inducer. The 
increase in CYPI activity in MCF7 cells caused by treatment of natural flavones was 
compared to TCDD, which was also used for positive control. It is intresting to note that 






































Figure 7.11 The effect of different concentrations of flavonoids on the expression of CYPI 
family enzymes in MCF7 cells after 24 hours. TCDD was used at 10 nM as positive control 
and 0.1 % DMSO as negative control. Concentration range included 0.3125,0.624,1.25,2.5 
and 0.625,1.25,2.5,5 pM respectively. Experiments were done in triplicate. Error bars 
represent mean ± SU. 
180 
The time dependence of the CYPI enzyme induction from the flavonoids was also 
investigated. After 24 hours incubation with 2.5 µM of flavones CYPI enzyme activity 
declined (Figure 7.12). The flavonoid-induced increase in CYPI activity was therelore 


















Figure 7.12 Time dependence of CYP1 enzyme induction from flavonoids (2.5 µM) in MCF7 
cells. Experiments were carried out in triplicate. Error bars represent mean ± SD. 
Since [RU! ) activity is not specific for a certain CYPI isoform, the effect of some of the 
above mentioned natural products on the transcription of C'YPIA I and C'YPI ßl in MCF7 
cells was investigated. The cells were treated with the compounds as before for 24 hours 
and the amount cif mRNA was measured by semi-quantitative RTPCR. Eupatorin caused 
an increase in the mRNA levels of both ('}PIAI and CYPIBI at the higher 
concentrations (5 µM) (Figure 7.13). 
181 
CD CD tý w v, 
a) 
bý 




. -" NW- OO 
Figure 7.13 The effect of eupatorin on the transcription of CYPIBI and CYPIAI in MCF7 
cells. a) /I-actin; lane 1: 100bp ladder, lane 2: 0.1% DMSO, lane 3: TCDD(IOnM), Iane 4 and 
5: 1 and 5µM eupatorin. b) CYPIAI; lane 1: 100bp ladder, lane 2: 0.1%, DMSO, lane 3: 
TCDI)(IOnM), lane 4 and 5: 1 and 5µM eupatorin. c) CYPIBI; lane 1: 0.1'%, DMSO, lane 2: 
1 µM eupatorin, lane 3: TCDD(IOnM), Iane 4: 5µM eupatorin, lane 8: 1kbp ladder. 
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Cirsiliol caused a dose dependent increase in the mRNA levels of'(')'/'/R/ and at 2.5 and 
1.25 µM an increase of CYPIA1 mRNA (Figure 7.14). At 5 µM cirsiliol had no major 
effect on the transcription of C'YPIAI (Figure 7.14). This compound is acting by inducing 
CYPIA/ and C'YPIB/ at low and high concentrations respectively. 
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Figure 7.14 Cirsiliol induction of CYPIAI and CYPIBI mRNA in MCF7 cells. a) left to 
right; /1-actin 0,1.25,2.5,5 µM cirsiliol, TCDD (10 nM), lkb ladder, CYPIAI 0,1.25,2.5,5 
µM cirsiliol, TCDD (10 nM). b) left to right; CYPIBI 1kb ladder, 1.25 µM cirsiliol, 0.1% 
DMSO, 2.5, _5 pM cirsiliol, 
10 nM TCDD. 
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7.2.4 Natural dietary flavonoids can induce their own metabolism. Role 
of CYPIBI in the prevention of cancer 
As mentioned in chapter 1 several studies in the past have examined the 
chemopreventative properties of flavonoids through different mechanisms of action. One 
of the most extensively studied mechanisms is the inhibition of steps in a carcinogen 
activation pathway. The phorbol esters such as TPA ( phorbol 12 -0-tetradecanoate 13- 
acetate) have been used from the early 70s to study the mechanism of carcinogenesis. 
Several compounds such as the flavonoids can influence the phorbol ester-induced 
carcinogenesis in cell lines or animal models and this mechanism of action has been used 
to explain their chemopreventative properties. A study (Shih et at.. 2000) has shown that 
flavonoids such as quercetin and green tea polyphenols can interact with the AN-1 
(activator protein-1) binding site of the human C'YPJA2 enhancer and thus influence TPA 
induced AP-1 and CYPIA2 transcription. In this study the authors found that green tea 
polyphenols inhibited TPA induced luciferase activity in a cell line derived from HepG2 
stably transfected with the CYPIA2 enhancer, whereas quercetin activated luciferase 
activity in a dose dependent manner, suggesting that dietary chemopreventative agents 
may work through different pathways to modulate gene expression. 
In the present study it is shown by EROD activity that dietary flavones induce the 
expression of CYPI enzymes in MCF7 cells. MCF7 cells were chosen, because previous 
studies have examined the induction of TCDD and flavonoids in this cell line extensively 
(Dohr et al., 1995, Ciolino et al., 1998). MDA-MB 468 cells have a constitutive 
expression of CYPI enzymes as shown by EROD activity in chapter 5, hence this would 
184 
interfere with the induction process. Furthermore the flavonoids of interest would be 
metabolised in that cell line and if there was any induction process occuring at all, it 
would be difficult to relate it to the parent compound or the active metabolites. 
Flavones with no hydroxy substitution on the B ring, such as chrysin and baicalein did 
not have a major effect on CYPI enzyme induction. Apigenin with a hydroxy substitution 
on the 3' position also showed little effects. Further hydroxy or methoxy substitution on 
the B ring e. g. luteolin and diosmetin, seemed to enhance the CYP1 inducing potential of 
the flavones. Methoxy substitutions on the A ring of the flavones had a profound effect 
on induced EROD activity. The compounds eupatorin, eupatorin-5-methyl ether and 
cirsiliol were strong inducers of CYP1 enzyme expression. Genkwanin with a methoxy 
substitution at position 7 showed a small increase in EROD activity. 
Furthermore the effects of eupatorin and cirsiliol on the trancription of CYPJA1 and 
CYPIBI were examined. Eupatorin induced CYPIAI and CYPJB1 mRNA levels at 5 
µM. The increase in CYPJB1 mRNA considerably higher than the one observed for 
CYPIAI. Cirsiliol caused a concentration dependent increase in CYP1131 mRNA levels. 
The greatest effect was seen at 5 µM. In contrast the increase in CYPJAJ mRNA from 
cirsiliol did not seem to be concentration dependent and was completely abolished at 5 
µM. 
Unfortunately it cannot be concluded from these studies, whether or not the induction of 
CYP1 enzyme expression and the transcription of CYPJAJ and CYPJBJ, noticed from 
the above flavones are AhR mediated. However it is known that the AhR favours 
compounds that are hydrophobic and have Van der Waals dimensions of 14 x 12 x5A 
(Lu et al., 1996). AhR also favours a stereocoplanar structure like the one observed for 
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the strongest agonist TCDD. Flavones have both these chemical characteristics. It has 
been shown from some studies that flavonoids can be antagonits of the AhR, by 
competing with the binding of TCDD (Lu et al., 1996). Some of them such as tamarixetin 
exhibit weak agonistic effects (Ashida et al., 2000). 3'-amino-4'-methoxy flavone induces 
CYP1A1 mRNA levels and binds with high affinity to the AhR. It did not inhibit TCDD 
induced transformation of the AhR (Roblin et al., 2004). Tamarixetin has a 4' methoxy 
group (-OCHS). We showed that diosmetin and eupatorin, which both contain methoxy 
groups induce CYP1 enzyme expression. Therefore it might be assumed that the 
mechanism of their induction could be AhR dependent. 
Diosmetin has already been reported to induce CYP1A1 expression through the AhR in 
MCF7 cells (Ciolino et al., 1998). Ciolino and coworkers have done extensive studies on 
the agonistic/antagonistic effects of some of the most commonly encountered flavonoids 
on the AhR. They investigated the effects of flavonoids such as galangin, quercetin, 
kaempferol, diosmetin, diosmin and the polyphenolic curcumin on the induction of 
CYP1A1 expression and activation of AhR in MCF7 cells, in a series of different studies 
(Ciolino and Yeh, 1999, Ciolino et al., 1999, Ciolino et at., 1998, Ciolino et at., 1998). 
They showed that quercetin is a strong inducer of CYP1A1 expression to the protein and 
mRNA level and a ligand for the AhR. Kaempferol did not induce CYP 1A1 activity but 
was shown to be a ligand of the AhR. Kaempferol and quercetin also inhibited DMBA 
(dimethylbenzanthracene) induced CYP1A1 EROD activity. Galangin, which is the 
flavonol equivalent of chrysin, was a weak ligand of the AhR and caused a small increase 
in CYP1A1 mRNA levels at the higher concentrations (5 µM). It also inhibited DMBA 
and TCDD induced EROD activity and cytotoxicity in MCF7 cells. Curcumin, diosmin 
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and diosmetin were shown to activate the AhR and induce CYPJA1 mRNA levels and 
EROD activity in MCF7 cells. Diosmin, the glucoside of diosmetin, was the most potent 
inducer amongst all the flavonoids examined in this series of studies. The proposed 
hypothesis of this group, regarding the mechanism of action of these natural products, is 
that they can act in two different ways. Flavonoids which are agonists of the AhR induce 
CYPIAI and phase II expression and prevent cancer by promoting detoxification of 
PAHs. In parallel flavonoids which are antagonists of the AhR compete with PAHs 
binding affinity and therefore reduce the metabolism of PAHs from CYP 1A1 to 
genotoxic metabolites. 
This proposed chemopreventative model does not explain why dietary flavonoids would 
induce CYP 1 enzyme expression in tumors, if they act as inhibitors of these enzymes. 
Moreover, if CYP1 enzymes contribute to the progression of cancer through metabolic 
activation of their substrates, dietary flavonoids would be more likely to cause cancer 
than prevent it. It was shown in chapters 4 and 5 that the flavones examined are 
substrates of CYPI enzymes and underlined that the EROD assay cannot distinguish 
between competitive inhibition and substrate specificity (chapter 3). Hence it is proposed 
that dietary flavonoids can induce the expression of CYP 1 family enzymes in tumors and 
they can be selectively metabolised to a cytotoxic molecule by the tumor cell. These 
results demonstrate that this mechanism of action is possible at concentrations (2.5 µM) 
close to the physiological levels of circulating flavones in plasma (see chapter 1 section 
1. ). 
Even though the AhR was identified initially as a major component of the carcinogen 
activation pathway, such as the one observed for TCDD, induction of CYP 1A1 and 
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CYP 1B1 expression accompanied by AhR translocation to the nucleus has been shown to 
be the mechanism of action of the antitumor agent DF203 (2-(4- 
aminophenyl)benzothiazoles with 3'-methyl substitution) (Loaiza-Perez et al., 2002). 
DF203 aquires its cytotoxicity by activating its own metabolism from CYP1A1, which 
eventually leads to induction of DNA damage and cell growth inhibition. In that regard 
DF203 may be regarded as a prodrug whose basis for efficacy is selective induction of 
CYP1A1 to produce an active species, which has antitumour effects. 
Induction of CYP1A1 and CYP1B1 in tumor cells does not necessarily aid the formation 
of mutagenic metabolites from PAHs and thereby promote carcinogenesis as was 
commonly believed. In fact this induction process could be the mechanism of action of a 
chemotherapeutic agent (e. g. DF203). Natural products can be classified as dietary 
chemopreventative prodrugs, inducing their own metabolism through cytochrome P450 
enzymes, such as CYP 1B1 and CYP 1A1. The present results also show that eupatorin 
and cirsiliol induced CYPIBI more selectively than CYPJA1, compared to the PAH 
TCDD, in the MCF7 cell line. This reinforces the possible role of CYP 1B1 acting as a 
tumour suppresor enzyme; through metabolic activation of dietary prodrugs. 
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8. CONCLUSION/FUTURE WORK 
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Role of CYP1 enzymes in carcinogenesis 
The cytochrome P450 enzymes CYP1A1 and CYP1B1 have been linked by several 
authors with the promotion of cancer, due to their ability to activate PAHs and related 
compounds. CYP1B1 is only expressed in cancer cells as reported by various studies and 
this was initially seen as further indication that this enzyme causes cancer. 
The results presented in this thesis are contradictory to the above hypothesis. Based on 
these data, it is proposed that CYP 1A1 and CYP 1B1 should be termed "cancer 
preventative" enzymes, because of their selective expression in tumor cells, which makes 
them a target for a molecular chemotherapeutic approach. It was demonstrated in in vitro 
enzyme and cell based assays(chapters 4,5 and 6) that this type of approach is possible 
and can yield molecules, which are causing selective inhibition of cancer cell growth. 
The prodrugs, which are not converted in normal cells, have very little or no effects on 
normal cell growth and development. 
The role of flavonoids in the prevention of cancer 
Flavonoids have been termed "cancer preventative" , because of their various types of 
bioactivity towards tumor cells and the different mechanisms of their action have been 
explained in more detail in section 1.2.3. The hypothesis, which is based on the results 
presented in this thesis, provides a more conclusive concept about the relationship 
between diet and chemoprevention, as opposed to the previously developed theories 
(antioxidants, antimutagenic etc. ). This is based on a very simple observation: The 
chemical structures of several of the flavonoid subclasses can be overlayed on the 
structure of oestradiol. This means that in theory most of the flavonoids encountered in 
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the diet are substrates for CYP 1B1 and CYP 1A1. CYP 1A1 and CYP 1B1 catalyse 
aromatic hydroxylation reactions on the A or B ring of the flavonoids. To date most of 
the studies, which have examined this type of bioconversion on flavonoids or related 
compounds from cytochrome P450s have concluded that it results in increased activity of 
the metabolites compared to the parent compound. The studies presented here confirm 
these findings. Therefore dietary flavonoids can stop the development of tumors after 
bioactivation by CYP 1 Al or CYP 1B1. 
The compounds investigated in this thesis are all natural products, and present a vast 
variety of structurally related analogues. Such molecules, could be lead compounds for 
the development of synthetic prodrugs with similar or even greater activity than the 
natural products examined. 
Further evidence about a possible link between diet and chemoprevention is provided 
(Chapter 4,5 and 6). Flavonoids present in the diet, are likely to be metabolised from 
tumor cells and their metabolic products cause selective cell death (Chapter 5). In 
addition the dietary flavonoids can induce their own metabolism in tumors where 
CYP 1B1 and CYP 1A1 active protein is not expressed (chapter 7). 
The drawbacks and limitations of the experiments presented in this thesis are listed 
below: 
1) The 24 hr time point has been used in the past from Ciolino (1998,1999) to investigate 
the induction process in MCF7 cells. This time point seems appropriate for protein 
expression of CYP 1 enzymes, as evident by EROD activity results, however as far as 
CYPI enzyme mRNA levels are concerned, a shorter time window is required, since 
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mRNA induction precedes protein induction. This was demonstrated by Dohr et al., 1995 
using TCDD as an inducer. The maximum time point where mRNA levels of CYPIAI 
and CYPJB1 were examined was 10 hrs, whereas EROD assay was conducted at the 24 
hr time period. 
Real time PCR can also be performed to produce a more accurate measurement of the 
amplification reaction and instead of providing an endpoint result, it would ensure 
continuos monitoring of the reaction. Real time PCR has been used to investigate 
induction of CYP1A1 and CYP1B1 in MCF7 cells by indirubin (Spink et al., 2003) as 
well as in HepG2 and MOG-G-CCM by 3-methylcholanthrene (McFadyen et al., 2003). 
3) The induction of CYP1 enzyme expression from natural products can be investigated 
by HPLC, which would be the most sensitive assay, since it would directly relate to 
functional activity and neither to protein nor to mRNA levels. However the limitation of 
this technique in the present thesis, which was also seen in the metabolism studies in 
cells, is that no compound examined was selectively metabolized by a certain CYPI 
enzyme. All compounds investigated were substrates to a greater or smaller extent by all 
three CYP 1 enzymes. The oestradiol hydroxylation assay has been employed in the past 
by some studies (Hayes et al., 1996, Spink et al., 1998, Spink et al., 2003) to investigate 
expression of CYP 1A1 or CYP 1B1 in cells, since CYP 1B1 will hydroxylate in the 4 
position and CYP 1A1 in the 2. However even this assay is not entirely selective and 
CYP1A2 has been shown to also hydroxylate to a smaller extent at the 2,4 and 16 
position (Badawi et al., 2001). 
4) A CYP 1B1 selective substrate would also overcome the lack of specificity seen in the 
case of the Gentest antibody. Alternatively monoclonal or polyclonal antibodies can be 
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raised and this has been done by Murray et al., 1997,1999, but this would be a difficult 
and time consuming challenge. A different protocol with Gentest CYP 1B1 antibody 
cannot be ruled out though, which would include overnight blocking and 3 hr exposure to 
the primary antibody as it has been shown by Chua et al., 2000. This would in theory 
reduce background reactivity. Moreover microsomes from MDA-MB 468 cells could be 
prepared to provide a relatively purer sample, which would contain less non specific 
proteins. 
5) Other techniques could be employed to study CYP1 protein expression, such as 
immunofluoresence or flow cytometry using a secondary FITC labeled antibody, but the 
limitations are again that they rely on the specificity of the primary antibody. For 
example flow cytometry has been employed to study the acetylation levels of histone H3 
or H4 and the results were more sensitive than those seen in western blotting techniques 
(Ronzoni et al., 2005). 
6) Finally the DNA analysis used in this thesis has to be combined with another 
technique to provide more insight on the mechanism of action of each compound. CDK 
assays can be performed to investigate if a compound is directly inhibiting CDKs. 
Moreover upregulation of cell cycle inhibitors such as p21 or p53 can be investigated 
with western blotting, as it has been shown by Pan et al., 2002. G2/M arrest could be 
further investigated by using the Comet assay, which will show whether a compound is 
binding on DNA and causing single or double strand breaks. However given the 
structures of the flavones investigated in this thesis, the most likely explanation for 
eupatorin and cirsiliol G2/M arrests could probably be that they or their metabolites are 
antimitotic agents. This can be investigated by using confoqal microscopy to examine 
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tubulin damage by using a a-tubulin primary antibody, as it has been shown by 
Kobayakawa et al., 2004. 
Possible ideas for improvement and extension of these studies are listed below: 
Flavones as substrates for CYP1 enzymes 
1. The cell line used as the main tool of CYPI mediated metabolism is MDA-MB 468. 
This cell line expresses both CYP1A1 and CYP1B1 as shown by the literature and the 
present studies. It is important to select a cell line, devoid of any CYP isoforms. Then this 
cell line can be transfected to express constituvely either CYP 1A1 or CYP 1B1 or other 
CYPs to further investigate metabolism in a cell-based system. 
2. The flavonoids examined in the enzyme and cell based assays, should be screened 
against a human P450 panel, with the exception of diosmetin. It is necessary to ensure, at 
least for the compounds which show promising activity, that they are not metabolised or 
activated in the liver, before reaching the tumour site. Flavonoids can be screened in 
enzyme assays against various liver CYPs or alternatively incubated with a liver 
homogenate and analysed by HPLC. 
3. Metabolism of flavonoids is not limited to the liver. As mentioned briefly in the 
introduction, flavonoids can be directly absorbed from the small intestine. The flavonoid 
glycosides can be hydrolysed in the intestine by the enzyme lactase phlorizin hydrolase 
(LPH), which is present on the brush border surface. The resulting aglycones can be 
further conjugated with sulfate and glucuronide groups and either excreted into the 
intestinal lumen or carried back to the liver via enterohepatic circulation. It would be of 
interest to examine the metabolism of the flavonoid glycosides by enzyme assays or 
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CaCo-2 cell culture model. Briefly CaCo-2 cells can be used as a model to predict 
intestinal absorbtion of a drug, by measuring initial concentration and the concentration 
of the drug after it has penetrated through the monolayer. 
4. A further characterisation of the products of CYP 1 enzyme conversion is necessary. 
For example we could combine HPLC with mass spectrometry. Mass spec data will give 
more conclusive information on the identification of the metabolites, resulting from P450 
metabolism. 
5. Finally other flavonoids such as the catechins and the anthocyanidins can be 
investigated as possible CYP 1 family enzyme substrates. 
Biological activity of natural flavones and their CYP1 conversion 
products 
6. The biological activity of the metabolites has to be examined more thoroughly to 
provide supportive evidence on the CYP1A1/CYPIBI bioactivation process. Tyrosine 
kinase assays can be performed, to compare the ability of the metabolites to inhibit 
tyrosine kinase enzyme activity with the parent compound. This can be assayed on a total 
tyrosine kinase assay kit or specific tyrosine kinases can be extracted and used in such 
assays, e. g. luteolin is an inhibitor of EGFR. 
7. Some of the flavonoids examined, such as eupatorin, showed promising activity in 
MDA-MB 468 cells, in various different assays. It is necessary to ensure whether this 
effect is due to CYP 1A1 or CYP 1B1. Acacetin or a-napthoflavone are not selective and 
will inhibit both CYP 1A1 and CYP 1B1. SiRNA can be used to knock down either 
CYP 1 Al or CYP 1B1. MTT assays can then be performed on the knock down cell lines. 
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Cell viability can be related to activity and hence we can speculate whether CYP 1B1 will 
produce more cytotoxic metabolites of a compound than CYP1AI. Once the siRNA 
experiment has been completed animal studies can also be performed to show an in vivo 
representation of this type of molecular cancer therapeutic approach (P450 activated 
prodrugs). 
Regulation of CYP1 activity by dietary flavones 
8. The induction of eupatorin, eupatorin-5-methyl ether and cirsiliol was not fully 
investigated. Whether these compounds induce their own metabolism via the AhR still 
remains unknown. RTPCR studies were not carried out for eupatorin-5-methyl ether. 
Moreover a time profile of CYPIB1 and CYP1A1 mRNA levels after treatment with 2.5 
or 5 µM of these compounds will be of particular interest. 
9. Why would CYP 1B1 and CYP 1A1 mRNA be present when the protein is not there? 
Both of these enzymes were expressed to the mRNA level (chapter 7) in MCF7 cells, 
however they were completely inactive to the protein level, unless induced with TCDD or 
a natural inducer, as shown by EROD and HPLC (chapters 5 and 7). By using a potent 
natural or chemical inducer of CYPIA1 and CYP1B1 the transcriptional and translational 
regulation of these two enzymes could be investigated in MCF7 cells. Or is it that the 
protein is present and subject to postranslational modifications, which activate it to the 
form that we detect by EROD or HPLC? 
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The role of CYP1 enzymes in cancer prevention 
In this thesis a variety of data is presented that, combined, make a strong case for a role 
of the CYPI enzymes in the prevention of cancer, rather than in the development of 
cancer. It is a well established fact, that a diet rich in fruit and vegetables, can play an 
! hj, ortant role in the prevention of cancer. Iii this thesis it is shown that several flavones, 
that commonly occur in a diet that is rich in fruits and vegetables, are substrates for 
ýYPI enzymes and preliminary data suggest strongly that the bioconversion products, or 
the activated products, selectively inhibit growth of CYP 1 expressing cells. 
Much work still needs to be done in order td get a full understanding of the mechanisms 
that underly the CYP1-activated prodrug model, but the data presented so far justify that 
this model is considered as a serious addition to the existing models that have tried to 
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